

June, 2006

CURRICULUM VITAE

NAME: Louis J. Ignarro **DATE OF BIRTH:** May 31, 1941
SOC. SEC. NO.: 113-34-4308 **PLACE OF BIRTH:** Brooklyn, New York
CITIZENSHIP: U.S. Citizen
MARITAL STATUS: Married to Sharon E. Williams, M.D.
ADDRESS: 264 El Camino Drive, Beverly Hills, CA 90212
TELEPHONE: Office: (310) 825-5159 / 825-7137
Home: (310) 859-3980
Fax: (310) 206-0589
Lab: (310) 825-9930

TRAINING:

Degree of B.S., Pharmacy, 1962
Columbia University, New York
Degree of Ph.D., Pharmacology, major - Physiology, minor, 1966
University of Minnesota, Minneapolis, Minnesota
Postdoctoral Fellowship, Chemical Pharmacology, 1968
N.H.I., N.I.H.

POSITIONS:

Jerome J. Belzer, MD, Distinguished Professor of Pharmacology, Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California 90095	11/97 - present
Professor, Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California 90095	11/93 - 09/97
Professor of Pharmacology and Assistant Dean for Student Research, UCLA School of Medicine, Los Angeles, California 90024	11/90 - 10/93
Professor and Acting Chairman, Department of Pharmacology, UCLA School of Medicine, Los Angeles, California 90024	07/89 - 06/90
Professor, Department of Pharmacology, UCLA School of Medicine, Los Angeles, California 90024	06/85 - present
Professor, Department of Pharmacology, Tulane University School of Medicine, New Orleans, LA 70112	01/79 - 05/85
Associate Professor, Department of Pharmacology, Tulane University School of Medicine, New Orleans, LA 70112	09/73 - 12/78
Assistant Professor, Department of Pharmacology, Tulane University School of Medicine, New Orleans, LA 70112	01/73 - 08/73
Staff Scientist, Research Department, Pharmaceutical Division CIBA-GEIGY Corporation, Ardsley, N.Y.	1968 - 1972

CURRENT RESEARCH INTERESTS:

- I. Bioregulation of cyclic GMP and cyclic AMP biosynthesis in mammalian tissues.
- II. Purification, properties, and regulation of soluble guanylate cyclase.
- III. Role of cyclic GMP in vascular smooth muscle relaxation and inhibition of platelet function by nitrovasodilators and EDRF or nitric oxide.
- IV. Biosynthesis and metabolism of endogenous nitric oxide in mammalian cells.
- V. Role of endogenous nitric oxide in mediating penile erection.
- VI. Role of nitric oxide, superoxide anion and peroxynitrite anion in mediating ischemic reperfusion tissue injury.
- VII. Role of nitric oxide in mediating cytotoxicity by activated macrophages.
- VII. Regulation of high output production of nitric oxide.
- VIII. Induction and regulation of arginase and arginine levels.
- IX. Role of arginase and its regulation in cell proliferation.
- X. S-Nitrosylation reactions involving nitric oxide in physiology.
- XI. Regulation of arginase expression in vascular smooth muscle cells.
- XII. Role of nitric oxide in exercise-induced protection against atherosclerosis.

RESEARCH INTERESTS DURING POSTDOCTORAL FELLOWSHIP:

1966 – 1968 National Institutes of Health Postdoctoral Fellow
 Laboratory of Chemical Pharmacology
 National Heart Institute, Bethesda, Maryland
 Research Director: Dr. Elwood O. Titus

1. Isolated mouse splenic smooth muscle; potential usefulness as a pharmacological model for contractile and relaxant drugs.
2. Adrenergic drug-receptor interactions.
3. Biochemical nature of the adrenergic α -receptor: Covalent binding of tritium-labeled alkylating agent N,N-dimethyl-2-bromo-p-methyl phenethylamine HBr (L-35-H³), to α receptors and to sympathetic nerve endings.

RESEARCH IN GRADUATE SCHOOL:

1962 – 1966 U.S.P.H.S. Predoctoral Fellow in Pharmacology
 University of Minnesota, Minneapolis, Minnesota
 Research Director: F. E. Shideman, Ph.D., M.D.

THESIS TITLE: Catecholamines and the Enzymes Involved in Their Synthesis and Metabolism in the Embryonic and Developing Chick

Part I. Catechol-O-Methyl Transferase and Monoamine Oxidase Activities in the Heart of the Embryonic and Developing Chick.

- Part II. Dopa, Dopamine, Norepinephrine and Epinephrine Concentrations in the Heart of the Embryonic and Developing Chick.
- Part III. Uptake and Subcellular Distribution of Catecholamines by the Embryonic Heart and Whole Embryo of the Chick.
- Part IV. Sequence of Appearance of the Catecholamine Biosynthesizing Enzymes in the Developing Chick Embryo.

SOCIETY MEMBERSHIPS:

American Society for Pharmacology and Experimental Therapeutics
American Society for Biochemistry and Molecular Biology
American Physiological Society
American Society for Cell Biology
American Rheumatism Association
American Society of Hematology
 Society for Experimental Biology and Medicine
 American Heart Association (Councils: Basic Sci; Cardiopul & Crit Care; Circulation)
 American Federation for Clinical Research
 Society of the Sigma Xi
Rho Chi Pharmaceutical Honor Society
 Research Society of America
 American Association for the Advancement of Science
 New York Academy of Sciences
 Golden Key National Honor Society
National Academy of Sciences
American Academy of Arts and Sciences
American Philosophical Society

NATIONAL COMMITTEES/ORGANIZATIONS:

Pharmacology Study Section (N.I.H.), 1981 - 1985
 Experimental Cardiovascular Sciences Study Section (N.I.H.), 2001

JOURNAL EDITORIAL SERVICES:

J. Pharmacol. Exp. Ther.; Biochem. Pharmacol.; Molec. Pharmacol.; Metabolism; J. Cyclic Nucleotide Res.; Can. J. Physiol. Pharmacol.; Science; J. Biol. Chem.; Circ. Res.; Am. J. Physiol.; Hypertension; Eur. J. Pharmacol.; Nature

Member of editorial board: Biochem. Pharmacol.; Circ. Res.; Arch. Biochem. Biophys.

Founder and Editor-in-Chief: *NITRIC OXIDE* Biology and Chemistry (Academic Press).

Editor: Proceedings of the National Academy of Sciences

AWARDS:

U.S.P.H.S. CAREER DEVELOPMENT AWARD	1975 - 1980
Pharmaceutical Manufacturers Association Foundation Research Award	1973
Tulane University School of Medicine Faculty Development Award	1973
Edward G. Schlieder Foundation Award	1973 - 1976
Arthritis Foundation Research Award	1975 - 1977
Merck Research Award	1974
Research Fellow of the Arthritis Foundation (Louisiana Chapter)	1975
First recipient of the George Clark Memorial Arthritis Fund	1975

First recipient of the James Woodrow Waggoner Arthritis Fund	1976
Edward G. Schlieder Foundation Grant Award	1978 - 1981
Smith, Kline & French Research Award	1977
Lilly Research Award	1978
Merck Research Award	1978
American Men and Women of Science	
Tulane Medical School - Outstanding Teacher Award	1983
UCLA School of Medicine - Outstanding Teacher Award	1986
1987 AMSA Golden Apple Award (for teaching) - UCLA School of Medicine	
1988 AMSA Golden Apple Award (for teaching) - UCLA School of Medicine	
1989 AMSA Golden Apple Award (for teaching) - UCLA School of Medicine	
1990 AMSA Golden Apple Award (for teaching) - UCLA School of Medicine	
Alpha Omega Alpha - Honorary Member - elected in 1990	
1991 AMSA Golden Apple Award (for teaching) - UCLA School of Medicine	
1993 AMSA Golden Apple Award (for teaching) - UCLA School of Medicine	
1993 UCLA School of Medicine <i>Award for Excellence in Education</i>	
1994 AMSA Golden Apple Award (for teaching) - UCLA School of Medicine	
1995 AMSA Golden Apple Award (for teaching) - UCLA School of Medicine	
Wellcome Visiting Professor - Marshall University School of Medicine	1995
1997 AMSA Golden Apple Award (for teaching) - UCLA School of Medicine	
1998 AMSA Golden Apple Award (for teaching) - UCLA School of Medicine	
1999 AMSA Golden Apple Award (for teaching) - UCLA School of Medicine	

SPECIAL AWARDS:

ROUSSEL UCLAF PRIZE - 1994 - for Cell Communication and Signaling in recognition of the discovery that "*Nitric Oxide (NO), a Radical Gas, is a Biological Mediator in Mammals*". Shared with Dr. Salvador Moncada and Dr. Robert Furchgott.

CIBA AWARD FOR HYPERTENSION RESEARCH - 1995 - for Discovery of the Roles of Nitric Oxide and Cyclic GMP in Vascular Function. Shared with Dr. Salvador Moncada.

BASIC RESEARCH PRIZE of the American Heart Association - 1998 - in recognition of outstanding contributions to the advancement of cardiovascular science.

NOBEL PRIZE IN PHYSIOLOGY OR MEDICINE - 1998 - for “nitric oxide as a signaling molecule in the cardiovascular system”. Shared with Robert Furchgott and Ferid Murad.

National Academy of Sciences - elected in **1999**

American Academy of Arts and Sciences - elected in **1999**

Institute of Medicine - elected in **2002**

American Philosophical Society - elected in **2007**

HONORARY DOCTORATE DEGREES:

University of Buenos Aires School of Medicine - Republic of Argentina, 1996
 University of Napoli School of Medicine I - Italy, 1999
 University of Napoli School of Medicine II - Italy, 1999
 University of the Republic - Montevideo, Uruguay, 1999
 UniNorte School of Medicine - Asuncion, Paraguay, 2000
 Charles University School of Medicine - Prague, Czech Republic, 2000
 University of Bologna School of Medicine - Italy, 2000
 Tulane University - New Orleans, LA, 2001
 University of Minnesota - Minneapolis, MN, 2002

University of Athens - Greece, 2002
 University of Perugia - Italy, 2004
 Medical University of Warsaw – Poland, 2006
RESEARCH RELATED ACTIVITIES:

Founder and President of Board of Directors of the new professional society: **NITRIC OXIDE Society** incorporated 1996

Founder and Editor-In-Chief of the new scientific journal: ***NITRIC OXIDE Biology and Chemistry*** Academic Press ,1996

TEXTBOOK EDITOR:

Nitric Oxide - Biology and Pathobiology Edited by Louis J. Ignarro. Over 1,000 pages and 58 chapters. Academic Press, San Diego, 2000.

FEDERALLY FUNDED GRANT SUPPORT (since 1981):

1. U.S.P.H.S., N.I.H., NIAMDD (1981 - 1984) P/I “Role of Cyclic GMP in Cellular Function” (\$215,500).
2. U.S.P.H.S., N.I.H., NHLBI (1982 - 1985) P/I “Role of Cyclic GMP in Vascular Smooth Muscle Relaxation” (\$205,750).
3. U.S.P.H.S., N.I.H., NIAMDD (1984 - 1987) P/I “Regulation of Cyclic GMP Metabolism by Porphyrins and Metalloporphyrins” (approx. \$260,550).
4. U.S.P.H.S., N.I.H., NHLBI (1985 - 1990) P/I “Mechanisms of Action of Vasodilator Drugs” (\$844,512).
5. U.S.P.H.S., N.I.H., NHLBI (1990 - 1995) P/I “Pharmacodynamics of Endothelium-Derived Nitric Oxide” (\$1,240,140).
6. U.S.P.H.S., N.I.H., NHLBI (1991 - 1995) P/I “Regulation of Nitric Oxide Formation in Vascular Tissue” (\$649,775).
7. U.S.P.H.S., N.I.H., NICHD (1989 - 1992) Co-P/I “EDRF and Prostacyclin in Human Umbilical Vessels” (\$461,773).
8. U.S.P.H.S., N.I.H., NICHD (1992 - 1995) Co-P/I “EDNO and Uterine Blood Flow in Pregnancy” (\$480,137).
9. U.S.P.H.S., N.I.H., NICHD (1994) P/I “Biochemistry and Molecular Biology of Nitric Oxide” (International Conference) (\$15,000).
10. U.S.P.H.S., N.I.H., NHLBI (1995 – 2000) P/I “Regulation of Activity and Expression of NO Synthase” (\$1,366,235).
11. U.S.P.H.S., N.I.H., NHLBI (1997 - 2002) P/I “Regulation of Nitric Oxide Formation in Vascular Tissue” (\$1,476,128).
12. U.S.P.H.S., N.I.H., NICHD (1997 - 2002) Co-P/I “EDNO and Uterine Blood Flow in Pregnancy” (\$865,150).
13. U.S.P.H.S., N.I.H., NHLBI (1997 - 2000) Co-P/I “Physiological Role of N-Hydroxyarginine” (\$595,000).

14. U.S.P.H.S., N.I.H., NHLBI (1999 - 2002) P/I "Role of NO Synthase in Cell Proliferation" (\$650,000).
15. U.S.P.H.S., N.I.H., NHLBI (1999 - 2003) P/I "Regulation of Expression of NO Synthase" (\$950,000).
16. U.S.P.H.S., N.I.H., NHLBI (1999 - 2002) P/I "Cytostatic Role of the Arginine-Nitric Oxide Pathway" (\$585,000).
17. U.S.P.H.S., N.I.H., NHLBI (2001 - 2005) P/I "Arginase and Nitric Oxide in Atherosclerosis" (\$1,065,000).

PUBLICATIONS

ABSTRACTS:

1. Louis J. Ignarro and F.E. Shideman. Catechol-O-methyl transferase (COMT) and monoamine oxidase (MAO) activities in the heart of the developing chick embryo. Fed. Proc. **24**:388, 1965.
2. Louis J. Ignarro and F.E. Shideman. Norepinephrine (NE) and epinephrine (E) concentrations in the heart of the embryonic and developing chick. The Pharmacologist **7**:184, 1965.
3. Louis J. Ignarro and F.E. Shideman. Dopa and dopamine concentrations in the heart of the embryonic and developing chick. Fed. Proc. **25**:383, 1966.
4. Louis J. Ignarro. The presence of alpha and beta-adrenergic receptors in the spleen of the mouse. Fed. Proc. **26**:401, 1967.
5. Louis J. Ignarro and Elwood O. Titus. Existence of an alpha-adrenergic receptor reserve in the spleen of the mouse. The Pharmacologist **9**:234, 1967.
6. Louis J. Ignarro. Lysosome membrane stabilization: An effect apparently selective for anti-inflammatory drugs. Fed. Proc. **29**:784, 1970.
7. Louis J. Ignarro and Joseph Slywka. Changes in lysosome and erythrocyte membrane stability and both local and systemic lysosomal enzyme levels in adjuvant-induced polyarthritis. The Pharmacologist **12**:202, 1970.
8. Louis J. Ignarro. Lysosome membrane stabilization in vivo: Effects of steroidal and non-steroidal anti-inflammatory drugs. The Pharmacologist **13**, 1971.
9. Louis J. Ignarro, Natalie Krassikoff and Joseph Slywka. Inhibition of lysosomal enzyme release by catecholamines, histamine, serotonin and adenosine-5'-triphosphate (ATP): possible mediation by cyclic 3',5'-adenosine monophosphate (cAMP). Fed. Proc. **31**:281, 1972.
10. Louis J. Ignarro and Jeffrey Winters. Effect of drugs on filipin-induced acute inflammation in the rat. The Pharmacologist **14**, 1972.
11. Arnold L. Oronsky, Robert J. Perper and Louis J. Ignarro. Use of canine asthma for detection of clinically active anti-asthmatic agents. The Pharmacologist **14**, 1972.
12. Carmelo Colombo, Louis J. Ignarro and Jerome J. Chart. Enzyme release from polymorphonuclear leukocyte (PMN) lysosomes: Inhibition by catecholamines and cyclic AMP, acceleration by cholinergic agents and cyclic GMP. Fed. Proc. **32**, April 1973.
13. Arnold L. Oronsky, Louis J. Ignarro and Robert J. Perper. An in vitro model for estimating chondromucoprotein degradation by human polymorphonuclear leukocytes utilizing ³⁵S-labelled cartilage. Fed. Proc. **32**, April 1973.
14. Louis J. Ignarro, Arnold L. Oronsky and Robert J. Perper. Release of cartilage mucopolysaccharide-degrading neutral protease from human leukocytes in the presence of aggregated gamma globulin. Fed. Proc. **32**, April, 1973.
15. Louis J. Ignarro. Phagocytic release of neutral protease from human leukocytes: Acceleration by acetylcholine and cyclic GMP, inhibition by norepinephrine and cyclic AMP. Pharmacologist **15**, Fall, 1973.

16. William J. George, Richard J. Paddock and Louis J. Ignarro. Cyclic GMP and cyclic AMP levels in human neutrophils during lysosomal enzyme release: Elevation of cyclic GMP by acetylcholine and of cyclic AMP by epinephrine. Pharmacologist **15**, Fall, 1973.
17. L.E. White, L.J. Ignarro and W.J. George. Stimulation of rat cardiac guanyl cyclase by acetylcholine. Pharmacologist **15**, Fall, 1973.
18. Robert J. Smith, Louis J. Ignarro and James W. Fisher. Lysosomal Membrane Labilization: A possible role for cobalt in erythropoietin production. Pharmacologist **15**, Fall 1973.
19. Robert J. Smith, Louis J. Ignarro and James W. Fisher. Cobalt and Erythropoiesis: Effects of cobalt and other metals on subcellular organelles in the light mitochondrial fraction (LMF) of rat kidney. Meeting of the American Society of Hematology, December 1973.
20. Louis J. Ignarro, LuAnn E. White, Robert D. Wilkerson and William J. George. Cardiac guanyl cyclase: Stimulation by acetylcholine and calcium. Circulation **48**:43, 1973.
21. Louis J. Ignarro, Stella Y. Monday and William J. George. Hormonal control of lysosomal enzyme release from human neutrophils: Elevation of cyclic 3'.5'-guanosine monophosphate during cell contact with immune reactants. Fed. Proc. **33**, April 1974.
22. William J. George, LuAnn E. White, Richard J. Paddock and Louis J. Ignarro. Effects of autonomic agents on contractile force and tissue levels of cyclic GMP and cyclic AMP in isolated rabbit atria. Fed. Proc. **33**:344, April 1974.
23. Louis J. Ignarro, Stella Y. Cech and William J. George. Mediation of lysosomal enzyme secretion from human neutrophils by cyclic GMP: Requirement of calcium, and inhibition by cyclic AMP. Pharmacologist **16**, Fall 1974.
24. Robert J. Smith and Louis J. Ignarro. Stimulation-Secretion coupling in human neutrophils: Link between calcium influx and cyclic GMP accumulation in lysosomal enzyme secretion. Pharmacologist **16**, Fall 1974.
25. Louis J. Ignarro and William J. George. Hormonal control of lysosomal enzyme release from human neutrophils by autonomic neurohormones and cyclic nucleotides. Clin. Res. **22**:68A, 1974.
26. Richard J. Paddock, Robert D. Wilkerson, Louis J. Ignarro and William J. George. Effects of derivatives of cyclic GMP and cyclic AMP on contractile force of cat papillary muscle. Clin. Res. **22**, Abs., 1974.
27. LuAnn White, Louis J. Ignarro and William J. George. Kinetic effects of acetylcholine on cardiac guanyl cyclase. Clin. Res. **22**:57A, 1974.
28. Louis J. Ignarro, Stella Y. Cech and William J. George. Inhibition of cyclic GMP accumulation in, and lysosomal enzyme secretion from, human neutrophils by glucocorticosteroids. Fed. Proc. **34**:231, 1975.
29. R.W. Busuttil, L.J. Ignarro, H.C. Shirkey and W.J. George. Improved recovery of the anoxic heart with methylprednisolone: A mechanism involving lysosomal enzyme release by cyclic nucleotides. Fed. Proc. **34**:265, 1975.
30. Louis J. Ignarro and Stella Y. Cech. Inhibition of neutrophil-mediated cartilage degradation by prostaglandins and glucocorticosteroids. Arthritis Rheum. **18**:406A, 1975.

31. Darlene Yao, Rosemarie Gross, Sahba Abdi and Louis J. Ignarro. Subcellular localization of guanylate cyclase in rat lung: Technical problems associated with the use of manganese and theophylline. Pharmacologist 17:269, 1975.
32. Rosemarie Gross, Sahba Abdi, Darlene Yao and Louis J. Ignarro. Guanylate cyclase in soluble fraction of rat lung: Stimulation by acetylcholine, pilocarpine, serotonin, histamine and bradykinin: inhibition by epinephrine and isoproterenol. Pharmacologist 17:269, 1975.
33. Louis J. Ignarro and William J. George. Guanylate cyclase activity in purified human polymorphonuclear leukocytes. Pharmacologist 17:270, 1975.
34. W.J. George, R.W. Busuttil and L.J. Ignarro. Reduction of myocardial cyclic GMP content as a possible mechanism for protection of the hypoxic heart by methylprednisolone (MP). Pharmacologist 17:269, 1975.
35. Louis J. Ignarro and Stella Y. Cech. Inhibition of human neutrophil-mediated cartilage degradation by methylprednisolone. Clin. Res. 24:17A, 1976.
36. Louis J. Ignarro, Rosemarie A. Gross and Dennis M. Gross. Inhibition of mammalian soluble guanylate cyclase activity by adenosine 5'-tetraphosphate and guanosine 5'-tetraphosphate. Pharmacologist 18:221, 1976.
37. Stella Y. Cech, Rosemarie A. Gross and Louis J. Ignarro. Cytidylate cyclase (CC) activity and the formation of cyclic 3',5'-cytidine monophosphate (cCMP) in mouse liver, spleen and myeloid leukemic tumors. Pharmacologist 18:223, 1976.
38. Stella Y. Cech, Rosemarie A. Gross and Louis J. Ignarro. Cytidylate cyclase (CC) activity and the possible formation of cyclic 3',5'-cytidine monophosphate (cCMP) in the mouse liver. Clin. Res. 25:11A, 1977.
39. Stella Y. Cech and Louis J. Ignarro. Cytidine 3',5'-monophosphate (cCMP) synthesis in vitro by mouse liver homogenates. Pharmacologist 19:202, 1977.
40. Stella Y. Cech and Louis J. Ignarro. Formation of a new cyclic nucleotide-- cytidine 3',5'-monophosphate (cyclic CMP)--by mammalian tissues. Clinical Res. 26:31, 1978.
41. Darlene Yao Gruetter and Louis J. Ignarro. Activation of guanylate cyclase from guinea pig lung by arachidonic acid and prostaglandins. Clinical Res. 26:32, 1978.
42. Louis J. Ignarro and Rosemarie A. Gross. Somatostatin inhibition of glucagon- activated liver adenylate cyclase and cyclic AMP formation. Clinical Res. 26:33, 1978.
43. Louis J. Ignarro and Rosemarie A. Gross. Somatostatin inhibition of glucagon- activated liver adenylate cyclase and cyclic AMP formation: An effect specific for glucagon. Fed. Proc. 37:339, 1978.
44. Stella Y. Cech and Louis J. Ignarro. Cyclic CMP (cytidine 3',5'-monophosphate) formation from CTP by cytidylate cyclase in the mammalian species. Fed. Proc. 37:390, 1978.
45. D.Y. Gruetter, A.L. Hyman, P.J. Kadowitz and L.J. Ignarro. Stimulation of lung guanylate cyclase and cyclic 3',5'-guanosine monophosphate formation by lipoxidase, phospholipase A-2 and arachidonate. Clinical Res. 26:756A, 1978.

46. E. Ohlstein, D.B. McNamara, C.A. Gruetter and L.J. Ignarro. Guanylate cyclase activation by nitroprusside and methyl-nitro-nitrosoguanidine: Differences in mechanism and similarities in vascular smooth muscle relaxation. Clinical Res. 26:757A, 1978.
47. J. Rothman and L.J. Ignarro. Effect of anti-insulin on pancreatic somatostatin release. Clinical Res. 26:775A, 1978.
48. C.A. Gruetter, B.K. Barry, D.B. McNamara, P.J. Kadowitz and L.J. Ignarro. Nitric oxide, cigarette smoke and nitrosoamines relax coronary artery and activate soluble guanylate cyclase. Fed. Proc. 38: 432, 1979.
49. E.H. Ohlstein, D.Y. Gruetter and L.J. Ignarro. Methemoglobin blockade of guanylate cyclase activation by nitroso compounds: reversal by sulfhydryl agents: dithiothreitol enhances release of nitric oxide from nitroso compounds. Fed. Proc. 38:432, 1979.
50. D.Y. Gruetter, P.J. Kadowitz and L.J. Ignarro. Arachidonic acid activates guanylate cyclase by two independent mechanisms: involvement of the cyclooxygenase and lipoxygenase pathways. Fed. Proc. 38:432, 1979.
51. B.K. Barry, D.Y. Gruetter, E.H. Ohlstein and L.J. Ignarro. Activation of coronary arterial soluble guanylate cyclase by nitroprusside (NP), nitric oxide (NO) and compounds which form NO: enhancement and inhibition of activation with reductants and oxidized heme, respectively. Pharmacologist 21:252, 1979.
52. D.B. McNamara, P.J. Kadowitz and L.J. Ignarro. Cyclic AMP formation from ATP by guanylate cyclase activated with nitric oxide (NO), nitroprusside (NP) and nitrosoguanidine (MNNG): enhancement by dithiothreitol and inhibition by heme proteins and oxidants. Pharmacologist 21:252, 1979.
53. E.H. Ohlstein, B.K. Barry, D.Y. Gruetter, C.A. Gruetter and L.J. Ignarro. Activation of hepatic and coronary arterial soluble guanylate cyclase by nitric oxide (NO), nitroprusside (NP) and nitrosoguanidine (MNNG): differences in enhancement with reductants and inhibition with heme proteins. Pharmacologist 21:252, 1979.
54. D.Y. Gruetter, B.K. Barry, A.L. Hyman, P.J. Kadowitz and L.J. Ignarro. Calcium and arachidonic acid inhibit activation of Mg-dependent soluble guanylate cyclase from coronary artery by nitric oxide (NO), nitroprusside (NP) and nitrosoguanidine (MNNG). Pharmacologist 21:246, 1979.
55. C.A. Gruetter, D.Y. Gruetter, B.K. Barry, P.J. Kadowitz and L.J. Ignarro. Studies on the mechanism by which reductants enhance activation of guanylate cyclase by nitroprusside, nitrite and nitrosoguanidine. Pharmacologist 21:247, 1979.
56. B. Theo Mellion, Eliot H. Ohlstein, Albert L. Hyman, Louis J. Ignarro and Philip J. Kadowitz. Inhibition of platelet aggregation by nitric oxide, tobacco smoke and nitroso compounds which activate platelet soluble guanylate cyclase. Pharmacologist 21:247, 1979.
57. L.J. Ignarro, B.K. Barry, D.Y. Gruetter, C.A. Gruetter, E.H. Ohlstein and W.H. Baricos. Guanylate cyclase activation by nitric oxide complexes of heme and nonheme iron electron transfer proteins and S-nitrosothiols: Reduction as a mechanism of enzyme activation. Fed. Proc. 39:743, 1980.

58. C.A. Gruetter, B.K. Barry, D.Y. Gruetter, P.J. Kadowitz and L.J. Ignarro. Possible involvement of S-nitrosothiol intermediates in the mechanism of guanylate cyclase activation and relaxation in bovine coronary arterial smooth muscle by glyceryl trinitrate and NaNO₂. Fed. Proc. **39**:743, 1980.
59. S.A. Napoli, C.A. Gruetter, L.J. Ignarro and P.J. Kadowitz. Relaxation of bovine coronary arterial smooth muscle by cyclic GMP, cyclic AMP and analogs. Fed. Proc. **39**:742, 1980.
60. L.J. Ignarro, E.H. Ohlstein, P.J. Kadowitz and W.H. Baricos. Regulation of guanylate cyclase activation by cysteine and S-nitrosocysteine: Reduced form of guanylate cyclase represents the catalytically active state. Fed. Proc. **40**:688, 1981.
61. B.T. Mellion, L.J. Ignarro, A.L. Hyman and P.J. Kadowitz. S-Nitrosothiols elevate cyclic GMP levels and inhibit aggregation of human platelets. Fed. Proc. **40**:688, 1981.
62. C.A. Gruetter, D.Y. Gruetter, P.J. Kadowitz and L.J. Ignarro. Evidence that cyclic GMP formation may mediate vascular smooth muscle relaxation induced by nitrates, nitrites, nitroso compounds and S-nitrosothiols. Fed. Proc. **40**:688, 1981.
63. L.J. Ignarro, B.K. Barry and C.A. Gruetter. Mechanism by which glyceryl trinitrate and sodium nitrite activate coronary arterial guanylate cyclase: Involvement of novel S-nitrosothiols as active intermediates. Clin. Res. **27**:728, 1979.
64. C.B. Myers, B.T. Mellion, E. Pontecorvo, A.L. Hyman, L.J. Ignarro and P.J. Kadowitz. Inhibition of aggregation and the formation of cyclic GMP in human platelets. Clin. Res. **28**:825, 1980.
65. L.J. Ignarro, C.A. Gruetter, A.L. Hyman and P.J. Kadowitz. Requirement of thiols for activation of purified coronary arterial guanylate cyclase by nitrogen oxide-containing vasodilators. Fed. Proc. **40**:1793, 1981.
66. L.J. Ignarro, H.L. Lipton, J.C. Edwards, A.L. Hyman, P.J. Kadowitz and C.A. Gruetter. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites and nitroprusside: formation of potent, unstable, S-nitrosothiol metabolites. Pharmacologist **23**:187, 1981.
67. L.J. Ignarro, K.S. Wood and M.S. Wolin. Activation of purified guanylate cyclase by protoporphyrin IX: comparison of heme-deficient and heme-containing forms of soluble enzyme purified from bovine lung. Fed. Proc. **41**:1470, 1982.
68. M.S. Wolin, K.S. Wood and L.J. Ignarro. A kinetic characterization of the regulation of purified soluble guanylate cyclase isolated from bovine lung by protoporphyrin IX, hematin and free metal (Mg²⁺ and Mn²⁺). Fed. Proc. **41**:1470, 1982.
69. E.H. Ohlstein, K.S. Wood and L.J. Ignarro. Purified heme-deficient hepatic soluble guanylate cyclase requires heme for activation by NO: restoration of responsiveness by reconstitution of enzyme with heme. Fed. Proc. **41**:1470, 1982.
70. B.T. Mellion, P.M. Horwitz, L.J. Ignarro and P.J. Kadowitz. Cyclic AMP and cyclic GMP act synergistically to inhibit human platelet aggregation. Fed. Proc. **41**:1304, 1982.
71. J.C. Edwards, P.J. Kadowitz and L.J. Ignarro. Relaxation of bovine intrapulmonary arteries and veins by cyclic GMP and agents which elevate vascular levels of cyclic GMP. Fed. Proc. **41**:1234, 1982.

72. L.J. Ignarro, C.A. Gruetter, H. Lipton, J.C. Edwards, A.L. Hyman and P.J. Kadowitz. Mechanism of vascular smooth muscle relaxation by nitrogen oxide-containing vasodilators: Involvement of S-nitrosothiols and cyclic GMP. J. Mol. Cell. Cardiol. 14(1):40, 1982.
73. M.S. Wolin, K.S. Wood, B. Ballot and L.J. Ignarro. Porphyrin modulation of guanylate cyclase activity: A study on structure-activity relationships. Fed. Proc. 42:1366, 1983.
74. L.J. Ignarro, K.S. Wood, B. Ballot and M.S. Wolin. Mechanism of activation of purified soluble guanylate cyclase by phenylhydrazine: Formation of active hemoprotein-phenyl complexes. Fed. Proc. 42:1366, 1983.
75. M.S. Wolin and L.J. Ignarro. Activation of purified soluble guanylate cyclase by arachidonic acid and catalase: Evidence for two separate mechanisms. Fed. Proc. 42:1853, 1983.
76. L.J. Ignarro, T. Burke, K.S. Wood and P.J. Kadowitz. Association between cyclic GMP accumulation and acetylcholine-elicited relaxation of bovine intrapulmonary artery. Circulation 68:III-323, 1983.
77. K.S. Wood and L.J. Ignarro. Influence of several classes of guanylate cyclase activator on hepatic levels of cyclic GMP. Effect of various inhibitors. Fed. Proc. 43:451, 1984.
78. L.J. Ignarro, R. Harbison, T. Burke, M. Wolin and P.J. Kadowitz. Endothelium-dependent relaxation of bovine intrapulmonary artery by arachidonic acid. Involvement of two distinct mechanisms. Fed. Proc. 43:737, 1984.
79. J.M. Grazer, P.M. Horwitz, D.B. McNamara, L.J. Ignarro, H.L. Lipton and P.J. Kadowitz. Effects of amrinone on platelet aggregation and cyclic nucleotide levels. Fed. Proc. 43:980, 1984.
80. H.L. Lipton, L.J. Ignarro, W.M. Armstead, A.L. Hyman and P.J. Kadowitz. Comparison of the vascular activity of SNAP, a nitric oxide-containing substance, to nitroglycerin. Fed. Proc. 43:1101, 1984.
81. L.J. Ignarro, R. Harbison, K.S. Wood and J.J. Kadowitz. Involvement of both cyclic GMP and cyclic AMP in endothelium-dependent relaxation of bovine intrapulmonary artery by arachidonic acid. Circulation 70:II-121, 1984.
82. R.G. Harbison, K.S. Wood, A.L. Hyman, P.J. Kadowitz and L.J. Ignarro. Endothelium-dependent and independent regulation of cyclic GMP formation and relaxation of intrapulmonary artery by peptides. Fed. Proc. 44:1235, 1985.
83. L.J. Ignarro, R.G. Harbison, K.S. Wood and P.J. Kadowitz. Role of endothelium-derived relaxing factor (EDRF) in regulation of vascular smooth muscle cyclic GMP levels and tone: properties of the guanylate cyclase inhibitor methylene blue. Fed. Proc. 44:1235, 1985.
84. P.R. Mayeux, L.J. Ignarro, A.L. Hyman, P.J. Kadowitz and D.B. McNamara. Bovine coronary arterial prostacyclin synthetase (PGI₂ase): effect of nitroglycerin (GTN) and sodium nitroprusside (SNP). Fed. Proc. 44:1469, 1985.
85. P.M. Horwitz, J.B. Adams, K.S. Wood and L.J. Ignarro. Guanylate cyclase activation by nitrosyl-hemoproteins involves exchange of NO-HEME between hemoproteins and heme-deficient soluble guanylate cyclase. Fed. Proc. 44:1817, 1985.

86. L.J. Ignarro, A.L. Hyman and P.J. Kadowitz. Role of vascular endothelium in regulation of cyclic nucleotide metabolism and tone. The 50th Hungarian Physiological Society. P. 309, 1985.
87. L.J. Ignarro, K.S. Wood, R.G. Harbison and P.J. Kadowitz. Endothelium-dependent regulation of arterial and venous tone and activation of soluble guanylate cyclase. Circulation 72:III-266, 1985.
88. L.J. Ignarro, K.S. Wood, R.G. Harbison and P.J. Kadowitz. Activation of purified lung soluble guanylate cyclase by endothelium-derived relaxing factor released from intrapulmonary artery and vein. Blood Vessels 23:78, 1986.
89. L.J. Ignarro, R.E. Byrns and K.S. Wood. Pharmacological and biochemical properties of endothelium-derived relaxing factor (EDRF): Evidence that EDRF is closely related to nitric oxide (NO) radical. Circulation 74:II-287, 1986.
90. L.J. Ignarro, R.E. Byrns, G.M. Buga and K.S. Wood. Endothelium-derived relaxing factor (EDRF) released from artery and vein appears to be nitric oxide (NO) or a closely related radical species. Fed. Proc. 46:640, 1987.
91. L.J. Ignarro, G.M. Buga, R.E. Byrns, K.S. Wood and G. Chaudhuri. Pharmacological, biochemical and chemical characterization of arterial and venous EDRF as nitric oxide. Circulation 76:IV-51, 1987.
92. K.S. Wood, R.E. Byrns, G. Chaudhuri, M.E. Gold, G. Frank and L.J. Ignarro. Polypeptides containing basic L-amino acids cause endothelium-dependent arterial and venous smooth muscle relaxation, cyclic GMP formation, and tolerance to relaxation by endothelium-dependent vasodilators. FASEB J. 2:A710, 1988.
93. R.E. Byrns, K.S. Wood and L.J. Ignarro. Inhibition of endothelium-dependent but not independent relaxation of artery and vein by agents that alter oxidative phosphorylation and intracellular K⁺ and H⁺. FASEB J. 2:A518, 1988.
94. G. Chaudhuri, G.M. Buga, M.E. Gold and L.J. Ignarro. Properties of endothelium-derived relaxing factor (EDRF) released from perfused human umbilical vein (HUV) are indistinguishable from those of nitric oxide (NO). FASEB J. 2:A314, 1988.
95. M.E. Gold, G.M. Buga, R.E. Byrns, K.S. Wood and L.J. Ignarro. Extracellular magnesium (Mg) depletion enhances vascular EDRF and endothelium (E)-dependent cyclic GMP formation, whereas Mg repletion causes E- and cyclic GMP-independent relaxation. FASEB J. 2:A710, 1988.
96. G.M. Buga, G. Chaudhuri and L.J. Ignarro. Formation and properties of endothelium-derived relaxing factor (EDRF) from perfused pulmonary artery and vein are indistinguishable from one another or from nitric oxide (NO) as assessed by bioassay. FASEB J. 2:A314, 1988.
97. G. Chaudhuri, G. Buga and L.J. Ignarro. Pharmacological similarity between umbilical vein endothelium-derived relaxing factor (EDRF) and nitric oxide (NO). Soc. Gyn. Invest. 35:191, 1988.
98. M.E. Gold, G.M. Buga, R.E. Byrns, K.S. Wood and L.J. Ignarro. Modulatory role of magnesium and calcium on vascular smooth muscle tone by endothelium-dependent and endothelium-independent mechanisms. Pharmacologist 30:A3, 1988.

99. J. Chou, G.W. Frank and L.J. Ignarro. Comparison of endothelium-dependent cyclic GMP formation in rat pulmonary artery and artery. Circulation (Suppl. II) 78:320, 1988.
100. L.J. Ignarro, M.E. Gold, K.S. Wood, R.E. Byrns, G.M. Buga and G. Chaudhuri. Influence of arginine analogs and depletion on endothelium-dependent vascular smooth muscle relaxation. FASEB J. 3:A684, 1989.
101. L.J. Ignarro, M.E. Gold, K.S. Wood, R.E. Byrns, G.M. Buga, and G. Chaudhuri. Alteration of endothelium-dependent relaxation by arginine analogs and arginine depletion. J. Vasc. Med. Biol. 1:94, 1989.
102. M.E. Gold, G.M. Buga, K.S. Wood and L.J. Ignarro. Shear force-induced release of EDRF from bovine aortic endothelial cells grown on microcarrier beads and its inhibition by N^G-methyl-L-arginine. FASEB J. 4:A416, 1990.
103. L.J. Ignarro, M.E. Gold, K.S. Wood and J.M. Fukuto. Endothelium-dependent modulation of cyclic GMP biosynthesis by L-arginine and structural analogs of L-arginine. Arch. Int. Pharmacodyn. Ther. 305:254, 1990.
104. K.S. Wood, R.E. Byrns, J.M. Fukuto and L.J. Ignarro. Muscle-derived relaxing factor (MDRF): Endothelium-independent, nitric oxide (NO)-mediated, vascular smooth muscle relaxation caused by L-arginine and analogs. Arch. Int. Pharmacodyn. Ther. 305:295, 1990.
105. L.J. Ignarro. Heme-dependent activation of cytosolic guanylate cyclase by L-arginine-derived nitric oxide represents a novel transduction mechanism for transcellular communication. Eur. J. Pharmacol. 183:1624-1625, 1990.
106. M.E. Gold, J.M. Fukuto and L.J. Ignarro. Structural analogs of L-arginine cause endothelium-dependent and endothelium-independent, nitric oxide-mediated cyclic GMP formation and vasodilation, and cause vasoconstriction associated with decreased cyclic GMP formation. Eur. J. Pharmacol. 183:1610-1611, 1990.
107. R.W. Day, T.S. Klitzner and L.J. Ignarro. Regulation of smooth muscle protein kinase C and oxygen-mediated vasoconstriction. Pediat. Res. 27:18A, 1990.
108. R.W. Day, T.S. Klitzner and L.J. Ignarro. Hyperoxia stimulates the production or release of endothelium-derived relaxing factor in neonatal vessels. Am. J. Cardiol. 66:519, 1990.
109. G.M. Buga and L.J. Ignarro. Electrical field stimulation causes neuronally-independent but endothelium-dependent nitric oxide-cyclic GMP-mediated relaxation of bovine pulmonary artery. FASEB J. 5:A1728, 1991.
110. P.A. Bush, W. Aronson, J. Rajfer and L.J. Ignarro. Nitric oxide is responsible for nonadrenergic-noncholinergic (NANC) relaxation of corpus cavernosum leading to penile erection in rabbit and man. FASEB J. 5:A400, 1991.
111. P.A. Bush, W. Aronson, J. Rajfer and L.J. Ignarro. Relaxation of human corpus cavernosum (CC) and penile erection are mediated by the L-arginine-nitric oxide-cyclic GMP pathway. Pharmacologist 33:223, 1991.
112. W.J. Aronson, P.A. Bush, G.M. Buga, L.J. Ignarro and J. Rajfer. The mediator of human corpus cavernosum relaxation is nitric oxide. J. Urol. 145:341A, 1991.

113. W.J. Aronson, P.A. Bush, G.M. Buga, L.J. Ignarro and J. Rajfer. Nitric oxide is the mediator of human corpus cavernosum relaxation. J. Androl. Jan/Feb Suppl.:P-29, 1991.
114. S. Hibler, J. Anderson, L.J. Ignarro and U. Raj. Role of endothelium-derived nitric oxide (NO) in maintenance of basal vasomotor tone in newly born lambs. Am. Rev. Resp. Dis. 143:A404, 1991.
115. S. Hibler, J. Anderson, L.J. Ignarro and U. Raj. Role of endothelium-derived NO in the regulation of basal vasomotor tone in newly born lambs. Ped. Res. 23:302A, 1991.
116. W.W. Lai, R.W. Day, L.J. Ignarro and T.S. Klitzner. Response of aortic rings to hyperoxia and hypoxia: comparison of newborn and adult rabbits. Ped. Res. 29:20A, 1991.
117. P.A. Bush, W. Aronson, J. Rajfer and L.J. Ignarro. Nitric oxide is responsible for nonadrenergic-noncholinergic (NANC) relaxation of corpus cavernosum leading to penile erection in rabbit and man. Laverna Titus Young Investigators Forum (American heart Association) page 46, 1991.
118. P.A. Bush, G.M. Buga, W.J. Aronson, J. Rajfer and L.J. Ignarro. Nitric oxide mimics nonadrenergic noncholinergic (NANC) nerve stimulation in rabbit and human corpus cavernosum. FASEB J. 6:A1298, 1992
119. G.M. Buga and L.J. Ignarro. Role of nitric oxide in photorelaxation of pulmonary artery. FASEB J. 6:A1733. 1992
120. T. Hayashi, M. Navab, J. Fukuto, L.J. Ignarro and G. Chaudhuri. Tone related release of nitric oxide (NO) from aortic rings is increased in female rabbits. Endothelium-Derived Vasoactive Factors - 2nd International Symposium, Basel, April 22-25, 1992.
121. J.F. Pensabene, G. Chaudhuri, L.J. Ignarro and B.C. Bloor. Hypoxia induced changes in coronary vascular tone in vivo is mediated in part by nitric oxide. Endothelium-Derived Vasoactive Factors - 2nd International Symposium, Basel, April 22-25, 1992.
122. L.J. Ignarro. Mechanism of action of exogenous and endogenous nitric oxide: Heme-dependent activation of guanylate cyclase represents a unifying signal transduction mechanism. International Symposium "Smooth Muscle" - assessments of current knowledge, Fukuoka, January 29-February 1, 1992.
123. L.J. Ignarro. The role of nitric oxide in nonadrenergic-noncholinergic transmission. Nitric oxide: Implications for drug research, Philadelphia, June 1-2, 1992.
124. L.J. Ignarro. Cellular mechanisms of endothelial cell activation and vascular smooth muscle relaxation. A Century of Pediatrics in Groningen - International Symposium Pulmonary Circulatory Disorders in the Newborn, Infant and Child, Groningen, May 21-22, 1992.
125. J.M. Griscavage, M.P. Sherman and L.J. Ignarro. Inhibition of nitric oxide and superoxide formation in activated rat alveolar macrophages by serine protease and NO synthase inhibitors. FASEB J. 6:A1205, 1992.
126. M.P. Sherman, E.E. Aeberhard, C.T. Barrett and L.J. Ignarro. Cytochalasins and induction of nitric oxide synthase activity in rat alveolar macrophages. FASEB. J. 7:A243, 1993.

127. J.M. Griscavage, N.E. Rogers, M.P. Sherman and L.J. Ignarro. Negative feedback modulation of constitutive and inducible nitric oxide (NO) synthase by NO. FASEB. J. 7:A243, 1993.
128. G.M. Buga and L.J. Ignarro. Autocrine role of nitric oxide (NO) in the negative modulation of constitutive NO synthase in vascular endothelium. FASEB. J. 7:A244, 1993.
129. L.J. Ignarro, H. Sheng, G.M. Buga and F. Murad. Distribution of neuronal NO synthase in rat penis. FASEB J. 7:A257, 1993.
130. H. Sheng and L.J. Ignarro. Nitric oxide may be involved in phototransduction. FASEB J. 7:A260, 1993.
131. G.J. Chang, H.M. Honda and L.J. Ignarro. Nitric oxide oxidizes low density lipoprotein in a pH dependent manner. FASEB J. 7:A798, 1993.
132. M.P. Sherman, V.Z. Wong, E.E. Aeberhard, M.B. Gilliam and L.J. Ignarro. Nitric oxide versus superoxide anion production by pulmonary alveolar macrophages from neonatal, infant, and adult rats. Clin. Res. 41:90A, 1993.
133. M.P. Sherman, E.E. Aeberhard, V.Z. Wong and L.J. Ignarro. Dithiocarbamates inhibit expression of NO synthase in rat alveolar macrophages. Pediatr. Res. 33:158A, 1993.
134. M.P. Sherman and L.J. Ignarro. Nitric Oxide (NO) production by pulmonary alveolar macrophages (AM) from neonatal, infant, and adult rats. Pediatr. Res.
135. M.P. Sherman, G.D. Buckberg, K. Morita, K. Ihnken and L.J. Ignarro. Controlled reoxygenation on cardiopulmonary bypass (CPB) reduces nitric oxide (NO) production and oxidant injury of hypoxemic infant hearts. Pediatr. Res.
136. M.P. Sherman, G.D. Buckberg, K. Morita, K. Ihnken and L.J. Ignarro. Controlled reoxygenation on cardiopulmonary bypass reduces nitric oxide production and oxidant injury of hypoxemic infant hearts. Endothelium 1:s15, 1993.
137. L.J. Ignarro, J.M. Fukuto, J.M. Griscavage, N.E. Rogers and R.E. Byrns. Oxidation of nitric oxide in aqueous solution to nitrite but not nitrate: Comparison with enzymatically formed nitric oxide from L-arginine. Endothelium 1:s18, 1993.
138. A.J. Hobbs, J.M. Griscavage, N.E. Rogers, R.E. Byrns and L.J. Ignarro. Direct measurement of nitric oxide (NO) gas generated from L-arginine by inducible and constitutive NO synthase. Endothelium 1:s18, 1993.
139. G.M. Buga, G. Cohen, J.M. Griscavage, N.E. Rogers and L.J. Ignarro. Negative feedback regulation of NO synthase and endothelial cell function by nitric oxide. Endothelium 1:s19, 1993.
140. J.M. Griscavage, M.P. Sherman and L.J. Ignarro. Serine proteases modulate the L-arginine-nitric oxide pathway in rat alveolar macrophages. Endothelium 1:s40, 1993.
141. E.E. Aeberhard, M.P. Sherman, V.Z. Wong, J.M. Griscavage and L.J. Ignarro. Expression of NO synthase in rat alveolar macrophages is inhibited by pyrrolidine dithiocarbamate but not by FK506 or cyclosporin A. Endothelium 1:s41, 1993.
142. G. Chaudhuri, L. Nathan, L.J. Ignarro and B. Bloor. Nitric oxide (NO) and hypoxia-induced increase in coronary blood flow. Endothelium 1:s64, 1993.

143. P.J. Kadowitz, L.J. Ignarro, D.B. McNamara and T.J. McMahon. Influence of zaprinast on vascular tone and vasodilator responses in the cat pulmonary vascular bed. Endothelium 1:s72, 1993.
144. T. Hayashi, J.M. Fukuto, L.J. Ignarro and G. Chaudhuri. Gender differences in atherosclerosis formation: possible role of nitric oxide. Endothelium 1:s76, 1993.
145. D.B. McNamara, L.J. Ignarro, P.J. Kadowitz and D.L. Akers. The role of L-arginine in modulating intimal hyperplasia and acetylcholine-induced relaxation after balloon catheter-induced vascular injury. Endothelium 1:s77, 1993.
146. H. Sheng and L.J. Ignarro. Characterization of nitric oxide synthase from rat retina. 23rd Annual Meeting, Society for Neuroscience 19:116, 1993.
147. W. Radziszewski, A. Zembowicz, M. Chopra, R.J. Gryglewski, L.J. Ignarro and G. Chaudhuri. NO donors (NOD) induce efflux of cyclic GMP from human blood platelets. FASEB J. 8:A337, 1994.
148. L.J. Ignarro, J.M. Fukuto and J.M. Griscavage. Oxidation of nitric oxide (NO) in aqueous solution to nitrite but not nitrate: comparison with enzymatically formed NO from L-arginine. FASEB J. 8:A359, 1994.
149. A.J. Hobbs, J.M. Griscavage, N.E. Rogers, R.E. Byrns, J.M. Fukuto and L.J. Ignarro. Formation of free nitric oxide from L-arginine by nitric oxide synthase and enhancement of generation by superoxide dismutase. FASEB J. 8:A360, 1994.
150. J.M. Griscavage, N.E. Rogers, N.S. Arabolos, J.M. Fukuto and L.J. Ignarro. Regulation of purified neuronal nitric oxide synthase by NO. FASEB J. 8:A362, 1994.
151. E.E. Aeberhard, L.J. Ignarro and M.P. Sherman. Iron modulates nitric oxide synthase activity of rat lung macrophages. FASEB J. 8:A363, 1994.
152. S.A. Henderson, P.H. Lee, E.E. Aeberhard, L.J. Ignarro and M.P. Sherman. Nitric oxide inhibits early growth response-1 gene expression in rat lung macrophage. FASEB J. 8:A365, 1994.
153. G.A. Cohen, R.M. Fitch, D.M. Janoff, G. Chaudhuri, M.J. Zinner and L.J. Ignarro. Nitric oxide regulates endothelium-dependent vasodilator responses in the rabbit hindquarters vascular bed *in vivo*. FASEB J. 8:A532, 1994.
154. R.M. Fitch, G.A. Cohen, D. Janoff, M.J. Zinner, A.L. Hyman, H.L. Lipton and L.J. Ignarro. Adrenomedullin dilates the rabbit hindquarters vascular bed but not the mesenteric vascular bed *in vivo*. FASEB J. 8:A865, 1994.
155. M.P. Sherman, E.E. Aeberhard, S.A. Henderson, W.J. Murphy and L.J. Ignarro. Iron modulates NO synthase activity of rat lung macrophages activated with IFN- γ and LPS. Biochem. Mol. Biol. NO, UCLA Conference, July, 1994.
156. S.A. Henderson, E.E. Aeberhard, L.J. Ignarro, and M.P. Sherman. S-Nitroso-N-acetylpenicillamine reduces early growth response-1 gene expression in activated rat lung macrophages. Biochem. Mol. Biol. NO, UCLA Conference, July, 1994.
157. E.E. Aeberhard, S.A. Henderson, J.M. Griscavage, N.S. Arabolos, F.E. Castro, C.T. Barrett and L.J. Ignarro. Nonsteroidal anti-inflammatory drugs inhibit expression of the nitric oxide synthase gene in rat alveolar macrophages. J. Invest. Med. 43:Suppl. 1, 133A, 1995.

158. S.A. Henderson, E.E. Aeberhard, J.M. Griscavage, N.S. Arabolos, F.E. Castro, C.T. Barrett and L.J. Ignarro. Inducible NO synthase gene expression is inhibited by nonsteroidal anti-inflammatory drugs. FASEB J., 1995.
159. B. Mitrovic, M. Ding, H.V. Vinters, L.J. Ignarro, P.C. Medberry, J. Parkinson and J.E. Merrill. Nitric oxide as a possible mediator of multiple sclerosis. 9th International Congress of Immunology, 1995.
160. D.Drinkwater, H. Laks, A. Chung, A. Blitz, L. Ignarro and P. Chang. Preservation of endothelium-dependent vasodilation with low potassium University of Wisconsin solution. 21st Annual Meeting of the Western Thoracic Surgical Association, 1995.
161. A. Mizuno, R. Baretti, G. Buckberg, J. Vinten-Johansen, H. Young and L. Ignarro. Endothelial stunning and myocyte recovery after reperfusion of jeopardized muscle: A role of L-arginine blood cardioplegia. The American Association for Thoracic Surgery, 1996.
162. J. Merrill, L. Ignarro, H. Halks-Miller, V. DelVecchio, P. Medberry, J. Parkinson, M. Ding and S. Murphy. What can glial cell production and response to nitric oxide tell us about demyelinating disease processes? Fourth Altschul Symposium, 1996.
163. G.M. Buga, R. Singh, S. Pervin, N.E. Rogers, D.A. Schmitz, C.P. Jenkinson, S.D. Cederbaum and L.J. Ignarro. Constitutive and inducible arginase activity in endothelial cells. Inhibition by N-hydroxyarginine during high output nitric oxide production. 2nd International Conference on the Biochemistry and Molecular Biology of Nitric Oxide. Los Angeles, CA, July 13-17, 1995, pp. 77.
164. G.M. Buga, R. Singh, S. Pervin, N.E. Rogers, D.A. Schmitz, C.P. Jenkinson, S.D. Cederbaum and L.J. Ignarro. Constitutive and inducible arginase activity in endothelial cells. FASEB Summer Research Conference on Endothelium and Cardiovascular Control. Copper Mountain, CO, June 29 - July 4, 1997.
165. K. Leong, G.M. Buga, L.J. Ignarro and G.H. Cryer. Inducible NO synthase mRNA expression in rat aortic endothelial cells peaks early following treatment in vitro and may propagate hypotension in vivo. Proc. 53rd Ann. Sessions Owen H. Wangenstein Surgical Forum. Orlando, FL, October 25-30, 1998, pp. 1-4.
166. P.M. Bauer, J.M. Fukuto, A.E. Pegg and L.J. Ignarro. Nitric oxide inhibits ornithine decarboxylase by S-nitrosylation. Acta Physiol. Scand. 167:5, 1999.
167. P.M. Bauer, J.M. Fukuto, G.M. Buga, A.E. Pegg and L.J. Ignarro. Nitric oxide inhibits ornithine decarboxylase by S-nitrosylation of cysteine 360 in the active site of the enzyme. FASEB J. 14: A403, 2000.
168. G.M. Buga and L.J. Ignarro. Nebivolol, a nitric oxide releasing β adrenergic antagonist and NCX-4016, a nitric oxide releasing aspirin derivative inhibit proliferation of rat aortic smooth muscle cells. NO Biol. Chem. 4:182, 2000.
169. P.M. Bauer, G.M. Buga and L.J. Ignarro. Nitric oxide inhibits proliferation of A7r5 rat aortic smooth muscle cells via inhibition of ornithine decarboxylase. NO Biol. Chem. 4:313, 2000.
170. A. Rastogi, R. Singh and L.J. Ignarro. Physiological significance of citrulline-arginine recycling in sustaining high output nitric oxide states. NO Biol. Chem. 4:213, 2000.
171. Rastogi, D. Lin and L.J. Ignarro. Effects of $\text{INF-}\gamma$ on arginase II mRNA and protein stability in LPS-treated rat aortic smooth muscle cells. NO Biol. Chem. 4:214, 2000.

172. L. Wei, A. Jacobs, S. Morris and L.J. Ignarro. IL-4 and IL-13 upregulate arginase I expression by cyclic AMP and possible JAK/STAT6 pathways in vascular smooth muscle cells. NO Biol. Chem. 4:233, 2000.
173. D. Sumi, T. Hayashi, M. Jayachandran, H. Kano, T. Tsunekawa, N.K. Thakur, A. Iguchi and L.J. Ignarro. A new β -blocker: NIPRADILOL up-regulates endothelial NO synthase expression through β -2 adrenergic receptors without affecting caveolin-1 expression in endothelial cells. NO Biol. Chem. 4:252, 2000.
174. A. Jacobs, J.M. Fukuto and L.J. Ignarro. Effect of nitric oxide releasing agents on the induction of IFN- β and iNOS mRNA and subsequent NO generation by RAW 264.7 macrophages. NO Biol. Chem. 4:263, 2000.
175. B. Azizzadeh, G.M. Buga, L.J. Ignarro and K.E. Blackwell. Nitric oxide inhibitors increase the rate of microvascular thrombosis. The American Academy of Facial Plastic and Reconstructive Surgery. Denver, CO, September 5-8, 2001.
176. B. Azizzadeh, H.T. Yip, K.E. Blackwell, T.C. Calcaterra, S.E. Srivastan, G.M. Buga, L.J. Ignarro and M.B. Wang. Nitric oxide improves cisplatin cytotoxicity in head and neck squamous cell carcinoma. The 104th Annual Meeting of the American Laryngological, Rhynological and Otological (Triological) Society. Palm Desert, CA, May 14-16, 2001.
177. M. Sisodia, G.M. Buga and L.J. Ignarro. Role of NO-releasing drugs, nebivolol and NCX-4016 on proliferation and migration of cultured rat aortic smooth muscle cells (RASMCs) and their implications in atherosclerosis. Undergraduate Poster Session. University of California, Los Angeles, CA, May 23, 2001.
178. G.M. Buga, P.M. Bauer, L.H. Wei, G. Wu and L.J. Ignarro. Further investigation of the role of nitric oxide in the regulation of vascular smooth muscle cell proliferation. 2nd International Conference on Biology, Chemistry and Therapeutic Applications of Nitric Oxide. Prague, Czech Republic, July 16-20, 2002. NO Biol. Chem. 6:367, 2002.
179. S.K. Chiang, B. Azizzadeh, G.M. Buga, L.J. Ignarro and K.E. Blackwell. Local administration of nitric oxide significantly impacts microvascular thrombosis. The 105th Annual Meeting of the American Laryngological, Rhynological and Otological (Triological) Society. Boca Raton, FL, May 12-14, 2002.

MANUSCRIPTS:

1. F.E. Shideman and Louis J. Ignarro. New species may create new problems: norepinephrine in the heart of the avian embryo. Fed. Proc. **26**:1137, 1967.
2. Louis J. Ignarro and F.E. Shideman. Catechol-O-methyl transferase and monoamine oxidase activities in the heart of the embryonic and developing chick. J. Pharmacol. Exp. Ther. **159**:29-37, 1968.
3. Louis J. Ignarro and F.E. Shideman. Appearance and concentrations of catecholamines and their biosynthesis in the embryonic and developing chick. J. Pharmacol. Exp. Ther. **159**:38-48, 1968.
4. Louis J. Ignarro and F.E. Shideman. Norepinephrine and epinephrine in the embryo and embryonic heart of the chick: Uptake and subcellular distribution. J. Pharmacol. Exp. Ther. **159**:49-58, 1968.
5. Louis J. Ignarro and F.E. Shideman. The requirement of sympathetic innervation for the active transport of norepinephrine by the heart. J. Pharmacol. Exp. Ther. **159**:59-65, 1968.
6. Louis J. Ignarro and Elwood O. Titus. The presence of antagonistically acting alpha and beta adrenergic receptors in the mouse spleen. J. Pharmacol. Exp. Ther. **160**:72-80, 1968.
7. Karl J. Doebel, Mary Lee Graeme, Norbert Gruenfeld. Louis J. Ignarro, Sam Piliero and Jan W.F. Wasley. Non-steroidal anti-inflammatory agents. Ann. Rep. Med. Chem. (1968) Pg. 207-217, 1969.
8. Karl J. Doebel, Mary Lee Graeme, Norbert Gruenfeld, Louis J. Ignarro, Sam Piliero and Jan W.F. Wasley. Non-steroidal anti-inflammatory agents. Ann. Rep. Med. Chem. (1969) Pg. 225-236, 1970.
9. Louis J. Ignarro. Effects of anti-inflammatory drugs on the stability of rat liver lysosomes in vitro. Biochem. Pharmac. **20**:2847-2860, 1971.
10. Louis J. Ignarro. Dissimilar effects of anti-inflammatory drugs on stability of lysosomes from peritoneal and circulating leucocytes and liver. Biochem. Pharmac. **20**:2861-2870, 1971.
11. Louis J. Ignarro, Joseph Slywka and Natalie Krassikoff. Inhibition of lysosomal enzyme release by catecholamines: possible mediation by cyclic 3',5'-adenosine monophosphate. Life Sci., Part I, **10**:1309-1315, 1971.
12. Louis J. Ignarro and Joseph Slywka. Changes in liver lysosome fragility, erythrocyte membrane stability and local and systemic lysosomal enzyme levels in adjuvant-induced polyarthritis. Biochem. Pharmac. **21**:875-886, 1972.
13. Louis J. Ignarro, Natalie Krassikoff and Joseph Slywka. Inhibition of lysosomal enzyme release by adenosine 5'-triphosphate and N⁶',O²'-dibutyryl cyclic 3',5'-adenosine monophosphate. Life Sci., Part I, **11**:317-322, 1972.
14. Louis J. Ignarro. Lysosome membrane stabilization in vivo: effects of steroidal and non-steroidal anti-inflammatory drugs on the integrity of rat liver lysosomes. J. Pharmacol. Exp. Ther. **182**:179-188, 1972.

15. Louis J. Ignarro and Carmelo Colombo. Enzyme release from guinea pig polymorphonuclear leucocyte lysosomes inhibited in vitro by anti-inflammatory drugs. Nature (New Biology) 239:155-157, 1972.
16. Louis J. Ignarro, Natalie Krassikoff and Joseph Slywka. Release of enzymes from a rat liver lysosome fraction: Inhibition by catecholamine and cyclic 3',5'-adenosine monophosphate, stimulation by cholinergic agents and cyclic 3',5'-guanosine monophosphate. J. Pharmacol. Exp. Ther. 186:86-99, 1973.
17. Louis J. Ignarro, Arnold L. Oronsky and Robert J. Perper. Effects of prostaglandins on release of enzymes from lysosomes of pancreas, spleen and kidney cortex. Life Sci., Part I, 12:193-201, 1973.
18. Louis J. Ignarro and Carmelo Colombo. Enzyme release from polymorphonuclear leukocyte lysosomes: Regulation by autonomic drugs and cyclic nucleotides. Science 180:1181-1183, 1973.
19. Louis J. Ignarro. Preservation of structural integrity of liver lysosomes and membrane stabilizing action of anti-inflammatory drugs, catecholamines and cyclic adenosine monophosphate in isotonic salt media. Biochem. Pharmac. 22:1269-1282, 1973.
20. Louis J. Ignarro, Arnold L. Oronsky and Robert J. Perper. Breakdown of non-collagenous, chondromucoprotein matrix by leukocyte lysosome granule lysates from guinea-pig, rabbit and human. Clin. Immun. Immunopath. 2:36-51, 1973.
21. Arnold L. Oronsky, Louis J. Ignarro and Robert J. Perper. Release of cartilage mucopolysaccharide degrading neutral protease from human leukocytes. J. Exp. Med. 138:461-472, 1973.
22. Louis J. Ignarro. Neutral protease release from human leukocytes regulated by neurohormones and cyclic nucleotides. Nature New Biol. 245:151-154, 1973.
23. Louis J. Ignarro. Nonphagocytic release of neutral protease and beta-glucuronidase from human neutrophils. Regulation by autonomic neurohormones and cyclic nucleotides. Arthritis Rheum. 17:25-36, 1974.
24. Louis J. Ignarro. Stimulation of phagocytic release of neutral protease from human neutrophils by cholinergic amines and cyclic 3',5'-guanosine monophosphate. J. Immunol. 112:210-214, 1974.
25. Louis J. Ignarro, Thomas F. Lint and William J. George. Hormonal control of lysosomal enzyme release from human neutrophils: Effects of autonomic agents on enzyme release, phagocytosis and cyclic nucleotide levels. J. Exp. Med. 139:1395-1414, 1974.
26. Louis J. Ignarro. Release of neutral protease and beta-glucuronidase from human neutrophils in the presence of cartilage treated with various immunologic reactants. J. Immunol. 113:298-308, 1974.
27. Louis J. Ignarro, Richard J. Paddock and William J. George. Hormonal control of neutrophil lysosomal enzyme release: Effect of epinephrine on adenosine 3',5'-monophosphate. Science 183:855-857, 1974.
28. Louis J. Ignarro and William J. George. Hormonal control of lysosomal enzyme release from human neutrophils: Elevation of cyclic nucleotide levels by autonomic neurohormones. Proc. Nat. Acad. Sci. USA 71:2027-2031, 1974.

29. Louis J. Ignarro and William J. George. Mediation of immunologic discharge of lysosomal enzymes from human neutrophils by cyclic GMP: Requirement of calcium, and inhibition by cyclic AMP. J. Exp. Med. 140:225-238, 1974.
30. Robert J. Smith, Louis J. Ignarro and James W. Fisher. Lysosomal enzyme release: A possible mechanism of action of cobalt as an erythropoietic stimulant. Proc. Soc. Exp. Biol. Med. 146:781-785, 1974.
31. Robert J. Smith, Louis J. Ignarro, Paul M. Heidger and James W. Fisher. Lysosomal enzyme release *in vivo*: An evaluation of the mechanism of cobalt polycythemia. J. Pharmacol. Exp. Ther. 191:564-574, 1974.
32. Robert J. Smith and Louis J. Ignarro. Stimulation-secretion coupling in human neutrophils: Link between calcium influx and cyclic GMP accumulation in lysosomal enzyme secretion. Proc. Nat. Acad. Sci. USA 72:108-112, 1975.
33. Louis J. Ignarro and Stella Y. Cech. Lysosomal enzyme secretion from human neutrophils mediated by cyclic GMP: Inhibition of cyclic GMP accumulation and neutrophil function by glucocorticosteroids. J. Cyclic Nucl. Res. 1:283-292, 1975.
34. William J. George, Louis J. Ignarro, Richard J. Paddock, LuAnn White and Philip J. Kadowitz. Oppositional effects of acetylcholine and isoproterenol on isometric tension and cyclic nucleotide concentrations in rabbit atria. J. Cyclic Nucl. Res. 1:339-347, 1975.
35. William J. George, Louis J. Ignarro and LuAnn E. White. Muscarinic stimulation of cardiac guanylate cyclase. Rec. Adv. Stud. Cardiac Struct. Metab. 7:381-390, 1975.
36. William J. George, Ronald W. Busuttil, Richard J. Paddock, LuAnn E. White and Louis J. Ignarro. Opposing regulatory influences of cyclic GMP and cyclic AMP in the control of cardiac muscle contraction. Rec. Adv. Stud. Cardiac Struct. Metab. 8:243-250, 1975.
37. Louis J. Ignarro and Stella Y. Cech. Bidirectional regulation of lysosomal enzyme secretion and phagocytosis in human neutrophils by cyclic GMP and cyclic AMP. Proc. Soc. Exp. Biol. Med. 151:448-452, 1976.
38. Louis J. Ignarro, Rosemarie A. Gross and Dennis M. Gross. Inhibition of mammalian soluble guanylate cyclase activity by adenosine 5'-tetraphosphate, guanosine 5'-tetraphosphate and other nucleotides. J. Cyclic Nucl. Res. 2:337-346, 1976.
39. Louis J. Ignarro. Glucocorticosteroid inhibition of nonphagocytic discharge of lysosomal enzymes from human neutrophils. Arthritis Rheum. 20:73-83, 1977.
40. Louis J. Ignarro and Rosemarie A. Gross. Stimulation of mammalian adenylate cyclase activity with guanosine 5'-tetraphosphate and other guanine nucleotides. Biochim. Biophys. Acta 541:170-180, 1978.
41. Stella Y. Cech and Louis J. Ignarro. Cytidine 3',5'-monophosphate (Cyclic CMP) formation in mammalian tissues. Science 198:1063-1065, 1977.
42. Stella Y. Cech and Louis J. Ignarro. Cytidine 3',5'-monophosphate (Cyclic CMP) formation by homogenates of mouse liver. Biochem. Biophys. Res. Comm. 80:119-125, 1978.

43. Carl A. Gruetter, Barbara K. Barry, Dennis B. McNamara, Darlene Y. Gruetter, Philip J. Kadowitz and Louis J. Ignarro. Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine. J. Cyclic Nucl. Res. 5:211-224, 1979.
44. Eliot H. Ohlstein, Barbara K. Barry, Darlene Y. Gruetter and Louis J. Ignarro. Methemoglobin blockade of coronary arterial soluble guanylate cyclase activation by nitroso compounds and its reversal with dithiothreitol. F.E.B.S. Letters 102:316-320, 1979.
45. Darlene Y. Gruetter and Louis J. Ignarro. Arachidonic acid activation of guinea pig lung guanylate cyclase by two independent mechanisms. Prostaglandins 18:541-556, 1979.
46. Louis J. Ignarro, James C. Edwards, Darlene Y. Gruetter, Barbara K. Barry and Carl A. Gruetter. Possible involvement of S-nitrosothiols in the activation of guanylate cyclase by nitroso compounds. F.E.B.S. Letters 110:275-278, 1980.
47. Steven A. Napoli, Carl A. Gruetter, Louis J. Ignarro and Philip J. Kadowitz. Relaxation of bovine coronary arterial smooth muscle by cyclic GMP, cyclic AMP and analogs. J. Pharmacol. Exp. Ther. 212:469-473, 1980.
48. Carl A. Gruetter, Barbara K. Barry, Dennis B. McNamara, Philip J. Kadowitz and Louis J. Ignarro. Coronary arterial relaxation and guanylate cyclase activation by cigarette smoke, N'-nitrosonornicotine and nitric oxide. J. Pharmacol. Exp. Ther. 214:9-15, 1980.
49. Louis J. Ignarro, Barbara K. Barry, Darlene Y. Gruetter, James C. Edwards, Eliot H. Ohlstein, Carl A. Gruetter and William H. Baricos. Guanylate cyclase activation by nitroprusside and nitrosoguanidine is related to formation of S-nitrosothiol intermediates. Biochem. Biophys. Res. Commun. 94:93-100, 1980.
50. Louis J. Ignarro and Carl A. Gruetter. Requirement of thiols for activation of coronary arterial guanylate cyclase by glyceryl trinitrate and sodium nitrite: Possible involvement of S-nitrosothiols. Biochim. Biophys. Acta 631:221-231, 1980.
51. Darlene Y. Gruetter, Carl A. Gruetter, Barbara K. Barry, William H. Baricos, Albert L. Hyman, Philip J. Kadowitz and Louis J. Ignarro. Activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and nitrosoguanidine -- Inhibition by calcium, lanthanum and other cations, enhancement by thiols. Biochem. Pharmacol. 29:2943-2950, 1980.
52. James C. Edwards, Barbara K. Barry, Darlene Y. Gruetter, Eliot H. Ohlstein, William H. Baricos and Louis J. Ignarro. Activation of hepatic guanylate cyclase by nitrosyl-heme complexes--Comparison of unpurified and partially purified enzyme. Biochem. Pharmacol. 30:2531-2538, 1981.
53. Dennis B. McNamara, Philip J. Kadowitz, Albert L. Hyman and Louis J. Ignarro. Cyclic AMP formation by preparations of rat liver soluble guanylate cyclase activated with nitric oxide, nitrosyl-ferroheme, S-nitrosothiols and other nitroso compounds. Canad. J. Physiol. Pharmacol. 58:1446-1456, 1980.
54. Carl A. Gruetter, Louis J. Ignarro, Albert L. Hyman and Philip J. Kadowitz. Contractile effects of 5-hydroxytryptamine in isolated intrapulmonary arteries and veins. Canad. J. Physiol. Pharmacol. 59:157-162, 1981.
55. Carl A. Gruetter, Philip J. Kadowitz and Louis J. Ignarro. Methylene blue inhibits coronary arterial relaxation and guanylate cyclase activation by nitroglycerin, sodium nitrite and amyl nitrite. Canad. J. Physiol. Pharmacol. 59:150-156, 1981.

56. Philip J. Kadowitz, Prem Nandiwada, Carl A. Gruetter, Louis J. Ignarro and Albert L. Hyman. Pulmonary vasodilator responses to nitroprusside and nitroglycerin in the dog. J. Clin. Invest. 67:893-902, 1981.
57. B. Theo Mellion, Louis J. Ignarro, Eliot H. Ohlstein, Eugene G. Pontecorvo, Albert L. Hyman and Philip J. Kadowitz. Evidence for the inhibitory role of guanosine 3',5'-monophosphate in ADP-induced human platelet aggregation. Blood 57:946-955, 1981.
58. Louis J. Ignarro, Philip J. Kadowitz and William H. Baricos. Evidence that regulation of hepatic guanylate cyclase involves interactions between catalytic site -SH groups and both substrate and activator. Arch. Biochem. Biophys. 208:75-86, 1981.
59. Louis J. Ignarro, Barbara K. Barry, Darlene Y. Gruetter, Eliot H. Ohlstein, Carl A. Gruetter, Philip J. Kadowitz and William H. Baricos. Selective alterations in responsiveness of guanylate cyclase to activation by nitroso compounds during enzyme purification. Biochim. Biophys. Acta 673:394-407, 1981.
60. Carl A. Gruetter, Darlene Y. Gruetter, Jeffrey E. Lyon, Philip J. Kadowitz and Louis J. Ignarro. Relationship between cyclic GMP formation and relaxation of coronary arterial smooth muscle by glyceryl trinitrate, nitroprusside, nitrite and nitric oxide: Effects of methylene blue and methemoglobin. J. Pharmacol. Exp. Ther. 219:181-186, 1981.
61. Louis J. Ignarro, Howard Lippton, James C. Edwards, William H. Baricos, Albert L. Hyman, Philip J. Kadowitz and Carl A. Gruetter. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: Evidence for the involvement of S-nitrosothiols as active intermediates. J. Pharmacol. Exp. Ther. 218:739-749, 1981.
62. Howard L. Lippton, Carl A. Gruetter, Louis J. Ignarro, Richard L. Meyer and Philip J. Kadowitz. Vasodilator actions of several N-nitroso compounds. Can. J. Physiol. Pharmacol. 60:68-75, 1982.
63. Louis J. Ignarro, Keith S. Wood and Michael S. Wolin. Activation of purified soluble guanylate cyclase by protoporphyrin IX. Proc. Natl. Acad. Sci. USA 79:2870-2873, 1982.
64. Louis J. Ignarro, Jonathan N. Degnan, William H. Baricos, Philip J. Kadowitz and Michael S. Wolin. Activation of purified guanylate cyclase by nitric oxide requires heme: comparison of heme-deficient, heme-reconstituted and heme-containing forms of soluble enzyme from bovine lung. Biochim. Biophys. Acta 718:49-59, 1982.
65. Eliot H. Ohlstein, Keith S. Wood and Louis J. Ignarro. Purification and properties of heme-deficient hepatic soluble guanylate cyclase: effects of heme and other factors on enzyme activation by NO, NO-heme and protoporphyrin IX. Arch. Biochem. Biophys. 218:187-198, 1982.
66. Michael S. Wolin, Keith S. Wood and Louis J. Ignarro. Guanylate cyclase from bovine lung: a kinetic analysis of the regulation of the purified soluble enzyme by protoporphyrin IX, heme and nitrosyl-heme. J. Biol. Chem. 257:13312-13320, 1982.
67. B. Theo Mellion, Louis J. Ignarro, Carl B. Myers, Eliot H. Ohlstein, Bryan A. Ballot, Albert L. Hyman and Philip J. Kadowitz. Inhibition of human platelet aggregation by S-nitrosothiols. Heme-dependent activation of soluble guanylate cyclase and stimulation of cyclic GMP accumulation. Mol. Pharmacol. 23:653-664, 1983.
68. Louis J. Ignarro, Keith S. Wood, Bryan Ballot and Michael S. Wolin. Guanylate cyclase from bovine lung: Evidence that enzyme activation by phenylhydrazine is mediated by iron-phenyl hemoprotein complexes. J. Biol. Chem. 259:5923-5931, 1984.

69. James C. Edwards, Louis J. Ignarro, Keith S. Wood, Albert L. Hyman and Philip J. Kadowitz. Relaxation of intrapulmonary artery and vein by nitrogen oxide-containing vasodilators and cyclic GMP. J. Pharmacol. Exp. Ther. 228:33-42, 1984.
70. Louis J. Ignarro, Terri Burke, Keith S. Wood and Philip J. Kadowitz. Association between cyclic GMP accumulation and acetylcholine-elicited relaxation of bovine intrapulmonary artery. J. Pharmacol. Exp. Ther. 228:682-690, 1984.
71. Louis J. Ignarro, Bryan Ballot and Keith S. Wood. Regulation of guanylate cyclase activity by porphyrins and metalloporphyrins. J. Biol. Chem. 259:6201-6207, 1984.
72. Louis J. Ignarro, Richard G. Harbison, Keith S. Wood, Michael S. Wolin, Dennis B. McNamara, Albert L. Hyman and Philip J. Kadowitz. Differences in responsiveness of intrapulmonary artery and vein to arachidonic acid: mechanism of arterial relaxation involves cyclic GMP and cyclic AMP. J. Pharmacol. Exp. Ther. 233:560-569, 1985.
73. Henry A. Pretus, Louis J. Ignarro, Harry E. Ensley and Larry P. Feigen. Inhibition of soybean lipoxygenase by SKF 525-A and metyrapone. Prostaglandins 30:591-598, 1985.
74. Louis J. Ignarro, Richard G. Harbison, Keith S. Wood and Philip J. Kadowitz. Dissimilarities between methylene blue and cyanide on relaxation and cyclic GMP formation in endothelium-intact intrapulmonary artery caused by nitrogen oxide-containing vasodilators and acetylcholine. J. Pharmacol. Exp. Ther. 236:30-36, 1986.
75. Louis J. Ignarro, Keith S. Wood, Richard G. Harbison and Philip J. Kadowitz. Atriopeptin II relaxes and elevates cyclic GMP in bovine pulmonary artery but not vein. J. Appl. Physiol. 60:1128-1133, 1986.
76. Louis J. Ignarro, Richard G. Harbison, Keith S. Wood and Philip J. Kadowitz. Activation of purified soluble guanylate cyclase by endothelium-derived relaxing factor from intrapulmonary artery and vein: stimulation by acetylcholine, bradykinin and arachidonic acid. J. Pharmacol. Exp. Ther. 237:893-900, 1986.
77. Louis J. Ignarro, John B. Adams, Philip M. Horwitz and Keith S. Wood. Activation of soluble guanylate cyclase by NO-hemoproteins involves NO-heme exchange: Comparison of heme-containing and heme-deficient enzyme forms. J. Biol. Chem. 261:4997-5002, 1986.
78. Donald G. Guinee, Dennis B. McNamara, Louis J. Ignarro, Albert L. Hyman and Philip J. Kadowitz. Arachidonic acid and acetylcholine induced relaxation of bovine coronary artery: effect of indomethacin and methylene blue. Can. J. Cardiol. 2:170-175, 1986.
79. Louis J. Ignarro, Russell E. Byrns and Keith S. Wood. Endothelium- dependent modulation of cyclic GMP levels and intrinsic smooth muscle tone in isolated bovine intrapulmonary artery and vein. Circ. Res. 60:82-92, 1987.
80. Louis J. Ignarro and Keith S. Wood. Activation of purified soluble guanylate cyclase by arachidonic acid requires absence of enzyme-bound heme. Biochim. Biophys. Acta 928:160-170, 1987.
81. Keith S. Wood and Louis J. Ignarro. Hepatic cyclic GMP formation is regulated by similar factors that modulate activation of purified hepatic soluble guanylate cyclase. J. Biol. Chem. 262:5020-5027, 1987.

82. Louis J. Ignarro, Russell E. Byrns, Georgette M. Buga and Keith S. Wood. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacological and chemical properties that are identical to those for nitric oxide radical. Circ. Res. **61**:866-879, 1987.
83. Louis J. Ignarro, Russell E. Byrns, Georgette M. Buga and Keith S. Wood. Mechanisms of endothelium-dependent vascular smooth muscle relaxation elicited by bradykinin and VIP. Am. J. Physiol. **253**:H1074-H1082, 1987.
84. Louis J. Ignarro, Georgette M. Buga, Keith S. Wood, Russell E. Byrns and Gautam Chaudhuri. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. USA **84**:9265-9269, 1987.
85. Louis J. Ignarro, Russell E. Byrns, Georgette M. Buga, Keith S. Wood and Gautam Chaudhuri. Pharmacological evidence that endothelium-derived relaxing factor is nitric oxide: Use of pyrogallol and superoxide dismutase to study endothelium-dependent and nitric oxide-elicited vascular smooth muscle relaxation. J. Pharmacol. Exp. Ther. **244**:181-190, 1988.
86. Louis J. Ignarro, Georgette M. Buga and Gautam Chaudhuri. EDRF generation and release from perfused bovine pulmonary artery and vein. Eur. J. Pharmacol. **149**:79-88, 1988.
87. Louis J. Ignarro, Georgette M. Buga, Russell E. Byrns, Keith S. Wood and Gautam Chaudhuri. Endothelium-derived relaxing factor and nitric oxide possess identical pharmacologic properties as relaxants of bovine arterial and venous smooth muscle. J. Pharmacol. Exp. Ther. **246**:218-226, 1988.
88. Georgette M. Buga, Michele E. Gold, Keith S. Wood, Gautam Chaudhuri and Louis J. Ignarro. Endothelium-derived nitric oxide relaxes nonvascular smooth muscle. Eur. J. Pharmacol. **161**:61-72, 1989.
89. Louis J. Ignarro, Michele E. Gold, Georgette M. Buga, Russell E. Byrns, Keith S. Wood, Gautam Chaudhuri and Gerard Frank. Basic polyamino acids rich in arginine, lysine, or ornithine cause both enhancement of and refractoriness to formation of endothelium-derived nitric oxide in pulmonary artery and vein. Circ. Res. **64**:315-329, 1989.
90. Steven Ashwal, William J. Pearce and Louis J. Ignarro. Hypoxia increases cyclic GMP and decreases calcium uptake in rabbit cranial arteries. Proc. West. Pharmacol. Soc. **31**:125-128, 1988.
91. Michele E. Gold, Keith S. Wood, Georgette M. Buga, Russell E. Byrns and Louis J. Ignarro. L-Arginine causes whereas L-argininosuccinic acid inhibits endothelium-dependent vascular smooth muscle relaxation. Biochem. Biophys. Res. Commun. **161**:536-543, 1989.
92. Michele E. Gold, Peggy A. Bush and Louis J. Ignarro. Depletion of arterial L-arginine causes reversible tolerance to endothelium-dependent relaxation. Biochem. Biophys. Res. Commun. **164**:714-721, 1989.
93. Michele E. Gold, Georgette M. Buga, Keith S. Wood, Russell E. Byrns, Gautam Chaudhuri and Louis J. Ignarro. Antagonistic modulatory roles of magnesium and calcium on release of endothelium-derived relaxing factor and smooth muscle tone. Circ. Res. **66**:355-366, 1990.

94. Michele E. Gold, Keith S. Wood, Russell E. Byrns, Jon M. Fukuto and Louis J. Ignarro. N^{G} -Methyl-L-arginine causes endothelium-dependent contraction and inhibition of cyclic GMP formation in artery and vein. Proc. Natl. Acad. Sci. USA 87:4430-4434, 1990.
95. Keith S. Wood, Georgette M. Buga, Russell E. Byrns and Louis J. Ignarro. Vascular smooth muscle-derived relaxing factor (MDRF) and its close similarity to nitric oxide. Biochem. Biophys. Res. Commun. 170:80-88, 1990.
96. Jon M. Fukuto, Keith S. Wood, Russell E. Byrns and Louis J. Ignarro. N^{G} -Amino-L-arginine: A new potent antagonist of L-arginine-mediated endothelium-dependent relaxation. Biochem. Biophys. Res. Commun. 168:458-465, 1990.
97. Louis J. Ignarro, Peggy A. Bush, Georgette M. Buga, Keith S. Wood, Jon M. Fukuto and Jacob Rajfer. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem. Biophys. Res. Commun. 170:843-850, 1990.
98. Louis J. Ignarro, Peggy A. Bush, Georgette M. Buga and Jacob Rajfer. Neurotransmitter identity in doubt: Nitric oxide as a mediator of penile erection. Nature 347:131-132, 1990.
99. Michele E. Gold, Keith S. Wood, Russell E. Byrns, Georgette M. Buga and Louis J. Ignarro. L-Arginine-dependent vascular smooth muscle relaxation and cyclic GMP formation. Am. J. Physiol. 259:H1813-H1821, 1990.
100. William J. Pearce, Anne-Marie Reynier-Rebuffel, James Lee, Pierre Aubineau, Louis J. Ignarro and Jacques Seylaz. Effects of methylene blue on hypoxic cerebral vasodilatation in the rabbit. J. Pharmacol. Exp. Ther. 254:616-625, 1990.
101. Gautam Chaudhuri, Georgette M. Buga, Michele E. Gold, Keith S. Wood and Louis J. Ignarro. Characterization and actions of human umbilical endothelium-derived relaxing factor. Br. J. Pharmacol. 102:331-336, 1991.
102. Hugo M. Vargas, Louis J. Ignarro and Gautam Chaudhuri. Physiological release of nitric oxide is dependent on the level of vascular tone. Eur. J. Pharmacol. 190:393-397, 1990.
103. Georgette M. Buga, Michele E. Gold, Jon M. Fukuto and Louis J. Ignarro. Shear stress-induced release of nitric oxide from endothelial cells grown on beads. Hypertension 17:187-193, 1991.
104. Gordon Ross, Gautam Chaudhuri, Louis J. Ignarro and Kuang-Yuh Chyu. Acetylcholine vasodilation of resistance vessels in vivo may not entirely depend on newly synthesized nitric oxide. Eur. J. Pharmacol. 195:291-293, 1991.
105. Hugo M. Vargas, Janis M. Cuevas, Louis J. Ignarro and Gautam Chaudhuri. Comparison of the inhibitory potencies of N^{G} -methyl, N^{G} -nitro- and N^{G} -amino-L-arginine on EDRF function in the rat: Evidence for continuous basal EDRF release. J. Pharmacol. Exp. Ther. 257:1208-1215, 1991.
106. Peggy A. Bush, William J. Aronson, Georgette M. Buga, Jacob Rajfer and Louis J. Ignarro. Nitric oxide is a potent relaxant of human and rabbit corpus cavernosum. J. Urol. 147:1650-1655, 1992.
107. Georgette M. Buga and Louis J. Ignarro. Electrical field stimulation causes endothelium-dependent and EDRF-mediated relaxation of pulmonary artery. Am. J. Physiol. 262:H973-H979, 1992.

108. Rajfer, J., Aronson, W.J., Bush, P.A., Dorey, F.J. and Ignarro, L.J. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N. Engl. J. Med. 326:90-94, 1992.
109. Louis J. Ignarro. Mechanism of action of nitric oxide: Heme-dependent activation of guanylate cyclase represents a unifying signal transduction mechanism. Jap. J. Pharmacol. 58 Suppl. II:207-212, 1992.
110. Georg Matheis, Michael P. Sherman, Gerald D. Buckberg, David M. Haybron, Helen H. Young and Louis J. Ignarro. Role of L-arginine-nitric oxide pathway in myocardial reoxygenation injury. Am. J. Physiol. 262:H616-H620, 1992.
111. Louis J. Ignarro. Haem-dependent activation of cytosolic guanylate cyclase by nitric oxide: a widespread signal transduction mechanism. Biochem. Soc. Trans. 20:465-470, 1992.
112. Peggy A. Bush, Norma E. Gonzalez, Jeanette M. Griscavage and Louis J. Ignarro. Nitric oxide synthase from cerebellum catalyzes the formation of equimolar quantities of nitric oxide and citrulline from L-arginine. Biochem. Biophys. Res. Commun. 185:960-966, 1992.
113. Peggy A. Bush, Norma E. Gonzalez and Louis J. Ignarro. Biosynthesis of nitric oxide and citrulline from L-arginine by constitutive nitric oxide synthase present in rabbit corpus cavernosum. Biochem. Biophys. Res. Commun. 186:308-314, 1992.
114. Peggy A. Bush, William J. Aronson, Jacob Rajfer, Georgette M. Buga and Louis J. Ignarro. Comparison of nonadrenergic, noncholinergic- and nitric oxide-mediated relaxation of corpus cavernosum. Int. J. Impotence Res. 4:85-93, 1992.
115. Norma E. Rogers and Louis J. Ignarro. Constitutive nitric oxide synthase from cerebellum is reversibly inhibited by nitric oxide formed from L-arginine. Biochem. Biophys. Res. Commun. 189:242-249, 1992.
116. Michael P. Sherman, Jeanette M. Griscavage and Louis J. Ignarro. Nitric oxide-mediated neuronal injury in multiple sclerosis. Medical Hypotheses 39:143-146, 1992.
117. Toshio Hayashi, Jon M. Fukuto, Louis J. Ignarro and Gautam Chaudhuri. Basal release of NO from aortic rings is greater in female rabbits than in male rabbits: Implications for atherosclerosis. Proc. Natl. Acad. Sci. USA 89:11259-11263, 1992.
118. Angelique F. Varela, Alice Runge, Louis J. Ignarro and Gautam Chaudhuri. Nitric oxide and prostacyclin inhibit fetal platelet aggregation: A response similar to that observed in adults. Am. J. Obstet. Gynecol. 167:1599-1604, 1992.
119. Michael P. Sherman, Ernesto E. Aeberhard, Vivian Z. Wong, Jeanette M. Griscavage and Louis J. Ignarro. Pyrrolidine dithiocarbamate inhibits induction of nitric oxide synthase activity in rat alveolar macrophages. Biochem. Biophys. Res. Commun. 191:1301-1308, 1993.
120. Flavio Trigo-Rocha, William J. Aronson, Markus Hohenfellner, Louis J. Ignarro, Jacob Rajfer and Tom F. Lue. Nitric oxide and cGMP: mediators of pelvic nerve-stimulated erection in dogs. Am. J. Physiol. 264:H419-H422, 1993.
121. Dennis B. McNamara, Brenda Bedi, Harmeet Aurora, Lawrence Tena, Louis J. Ignarro, Philip J. Kadowitz and Donald L. Akers. L-Arginine inhibits balloon catheter-induced intimal hyperplasia. Biochem. Biophys. Res. Commun. 193:291-296, 1993.

122. Timothy J. McMahon, Louis J. Ignarro and Philip J. Kadowitz. Influence of zaprinast on vascular tone and vasodilator responses in the cat pulmonary vascular bed. Am. J. Physiol. 74:1704-1711, 1993.
123. Ronald W. Day, Thomas S. Klitzner and Louis J. Ignarro. Endothelium-dependent relaxation and the acute pulmonary vascular response to alveolar hyperoxia in neonatal pigs. Biol. of the Neonate 63:389-396, 1993.
124. Ronald W. Day, Wyman W. Lai, Thomas S. Klitzner and Louis J. Ignarro. Oxygen-mediated regulation of neonatal and adult rabbit aortic tension. Devel. Pharmacol. Ther. 19:90-98, 1992.
125. Louis J. Ignarro, Jon M. Fukuto, Jeanette M. Griscavage, Norma E. Rogers and Russell E. Byrns. Oxidation of nitric oxide in aqueous solution to nitrite but not nitrate: Comparison with enzymatically formed nitric oxide from L-arginine. Proc. Natl. Acad. Sci. USA 90:8103-8107, 1993.
126. Jon. M. Fukuto, Adrian J. Hobbs and Louis J. Ignarro. Conversion of nitroxyl (HNO) to nitric oxide (NO) in biological systems: The role of physiological oxidants and relevance to the biological activity of HNO. Biochem. Biophys. Res. Commun. 196:707-713, 1993.
127. Jeanette M. Griscavage, Norma E. Rogers, Michael P. Sherman and Louis J. Ignarro. Inducible nitric oxide synthase from a rat alveolar macrophage cell line is inhibited by nitric oxide. J. Immunol. 151:6329-6337, 1993.
128. Jean E. Merrill, Louis J. Ignarro, Michael P. Sherman, Judy Melinek and Thomas E. Lane. Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J. Immunol. 151:2132-2141, 1993.
129. Georgette M. Buga, Jeanette M. Griscavage, Norma E. Rogers and Louis J. Ignarro. Negative feedback regulation of endothelial cell function by nitric oxide. Circ. Res. 73:808-812, 1993.
130. Mary B. Gilliam, Michael P. Sherman, Jeanette M. Griscavage and Louis J. Ignarro. A spectrophotometric assay for nitrate using NADPH oxidation by *Aspergillus* nitrate reductase. Anal. Biochem. 212:359-365, 1993.
131. B. Mitrovic, L.J. Ignarro, S. Montestrucque, A. Smoll and J.E. Merrill. Nitric Oxide as a potential pathological mechanism in demyelination: its differential effects on primary glial cells *in vitro*. Neuroscience 61:575-585, 1994.
132. Jeffrey M. Pearl, Hillel Laks, Davis C. Drinkwater, Thomas J. Sorensen, Paul Chang, Alon S. Aharon, Russell E. Byrns and Louis J. Ignarro. Loss of endothelium-dependent vasodilation and nitric oxide release after myocardial protection with University of Wisconsin solution. J. Thorac. Cardiovasc. Surg. 107:257-264, 1994.
133. Kiyozo Morita, Kai Ihnken, Gerald D. Buckberg, Michael P. Sherman, Helen H. Young and Louis J. Ignarro. Role of controlled cardiac reoxygenation in reducing nitric oxide production and cardiac oxidant damage in cyanotic infantile hearts. J. Clin. Invest. 93:2658-2666, 1994.
134. Jeanette M. Griscavage, Jon M. Fukuto, Yumiko Komori and Louis J. Ignarro. Nitric Oxide inhibits neuronal nitric oxide synthase by interacting with the heme prosthetic group: role of tetrahydrobiopterin in modulating the inhibitory action of nitric oxide. J. Biol. Chem. 269:21644-21649, 1994.

135. Adrian J. Hobbs, Jon M. Fukuto and Louis J. Ignarro. Formation of free nitric oxide from L-arginine by nitric oxide synthase: direct enhancement of generation by superoxide dismutase. Proc. Natl. Acad. Sci. USA **91**:10992-10996, 1994.
136. Scott A. Henderson, Peter H. Lee, Ernesto, E. Aeberhard, John W. Adams, Louis J. Ignarro, William J. Murphy and Michael P. Sherman. Nitric oxide reduces early growth response-1 gene expression in rat lung macrophages treated with interferon- γ and lipopolysaccharide. J. Biol. Chem. **269**:25239-25242, 1994.
137. Barbara S. Slusher, Anna E. Zacco, John A. Maslanski, Tyrrell E. Norris, Michael W. McLane, W. Craig Moore, Norma E. Rogers and Louis J. Ignarro. The cloned neurotensin receptor mediates cyclic GMP formation when coexpressed with nitric oxide synthase cDNA. Mol. Pharmacol. **46**:115-121, 1994.
138. George J. Chang, Pauline Woo, Henry M. Honda, Louis J. Ignarro, Leslie Young, Judith A. Berliner and Linda L. Demer. Oxidation of LDL to a biologically active form by derivatives of nitric oxide and nitrite in the absence of superoxide. Dependence on pH and oxygen. Arterioscler. Thromb. **14**:1808-1814, 1994.
139. Jinjoo Hyun, Yumiko Komori, Gautam Chaudhuri, Louis J. Ignarro and Jon M. Fukuto. The protective effect of tetrahydrobiopterin on the NO-mediated inhibition of purified NO synthase. Biochem. Biophys. Res. Commun. **206**:380-386, 1995.
140. Ameet. G. Patel, Mark T. Toyama, Thanh N. Nguyen, Gordon A. Cohen, Louis J. Ignarro, Howard A. Reber and Stanley W. Ashley. Role of nitric oxide in the relationship of pancreatic blood flow and exocrine secretion in cats. Gastroenterology **108**:1215-1220, 1995.
141. Ernesto E. Aeberhard, Scott A. Henderson, Nicole S. Arabolos, Jeanette M. Griscavage, Fidel E. Castro, Cynthia T. Barrett and Louis J. Ignarro. Nonsteroidal anti-inflammatory drugs inhibit expression of the inducible nitric oxide synthase gene. Biochem. Biophys. Res. Commun. **208**:1053-1059, 1995.
142. B. Mitrovic, L.J. Ignarro, H.V. Vinters, M.A. Akers, I. Schmid, C. Uittenbogaart and J.E. Merrill. Nitric oxide induces necrotic but not apoptotic cell death in oligodendrocytes. Neuroscience **65**:531-539, 1995.
143. Winnie W. Wang, Christopher P. Jenkinson, Jeanette M. Griscavage, Rita M. Kern, Nicole S. Arabolos, Russell E. Byrns, Steven D. Cederbaum and Louis J. Ignarro. Co-induction of arginase and nitric oxide synthase in murine macrophages activated by lipopolysaccharide. Biochem. Biophys. Res. Commun. **210**:1009-1016, 1995.
144. Husam M. Abu-Soud, Jianling Wang, Denis L. Rousseau, Jon M. Fukuto, Louis J. Ignarro and Dennis J. Stuehr. Neuronal nitric oxide synthase self-inactivates by forming a ferrous-nitrosyl complex during aerobic catalysis. J. Biol. Chem. **270**:22997-23006, 1995.
145. Jeanette M. Griscavage, Sherwin Wilk and Louis J. Ignarro. Serine and cysteine proteinase inhibitors prevent nitric oxide production by activated macrophages by interfering with transcription of the inducible NO synthase gene. Biochem. Biophys. Res. Commun. **215**:721-729, 1995.
146. Waldemar Radziszewski, Madhu Chopra, Artur Zembowicz, Richard Gryglewski, Louis J. Ignarro and Gautam Chaudhuri. Nitric oxide donors induce extrusion of cyclic GMP from isolated human blood platelets by a mechanism which may be modulated by prostaglandins. Int. J. Cardiol. **51**:211-220, 1995.

147. Toshio Hayashi, Jon M. Fukuto, Louis J. Ignarro and Gautam Chaudhuri. Gender differences in atherosclerosis: Possible role of nitric oxide. J. Cardiovasc. Pharmacol. 26: 792-802, 1995.
148. John Hunt, Russell E. Byrns, Louis J. Ignarro and Benjamin Gaston. Condensed expirate nitrite as a home marker for acute asthma. Lancet 346:1235, 1995.
149. Kai Ihnken, Kyoza Morita, Gerald D. Buckberg, F. Beyersdorf and Louis J. Ignarro. Reduction of reoxygenation injury and nitric oxide production in the cyanotic immature heart by controlling PO₂. Eur. J. Cardio-Thoracic Surg. 9:410-418, 1995.
150. Kiyozo Morita, Michael P. Sherman, Gerald Buckberg, Kai Ihnken, Georg Matheis, Helen Young and Louis J. Ignarro. Role of the L-arginine-nitric oxide pathway: The nitric oxide paradox. J. Thorac. Cardiovasc. Surg. 110:1200-1211, 1995.
151. Kai Ihnken, Kiyozo Morita, Gerald Buckberg, Michael P. Sherman, Louis J. Ignarro and Helen Young. Interaction between oxygen tension and cardioplegic composition in limiting nitric oxide production and oxidant damage. J. Thorac. Cardiovasc. Surg. 110:1274-1286, 1995.
152. Kyoza Morita, Kai Ihnken, Gerald D. Buckberg, Michael P. Sherman and Louis J. Ignarro. Pulmonary vasoconstriction due to impaired nitric oxide production after cardiopulmonary bypass. Ann. Thoracic. Surg. 61:1775-1780, 1996.
153. Jeongryul Lee, Davis C. Drinkwater, Jr., Hillel Laks, Albert Chong, Arie Blitz, Mary A. Chen, Louis J. Ignarro and Paul Chang. Preservation of endothelium-dependent vasodilation with low-potassium University of Wisconsin solution. J. Thorac. Cardiovasc. Surg. 112:103-110, 1996.
154. Gordon Cohen, Michael Zinner, Gautam Chaudhuri and Louis J. Ignarro. Nitric oxide regulates endothelium-dependent vasodilation in the hindquarters vascular bed in vivo. Am. J. Physiol. 271:H133-H139, 1996.
155. Jeanette M. Griscavage, Sherwin Wilk and Louis J. Ignarro. Inhibitors of the proteasome pathway interfere with induction of nitric oxide synthase in macrophages by blocking activation of nuclear factor-kappa B. Proc. Natl. Acad. Sci. USA 93:3308-3312, 1996.
156. Georgette M. Buga, Rajan Singh, Shehla Pervin, Norma E. Rogers, Debra A. Schmitz, Christopher P. Jenkinson, Stephen D. Cederbaum and Louis J. Ignarro. Arginase activity in endothelial cells: Inhibition by N^G-hydroxyarginine during high-output nitric oxide production. Am. J. Physiol. 271:H1988-H1998, 1996.
157. Azmi Atiya, Gordon Cohen, Louis J. Ignarro and F. Charles Brunicardi. Nitric oxide regulates insulin secretion in the isolated perfused human pancreas via a cholinergic mechanism. Surgery 120:322-327, 1996.
158. Michael P. Sherman, Vivian Z. Wong, Ernesto E. Aeberhard, Jon M. Fukuto and Louis J. Ignarro. Amplified nitric oxide production by pulmonary alveolar macrophages of newborn rats. Redox Report 2:309-316, 1996.
159. Hong Sheng and Louis J. Ignarro. Biochemical and immunohistochemical characterization of nitric oxide synthase in the rat retina. Pharmacol. Res. 33:29-34, 1996.
160. Kiyozo Morita, Kai Ihnken, Gerald D. Buckberg and Louis J. Ignarro. Oxidative insult associated with hyperoxic cardiopulmonary bypass in the infantile heart and lung. Jpn. Circ. J. 60:355-363, 1996.

161. Ettore Cicinelli, Louis J. Ignarro, Marcello Lograno, P. Galantino, G. Balzano and Luca Maria Schonauer. Circulating levels of nitric oxide in fertile women in relation to the menstrual cycle. Fertility and Sterility 66:1036-1038, 1996.
162. J. E. Merrill, S. P. Murphy, B. Mitrovic, A. Mackenzie-Graham, J. C. Dopp, M. Ding, J. Griscavage, L.J. Ignarro and C. J. Lowenstein. Inducible nitric oxide synthase and nitric oxide production by oligodendrocytes. J. Neurosci. Res. 48:372-384, 1997.
163. M. Ding, B. A. St. Pierre, J. F. Parkinson, P. Medberry, J. L. Wong, N. E. Rogers, L. J. Ignarro and J. E. Merrill. Inducible nitric oxide synthase and nitric oxide production in human fetal astrocytes and microglia. J. Biol. Chem. 272:11327-11335, 1997.
164. Rajan Singh, Sheila Pervin, Norma E. Rogers, Louis J. Ignarro and Gautam Chaudhuri. Evidence for the presence of an unusual nitric oxide and citrulline-producing enzyme in rat kidney. Biochem. Biophys. Res. Commun. 232:672-677, 1997.
165. Robert E. Glasgow, Georgette M. Buga, Louis J. Ignarro, Gautam Chaudhuri and Michael A. Heymann. Endothelium-derived relaxing factor as a mediator of bradykinin-induced perinatal pulmonary vasodilation in fetal sheep. Reprod. Fert. Dev. 9:213-216, 1997.
166. Ettore Cicinelli, Louis J. Ignarro, Marcello Lograno, Giuseppina Matteo, Nunziata Falco and Luca Maria Schonauer. Acute effects of transdermal estradiol administration on plasma levels of nitric oxide in postmenopausal women. Fertility and Sterility 67:63-66, 1997.
167. Kai Ihnken, Kiyozo Morita, Gerald D. Buckberg, B. Winkelmann, M. Schmitt, Michael P. Sherman and Louis J. Ignarro. Nitric oxide-induced reoxygenation injury in the cyanotic immature heart is prevented by controlling oxygen content during initial reoxygenation. Angiology 48:189-202, 1997.
168. A. Mizuno, R. Baretti, Gerald D. Buckberg, Helen H. Young, J. Vinten-Johnson, X.L. Ma and Louis J. Ignarro. Endothelial stunning and myocyte recovery after reperfusion of jeopardized muscle: A role of L-arginine blood cardioplegia. J. Thor. Cardiovasc. Surg. 113:379-389, 1997.
169. Georgette M. Buga, Liu Hua Wei, Philip M. Bauer, Jon M. Fukuto and Louis J. Ignarro. N-Hydroxyarginine and nitric oxide inhibit Caco-2 tumor cell proliferation by distinct mechanisms. Am. J. Physiol. 44:R1256-R1264, 1998.
170. Liu Hua Wei, Nicole Arabolos and Louis J. Ignarro. Certain substituted isothioureas not only inhibit NO synthase catalytic activity but also decrease translation and stability of inducible NO synthase protein. NO Biol. Chem. 2:155-164, 1998.
171. Minzhen Ding, Ming Zhang, Joyce Wong, Norma Rogers, Louis Ignarro and Rhonda Voskuhl. Cutting edge: Antisense knockdown of inducible nitric oxide synthase inhibits induction of experimental autoimmune encephalomyelitis in SJL/J mice. J. Immunol. 160: 2560-2564, 1998.
172. Benjamin Gaston, Emory Fry, Stephen Sears, W. Mitchell Heroman, Louis Ignarro and Jonathan S. Stamler. Umbilical Arterial S-nitrosothiols in stressed newborns: role in perinatal circulatory transition. Biochem. Biophys. Res. Commun. 253: 899-901, 1998.
173. Philip M. Bauer, Jon M. Fukuto, Georgette M. Buga, Anthony E. Pegg and Louis J. Ignarro. Nitric oxide inhibits ornithine decarboxylase by S-nitrosylation. Biochem. Biophys. Res. Commun. 262:355-358, 1999.

174. H. C. Champion, T. J. Bivalacqua, A. L. Hyman, L. J. Ignarro, W. J. G. Hellstrom and P. J. Kadowitz. Gene transfer of endothelial nitric oxide synthase to the penis augments erectile responses in the aged rat. Proc. Natl. Acad. Sci. USA 96:11648-11652, 1999.
175. Nestor Gonzalez-Cadavid, Louis J. Ignarro and Jacob Rajfer. Nitric oxide and the cyclic GMP system in the penis. Mol. Urol. 3:51-59, 1999.
176. Liu Hua Wei, Sidney M. Morris, Stephen D. Cederbaum, Masataka Mori and Louis J. Ignarro. Induction of arginase II in human Caco-2 tumor cells by cyclic AMP. Arch. Biochem. Biophys. 374:255-260, 2000.
177. Claudio Napoli, C. Ciacala, John L. Wallace, Franco de Negris, V. Santagada, G. Caliendo, F. Franconi, Louis J. Ignarro, and Giuseppe Cirino. Protease-activated receptor-2 modulates myocardial ischemia-reperfusion injury in the rat heart. Proc. Natl. Acad. Sci. USA 97:3678-3683, 2000.
178. Liu Hua Wei, Aaron T. Jacobs, Sidney M. Morris, Jr. and Louis J. Ignarro. IL-4 and IL-13 upregulate arginase I expression by cAMP and JAK/STAT6 pathways in vascular smooth muscle cells. Am. J. Physiol. 279:C248-C256, 2000.
179. T.J. Bivalacqua, H.C. Champion, Y.S. Mehta, A/B. Abdel-Mageed, S.C. Sikka, L.J. Ignarro, P.J. Kadowitz and W.J.G. Hellstrom. Adenoviral gene transfer of endothelial nitric oxide synthase (eNOS) to the penis improves age-related erectile dysfunction in the rat. Int. J. Impotence Res. 12: Suppl. 3, S8-S17, 2000.
180. Louis J. Ignarro, Georgette M. Buga, Liu Hua Wei, Philip M. Bauer, Guoyao Wu and Piero del Soldato. Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc. Natl. Acad. Sci. USA 98: 4202-4208, 2001.
181. Claudio Napoli, Giuseppe Cirino, Piero del Soldato, Raffaella Sorrentino, Vincenzo Sica, Mario Condorelli, Aldo Pinto and Louis J. Ignarro. Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice. Proc. Natl. Acad. Sci. USA 98: 2860-2864, 2001.
182. M. Jayachandran, Toshio Hayashi, Daigo Sumi, Navin K. Thakur, Hatsuyo Kano, Louis J. Ignarro and Akihisa Iguchi. Biochem. Biophys. Res. Commun. 280: 589-594, 2001.
183. Stefano Fiorucci, Antonio Morelli, Andrea Mencarelli, Barbara Palazzetti, Piero del Soldato and Louis J. Ignarro. An NO derivative of ursodeoxycholic acid protects against Fas-mediated liver injury by inhibiting caspase activity. Proc. Natl. Acad. Sci. USA 98: 2652-2657, 2001.
184. Li Ma, Susan N. Elliott, Giuseppe Cirino, Andre Buret, Louis J. Ignarro and John L. Wallace. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc. Natl. Acad. Sci. USA 98: 6470-6475, 2001.
185. Liu Hua Wei, Guoyao Wu, Sidney M. Morris, Jr. and Louis J. Ignarro. Elevated arginase I expression in rat aortic smooth muscle cells increases cell proliferation. Proc. Natl. Acad. Sci. USA 98: 9260-9264, 2001.
186. Philip M. Bauer, Georgette M. Buga, Jon M. Fukuto, Anthony E. Pegg and Louis J. Ignarro. Nitric oxide inhibits ornithine decarboxylase via S-nitrosylation of cysteine 360 in the active site of the enzyme. J. Biol. Chem. 276: 34458-34464, 2001.

187. Philip M. Bauer, Georgette M. Buga and Louis J. Ignarro. Role of p42/p44 mitogen-activated protein kinase and p21^{waf1/cip1} in the regulation of vascular smooth muscle cell proliferation by nitric oxide. Proc. Natl. Acad. Sci. USA **98**: 12802-12807, 2001.
188. Aaron T. Jacobs and Louis J. Ignarro. Lipopolysaccharide-induced expression of interferon- β mediates the timing of inducible nitric oxide synthase induction in RAW 264.7 macrophages. J. Biol. Chem. **276**: 4795-47957, 2001.
189. Claudio Napoli, Giancarlo Aldini, John L. Wallace, Filomena de Nigris, Roberto Maffei, Pasquale Abete, Domenico Bonaduce, Gianluigi Condorelli, Franco Rengo, Vincenzo Sica, Francesco P. D'Armiento, Chiara Mignogna, Gaetano de Rosa, Mario Condorelli, Lilach O. Lerman and Louis J. Ignarro. Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis. Proc. Natl. Acad. Sci. USA **99**: 1689-1694, 2001.
190. B. Azizzadeh, H.T. Yip, K.E. Blackwell, S. Horvath, T.C. Calcaterra, G.M. Buga, L.J. Ignarro and M.B. Wang. Nitric oxide improves cisplatin cytotoxicity in head and neck squamous cell carcinoma. The Laryngoscope **111**: 1896-1900, 2001.
191. M.V.S. Kashyap, T.D. Reil, W.S. Moore, T.X. Hoang, H.A. Gelabert, R.E. Byrns, L.J. Ignarro and J.A. Freischlag. Acute arterial thrombosis causes endothelial dysfunction: A new paradigm for thrombolytic therapy. J. Vasc. Surg. **34**: 323-329, 2001.
192. E. Cicinelli, L.J. Ignarro, P. Galantino, V. Pinto, B. Barba and S. Schonauer. Effects of tibolone on plasma levels of nitric oxide in postmenopausal women. Fertil. Steril. **78**:464-468, 2002.
193. L.J. Ignarro, R.E. Byrns, K. Trinh, M. Sisodia and G.M. Buga. Nebivolol: a selective beta(1)-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-dependent mechanisms. NO Biol. Chem. **7**:75-82, 2002.
194. L.J. Ignarro, M. Sisodia, K. Trinh, S. Bedrood, G. Wu, L.H. Wei and G.M. Buga. Nebivolol inhibits vascular smooth muscle cell proliferation by mechanisms involving nitric oxide but not cyclic GMP. NO Biol. Chem. **7**:83-90, 2002.
195. A. Ribas, S.N. Amarnani, G.M. Buga, L.H. Butterfield, V.B. Dissette, W.H. McBride, J.A. Glaspy, L.J. Ignarro and J.S. Economou. Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene-modified dendritic cell vaccines. Cancer Gene Ther. **9**:875-883, 2002.
196. C. Napoli, L.O. Lerman, F. de Nigris, J. Loscalzo, L.J. Ignarro. Glycoxidized low-density lipoprotein downregulates endothelial nitric oxide synthase in human coronary cells. J. Am. Coll. Cardiol. **40**:1515-1522, 2002.
197. S. Fiorucci, E. Antonelli, E. Distrutti, P. Del Soldato, R.J. Flower, M.J. Clark, A. Morelli, M. Perretti and L.J. Ignarro. NCX-1015, a nitric oxide derivative of prednisolone, enhances regulatory T cells in the lamina propria and protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice. Proc. Natl. Acad. Sci. U.S.A. **26**:15770-15775, 2002.
198. M. Castella, G.D. Buckberg, Z. Tan and L.J. Ignarro. Myocyte and endothelial effects of preconditioning the jeopardized heart by inhibiting Na/H exchange. J. Thorac. Cardiovasc. Surg. **124**:1113-1121, 2002.
199. A.T. Jacobs and L.J. Ignarro. Nuclear factor-kappa B and mitogen-activated protein kinases mediate nitric oxide-enhanced transcriptional expression of interferon-beta. J. Biol. Chem. **278**:8018-8027, 2003.

200. F. de Nigris, L.O. Lerman, S.W. Ignarro, G. Sica, A. Lerman, W. Palinski, L.J. Ignarro and C. Napoli. Beneficial effects of antioxidants and L-arginine on oxidation-sensitive gene expression and endothelial NO synthase activity at sites of disturbed shear stress. Proc. Natl. Acad. Sci. U.S.A. **100**:1420-1425, 2003.
201. B. Azizzadeh, G.M. Buga, G.S. Berke, B. Larian, L.J. Ignarro, K.E. Blackwell. Inhibitors of nitric oxide promote microvascular thrombosis. Arch. Facial Plast. Surg. **5**:31-35, 2003.
202. M.R. Davis, D.P. Ortegon, J.D. Kerby, L.J. Ignarro and V.S. Kashyap. Endothelial dysfunction after arterial thrombosis is ameliorated by L-arginine in combination with thrombolysis. J. Vasc. Interv. Radiol. **14**:233-239, 2003.
203. B.S. Allen, J.S. Veluz, G.D. Buckberg, E. Aeberhard and L.J. Ignarro. Deep hypothermic circulatory arrest and global reperfusion injury: avoidance by making a pump prime perfusate - a new concept. J. Thorac. Cardiovasc. Surg. **125**:625-632, 2003.
204. G. Cirino, R. Sorrentino, R. di Villa Bianca, A. Poppolo, A. Palmieri, C. Imbimbo, F. Fusco, N. Longo, G. Tajana, L.J. Ignarro and V. Mirone. Involvement of beta 3-arenergic receptor activation via cyclic GMP-but not NO-dependent mechanisms in human corpus cavernosum function. Proc. Natl. Acad. Sci. U.S.A. **100**:5531-5536, 2003.
205. D. Sumi, T. Hayashi, H. Matsui-Hirai, A.T. Jacobs, L.J. Ignarro and A. Iguchi. 17beta-estradiol inhibits NADPH oxidase activity through the regulation of p47phox mRNA and protein expression in THP-1 cells. Biochim. Biophys. Acta. **1640**:113-118, 2003.
206. A.T. Jacobs and L. J. Ignarro. Cell density-enhanced expression of inducible nitric oxide synthase in murine macrophages mediated by interferon-beta. NO Biol. Chem. **8**:222-230, 2003.
207. P.A. Juliet, T. Hayashi, A. Iguchi and L.J. Ignarro. Concomitant production of nitric oxide and superoxide in human macrophages. Biochim. Biophys. Res. Commun. **310**:367-370, 2003.
208. D. Sumi and L.J. Ignarro. Estrogen-related receptor alpha 1 up-regulates endothelial nitric oxide synthase expression. Proc. Natl. Acad. Sci. U.S.A. **100**:14451-14456, 2003.
209. M. Castella, G.D. Buckberg, S. Saleh, Z. Tan and L.J. Ignarro. A new role for cardioplegic buffering: should acidosis or calcium accumulation be counteracted to salvage jeopardized hearts? J. Thorac. Cardiovasc. Surg. **126**:1442-1448, 2003.
210. T. Hayashi, D. Sumi, P.A. Juliet, H. Matsui-Hirai, Y. Asai-Tanaka, H. Kano, A. Fukatsu, T. Tsunekawa, A. Miyazaki, A. Iguchi and L.J. Ignarro. Gene transfer of endothelial NO synthase, but not eNOS plus inducible NOS, regressed atherosclerosis in rabbits. Cardiovasc. Res. **61**:339-351, 2004.
211. K. Takeuchi, H. Watanabe, Q.K. Tran M. Ozeki, D. Sumi, T. Hayashi, A. Iguchi, L.J. Ignarro, K. Ohashi and H. Hayashi. Nitric oxide: inhibitory effects on endothelial cell calcium signaling, prostaglandin 12 production and nitric oxide synthase expression. Cardiovasc. Res. **62**:194-201, 2004.
212. H.J. Garban, G.M. Buga and L.J. Ignarro. Estrogen receptor-mediated vascular responsiveness to nebigolol: a novel endothelium-related mechanism of therapeutic vasorelaxation. J. Cardiovasc. Pharmacol. **43**:638-644, 2004.

213. C. Napoli, S. Williams Ignarro, F. de Nigris, L.O. Lerman, L. Rossi, C. Guarino, G. Mansueto, F. Di Tuoro, O. Pignalosa, G. De Rosa, V. Sica and L.J. Ignarro. Long-term combined beneficial effects of physical training and metabolic treatment on atherosclerosis in hypercholesterolemic mice. Proc. Natl. Acad. Sci. U.S.A. **101**:8797-8802, 2004.
214. D. Sumi and L.J. Ignarro. Regulation of inducible nitric oxide synthase expression in advanced glycation end product-stimulated RAW 264.7 cells: The role of heme oxygenase-1 and endogenous nitric oxide. Diabetes **53**:1841-1850, 2004.
215. D. Sumi and L.J. Ignarro. Sp1 transcription factor expression is regulated by estrogen-related receptor $\alpha 1$. Biochim. Biophys. Res. Commun. **328**:165-172, 2005.
216. H.J. Garban, D. Marquez-Garban, R. Pietras and L.J. Ignarro. Rapid nitric oxide-mediated S-nitrosylation of estrogen receptor: Regulation of estrogen-dependent gene transcription. Proc. Natl. Acad. Sci. U.S.A. **102**:2632-2636, 2005.
217. F. de Nigris, S. Williams Ignarro, L.O. Lerman, E. Crimi, C. Botti, G. Mansueto, F.P. D'Armiento, G. De Rosa, V. Sica, L.J. Ignarro and C. Napoli. Beneficial effects of pomegranate juice on oxidation-sensitive genes and endothelial nitric oxide synthase activity at sites of perturbed shear stress. Proc. Natl. Acad. Sci. U.S.A. **102**:4896-4901, 2005.
218. T. Hayashi, P.A. Juliet, H. Matsui-Hirai, A. Fukatsu, J. Funami, A. Iguchi and L.J. Ignarro. L-citrulline and l-arginine supplementation retards the progression of high-cholesterol-diet-induced atherosclerosis in rabbits. Proc. Natl. Acad. Sci. U.S.A. **102**:13681-13686, 2005.

REVIEWS, MONOGRAPHS AND BOOK CHAPTERS:

1. Louis J. Ignarro. Hormonal control of lysosomal enzyme release from human neutrophils by cyclic nucleotides and autonomic neurohormones. In: Cyclic Nucleotides in Disease. Ed. B. Weiss. University Park Press, pp. 187-210, 1975.
2. Louis J. Ignarro. Regulation of lysosomal enzyme release by prostaglandins, autonomic neurohormones and cyclic nucleotides. In: Lysosomes in Biology and Pathology. Eds. J. Dingle and R. Dean, Vol. 4, Chap. 15, pp. 481-523, 1975.
3. Louis J. Ignarro. Bioregulation of lysosomal enzyme secretion from human neutrophils. Agents and Actions, Vol. 4, pp. 241-258, 1974.
4. William J. George, Philip J. Kadowitz and Louis J. Ignarro. Effects of autonomic agents on force of contraction and levels of cyclic AMP or cyclic GMP in isolated paced artia. Advances in Cyclic Nucleotide Research, Vol. 5, p. 836, 1974.
5. Louis J. Ignarro and William J. George. Regulation of lysosomal enzyme discharge from human neutrophils. Advances in Cyclic Nucleotide Research, Vol. 5, p. 821, 1974.
6. William J. George and Louis J. Ignarro. Antagonistic effects of cyclic nucleotides in cardiac muscle. Myocardial Metabolism, Vol. 5, 1974.
7. William J. George, Louis J. Ignarro and LuAnn E. White. Muscarinic stimulation of cardiac guanylate cyclase. In: Myocardial Cell Damage, Vol. 4, University Park Press, Baltimore, Maryland, 1974.
8. Louis J. Ignarro. Pharmacologic modulation of lysosomal enzyme secretion. Rheumatology, Vol. 7, 1978.
9. Louis J. Ignarro. Regulation of polymorphonuclear leukocyte, macrophage and platelet function. In: Immunopharmacology. Eds. J.W. Hadden, R.G. Coffey and F. Spreafico, Plenum, New York, pp. 61-86, 1977.
10. Louis J. Ignarro. Cyclic nucleotides and lysosomal enzyme secretion. In: Cyclic Nucleotides: Mechanisms of Action. Eds. H. Cramer and J. Schultz, Wiley & Sons, Ltd., England, pp. 189-206, 1977.
11. Louis J. Ignarro and Rosemarie A. Gross. Opposing influences of guanosine 5'-tetraphosphate (GTetP) and adenosine 5'-tetraphosphate (ATetP) on mammalian adenylate and guanylate cyclase activities. Advances in Cyclic Nucleotide Research, Vol. 9, p. 740, 1978.
12. Stella Y. Cech and Louis J. Ignarro. Cytidine 3',5'-monophosphate (cCMP) formation from CTP by a whole homogenate fraction of mouse liver. Advances in Cyclic Nucleotide Research, Vol. 9, p. 770, 1978.
13. Louis J. Ignarro. Interference with stimulus-secretion coupling by glucocorticosteroids. Advances in Cyclic Nucleotide Research, Vol. 9, pp. 677-689, 1978.
14. Louis J. Ignarro and Stella Y. Cech. Enzymatic formation of cyclic CMP by mammalian tissues. In: Covalent and Non-covalent Modulation of Protein Function. ICN-UCLA Symposia on Molecular and Cellular Biology, Vol. 13. Eds. D. Atkinson and C.F. Fox, Academic Press, New York, NY, pp. 315-333, 1979.

15. Louis J. Ignarro, Carl A. Gruetter, Albert L. Hyman and Philip J. Kadowitz. Molecular mechanisms of vasodilatation. In: Dopamine Receptor Agonists. Eds. G. Poste and S.T. Crooke, Plenum, New York, pp. 259-288, 1984.
16. Louis J. Ignarro, Keith S. Wood and Michael S. Wolin. Regulation of purified soluble guanylate cyclase by porphyrins and metalloporphyrins: A unifying concept. Adv. Cyclic Nucleotide Res. 17:267-274, 1984.
17. Louis J. Ignarro and Philip J. Kadowitz. Pharmacological and physiological role of cyclic GMP in vascular smooth muscle relaxation. Annual Rev. Pharmacol. 25:171-191, 1985.
18. Louis J. Ignarro and Philip J. Kadowitz. Relationships among endothelium, cGMP, and relaxation of pulmonary vessels. In: Acute Lung Injury. Eds. H. Kazemi, A.L. Hyman and P.J. Kadowitz, PSG, MA, pp. 247-264, 1986.
19. Louis J. Ignarro, Russell E. Byrns and Keith S. Wood. Biochemical and pharmacological properties of EDRF and its similarity to NO radical. In: Vasodilatation: Vascular Smooth Muscle, Peptides, Autonomic Nerves, and Endothelium. Ed. P.M. Vanhoutte, Raven Press, pp. 427-435, 1988.
20. Louis J. Ignarro, Russell E. Byrns and Keith S. Wood. Endothelium-dependent regulation of resting cyclic GMP and cyclic AMP levels and tension in pulmonary artery and vein. In: Relaxing and Contracting Factors. Ed. P.M. Vanhoutte, Humana Press, New Jersey, pp. 309-332, 1988.
21. Louis J. Ignarro. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. (Invited Review) Circ. Res. 65:1-21, 1989.
22. Louis J. Ignarro. Endothelium-derived nitric oxide: actions and properties. (Invited Review) FASEB J. 3:31-36, 1989.
23. Louis J. Ignarro. Heme-dependent activation of soluble guanylate cyclase by nitric oxide: regulation of enzyme activity by porphyrins and metalloporphyrins. (Invited Review) Seminars in Hematology 26:63-76, 1989.
24. Louis J. Ignarro and Michele E. Gold. Alteration of endothelium-dependent arterial relaxation by arginine analogs and arginine depletion. In: Endothelium-Derived Vasoactive Factors. Ed. G.M. Rubanyi and P.M. Vanhoutte, Karger, Basel, pp. 64-74, 1990.
25. Louis J. Ignarro. Endothelium-derived nitric oxide: Pharmacology and relationship to the actions of organic nitrate esters. (Invited Review) Pharmaceut. Res. 6:651-659, 1989.
26. Louis J. Ignarro. Biosynthesis and metabolism of endothelium-derived nitric oxide. (Invited Review) Annu. Rev. Pharmacol. Toxicol. 30:535-560, 1990.
27. Louis J. Ignarro. Heme-dependent activation of guanylate cyclase and cyclic GMP formation by endogenous nitric oxide: A novel transduction mechanism for transcellular signaling. (Invited MiniReview) Pharmacol. Toxicol. 67:1-7, 1990.
28. Louis J. Ignarro. Endothelium-derived relaxing factor. (Invited Monograph) Encyclopedia of Human Biology Vol. 3, 371-376, 1991.
29. Louis J. Ignarro. Nitric Oxide: A novel signal transduction mechanism for transcellular communication. (Invited Review) Hypertension 16:477-483, 1990.

30. Louis J. Ignarro. Heme-dependent activation of guanylate cyclase by nitric oxide: A novel signal transduction mechanism. (Invited Monograph) Blood Vessels 28:67-73, 1991.
31. Louis J. Ignarro, Keith S. Wood, and Jon M. Fukuto. Continuous basal formation of endothelium-derived relaxing factor and muscle-derived relaxing factor, both of which are nitric oxide. (Invited Monograph) J. Cardiovasc. Pharmacol. 17:S229-S233, 1991.
32. Louis J. Ignarro. Signal transduction mechanisms involving nitric oxide (Invited Review) Biochem. Pharmacol. 41:485-490, 1991.
33. Louis J. Ignarro. Physiological significance of endogenous nitric oxide. In: Seminars in Perinatology - Endothelium-Derived Vasoactive Substances. Eds: G. Chaudhuri, L.J. Ignarro and D. McNellis; W.B. Saunders Company; 15:20-26, 1991.
34. Louis J. Ignarro, Gordon Ross and Jan Tillisch. Conferences and Reviews: Pharmacology of endothelium-derived nitric oxide and nitrovasodilators. West. J. Med. 154:51-62, 1991.
35. Louis J. Ignarro. Pharmacological, biochemical, and chemical evidence that EDRF is NO or a labile nitroso precursor. In: Endothelial Regulation of Vascular Tone. Eds: U.S. Ryan and G.M. Rubanyi; Marcel Dekker, Inc.; pp 37-49, 1992.
36. Louis J. Ignarro and georgette M. Buga. Vascular smooth muscle and endothelial cell function. In: Perinatal and Pediatric Pathophysiology: A Clinical Perspective. Eds: P.D. Gluckman and M.A. Heymann; Edward Arnold Publishers Ltd; pp.462-471, 1993.
37. Louis J. Ignarro. Nitric oxide as a communication signal in vascular and neuronal cells. In: NITRIC OXIDE Principles and Actions. Ed. J.R. Lancaster, Jr.; Academic Press; pp. 111-137, 1996.
38. Louis J. Ignarro. Regulation of cytosolic guanylyl cyclase by porphyrins and metalloporphyrins. In: Cyclic GMP: Synthesis, Metabolism and Function. Ed. F. Murad; Academic Press; Vol. 26:35-65, 1994.
39. Louis J. Ignarro. The physiological and pathophysiological significance of nitric oxide. In: Textbook of Critical Care. 3rd edition. Eds: A. Grenvik, P.R. Holbrook, W.C. Shoemaker; W.B. Saunders Company; Chapter 27, pp. 208-215, 1995.
40. Louis J. Ignarro. Nitric oxide-mediated vasorelaxation. In: Thrombosis and Haemostasis. Ed. M.B. Zucker; Vol. 70:148-151, 1993.
41. Peggy A. Bush, William J. Aronson, Jacob Rajfer and Louis J. Ignarro. The L-arginine-nitric oxide-cyclic GMP pathway mediates inhibitory nonadrenergic-noncholinergic neurotransmission in the corpus cavernosum of human and rabbit. Circulation 87 (Suppl. V):V-30 - V-32, 1993.
42. G. Chaudhuri, J.F. Pensabene, C.I. Kim, L.J. Ignarro and B.C. Bloor. Hyperoxia attenuates the vascular actions of endogenous nitric oxide in awake, chronically instrumented, miniswine in vivo. In: Biology of Nitric Oxide. pp. 142-149, 1993.
43. Louis J. Ignarro. Regulation of cytosolic guanylyl cyclase by porphyrins and metalloporphyrins. In: Advances in Pharmacology. Vol. 26: 35-65, 1994.
44. Jeanette M. Griscavage, Adrian J. Hobbs and Louis J. Ignarro. Negative modulation of nitric oxide synthase by nitric oxide and nitroso compounds. In: Advances in Pharmacology. Vol. 34: 215-234, 1995.

45. Louis J. Ignarro. Volume editor: Nitric Oxide - Biochemistry, Molecular Biology, and Therapeutic Implications. In: Advances in Pharmacology. Vol. 34, 1995, Academic Press.
46. Louis J. Ignarro. Physiology and pathophysiology of nitric oxide. In: 8th European Congress of Intensive Care Medicine, pp. 23-31, 1995.
47. Louis J. Ignarro. Physiology and pathophysiology of nitric oxide. Role of nitric oxide in the pathophysiology of hypertension. In: Kidney International. Vol. 49, Suppl. 55, pp. S2-S5, 1996.
48. Louis J. Ignarro. Nitric Oxide as a Communication Signal in Vascular and Neuronal Cells. In: Nitric Oxide Principles and Actions. Ed. Jack Lancaster, Jr.; Academic Press; pp. 111-137, 1996.
49. Adrian J. Hobbs and Louis J. Ignarro. Nitric Oxide-Cyclic GMP Signal Transduction System. In: Methods in Enzymology - Nitric Oxide - Part B - Physiological and Pathophysiological Processes. Ed. Lester Packer; Academic Press, Inc.; 269:134-148, 1996.
50. Adrian J. Hobbs and Louis J. Ignarro. The Nitric Oxide Cyclic GMP Signal Transduction System. In: Nitric Oxide and the Lung. Eds. W. M. Zapol and K. D. Bloch; Marcel Dekker, Inc.; pp. 1-57, 1997.
51. Louis J. Ignarro. Activation and regulation of the nitric oxide-cyclic GMP signal transduction pathway by oxidative stress. In: Oxidative Stress and Signal Transduction. Eds. E. Cadenas and H. J. Forman; Chapman & Hall, pp. 3-31, 1997.
52. Jon M. Fukuto and Louis J. Ignarro. *In vivo* aspects of nitric oxide (NO) chemistry: Does peroxynitrite (OONO) play a major role in cytotoxicity? Accounts Chem. Res. 30:149-152, 1997.
53. Adrian J. Hobbs and Louis J. Ignarro. Chemistry and Molecular Biology of Nitric Oxide Synthesis. In: The Haemodynamic Effects of Nitric Oxide. Eds. R.T. Mathie and T.M. Griffith; Imperial College Press, pp. 52-81, 1999.
54. Louis J. Ignarro. Nitric Oxide: A unique endogenous signaling molecule in vascular biology (Nobel Lecture). Angew. Chem. Int. Ed. 38: 1882-1892, 1999.
55. Louis J. Ignarro, Giuseppe Cirino, Alessandro Casini and Claudio Napoli. Nitric oxide as a signaling molecule in the vascular system: an overview. J. Cardiovascular Pharmacol. 34: 879-886, 1999.
56. Louis J. Ignarro. Nitric Oxide: A unique endogenous signaling molecule in vascular biology. Bioscience Reports 19: 51-71. 1999.
57. Louis J. Ignarro, Giuseppe Cirino, Alessandro Casini and Claudio Napoli. Nitric oxide as a signaling molecule in the vascular system: an overview. J. Cardiovasc. Pharmacol. 34: 876-884, 1999.
58. Louis J. Ignarro, Giuseppe Cirino, Alessandro Casini and Claudio Napoli. Nitric oxide as a signaling molecule in the vascular system: an overview. J. Cardiovascular Pharmacol. 34: 879-886, 1999.
59. Louis J. Ignarro. Nitric oxide in the regulation of blood flow. In: Nitric Oxide and the Regulation of the Peripheral Circulation. Eds. P.J. Kadowitz and D.B. McNamara; Birkhäuser, pp. 1-12, 2000.

60. Louis J. Ignarro. Introduction and Overview. In: Nitric Oxide – Biology and Pathobiology. Ed. L. J. Ignarro; Academic Press, San Diego, pp. 3-19, 2000.
61. Georgette M. Buga and Louis J. Ignarro. Nitric Oxide and Cancer. In: Nitric Oxide – Biology and Pathobiology. Ed. L. J. Ignarro; Academic Press, San Diego, pp. 895-920, 2000.
62. Louis J. Ignarro and Aaron Jacobs. Nitric oxide synthase and the production of nitric oxide. In: Handbook of Chemical Neuroanatomy, Volume 17 – Functional Neuroanatomy of the Nitric Oxide System. Eds. H.W.M. Steinbusch, J. De Vente and S.R. Vincent; Elsevier, pp. 1-17, 2000.
63. Claudio Napoli and Louis J. Ignarro. Nitric oxide and atherosclerosis. NO Biol. Chem. 5: 88-97, 2001.
64. Louis J. Ignarro, Claudio Napoli and Joseph Loscalzo. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide – an overview. Circ. Res. 90: 21-28, 2002.
65. Louis J. Ignarro. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J. Physiol. Pharmacol. 53:503-514, 2002.
66. Louis J. Ignarro. After 130 years, the molecular mechanism of action of nitroglycerin is revealed. Proc. Natl. Acad. Sci. U.S.A. 99:7816-7817, 2002.
67. John L. Wallace, Louis J. Ignarro and Stefano Fiorucci. Potential cardioprotective actions of NO-releasing aspirin. Nat. Rev. Drug Discov. 1:375-382, 2002.
68. Claudio Napoli and Louis J. Ignarro. Nitric oxide-releasing drugs. Annu. Rev. Pharmacol. Toxicol. 43:97-123, 2003.
69. Filomena de Nigris, A. Lerman, Louis J. Ignarro, Sharon Williams Ignarro, Vincenzo Sica, A.H. Baker, Lilach O. Lerman, Y.J. Geng and Claudio Napoli. Oxidation-sensitive mechanisms, vascular apoptosis and atherosclerosis. Trends Mol. Med. 9:351-359, 2003.

SPECIAL EVENTS:

1. One of four participants in Panel Discussion on "Lysosomes and the immune response." ASPET Meetings, Fall 1970.
2. Chairman, session on LYSOSOMES, 1972 FASEB in Atlantic City, New Jersey.
3. Invited speaker, Gordon Research Conference on LYSOSOMES, in Andover, N.H., July 1972.
4. President elect, 1972-1973, RESA (division of Sigma Xi), Westchester Branch.
5. Chairman and guest speaker, session on LYSOSOMES AND TISSUE INJURY, Biochemical Pharmacology Research Discussion Group (N.Y. Acad. Sci.), September 1972.
6. Chairman, session on CYCLIC NUCLEOTIDES, 1973 ASPET in East Lansing, Michigan.
7. Invited speaker, Symposium on CYCLIC NUCLEOTIDES IN DISEASE, sponsored by the Medical College of Pennsylvania and the Physiological Society of Philadelphia, in Philadelphia, Pa., April 1974.
8. Invited speaker, Gordon Research Conference on CYCLIC AMP, in Tilton, N.H., June 1974.
9. Invited speaker, Second International Congress of Immunology, in Brighton, England, July 1974.
10. Invited speaker, International Symposium on THE CHEMISTRY AND BIOLOGY OF THE KALLIKREIN-KININ SYSTEM IN HEALTH AND DISEASE, sponsored by the Fogarty International Center and the N.H.L.I. of the N.I.H., Reston, Va., October 1974.
11. Invited speaker, Texas Medical Association, Annual Meeting (1975), San Antonio, Texas, May 1, 1975.
12. Chairman, session on CYCLIC GMP, 1975 FASEB in Atlantic City, New Jersey.
13. Invited speaker, Gordon Research Conference on Cyclic Nucleotides, in Tilton, N.H., June 1975.
14. Chairman, session on CYCLIC GMP, 1975 ASPET in Davis, California.
15. Chairman, session on CYCLIC AMP, 1976 FASEB in Anaheim, California.
16. Chairman, session on CYCLIC AMP, 1977 FASEB in Chicago, Illinois.
17. Invited speaker, Symposium on Cyclic Nucleotides and Biologic Regulation, 1976 ASPET in New Orleans, Louisiana.
18. One of two chairmen, Third International Conference on Cyclic Nucleotides, 1977, New Orleans, Louisiana. An editor of Advances in Cyclic Nucleotide Research, Volume 9, 1977.
19. Invited speaker, ICN-UCLA Symposia on Molecular and Cellular Biology, "Covalent and Non-Covalent Modulation of Protein Function," Denver, Colorado, 1979.
20. Chairman, session on CYCLIC GMP, 1979 FASEB in Dallas, Texas.

21. Chairman, Symposium on Cyclic Nucleotides and Smooth Muscle Function, 1981 ASPET in Calgary, Canada.
22. Chairman, Symposium on Cyclic Nucleotides and Vascular Smooth Muscle Relaxation, 1982 FASEB in New Orleans, LA.
23. Chairman, session on CYCLIC NUCLEOTIDES, 1983 FASEB in Chicago, Illinois.
24. Invited speaker, Smith Kline & French Symposium on "Dopamine Receptor Agonists," Philadelphia, PA, 1983.
25. Chairman and Invited Speaker, session on GUANYLATE CYCLASE AND CYCLIC GMP, Fifth International Conference on Cyclic Nucleotides and Protein Phosphorylation, Milan, Italy, 1983.
26. Chairman and Invited Speaker, session on ORGANIC NITRATE VASODILATORS, Boehringer-Mannheim Symposium on Antihypertensive Drug Therapy, Montreaux, Switzerland, 1984.
27. Guest Symposium Speaker, The 50th Jubilee Congress of the Hungarian Physiological Society, IUPS sponsored Satellite Symposium "Endothelial Cell Function," Budapest, Hungary, 1985.
28. Invited Speaker, IV International Symposium on Mechanisms of Vasodilation, 1986, Rochester, Minnesota.
29. Invited Speaker, Gordon Research Conference on Chemistry of Pyrroles, Brewster, N.H., July 1986.
30. Invited Speaker, Workshop on Neurotransmitter Deficiencies in Alzheimer's Disease, 1986, Los Angeles, California.
31. Invited Speaker, XI International Congress on Thrombosis and Haemostasis, Brussels, Belgium, July 1987.
32. Invited Speaker, VI International Symposium on Vascular Neuroeffector Mechanisms, Melbourne, Australia, Sept. 1987.
33. Chairman and Speaker, Symposium on EDRF: Identification, Properties and Metabolism, F.A.S.E.B. Symposium, Las Vegas, May, 1988.
34. Chairman, session on Endothelium-Derived Relaxing Factor, F.A.S.E.B., Las Vegas, May, 1988.
35. Associate Editor, Chemical Rubber Company (CRC) series: Critical Reviews in Pharmacological Sciences, 1988-.
36. Invited speaker, VI European and American Cardiology at the Hammersmith, University of London, Royal Postgraduate Medical School, sessions on Mechanisms of Vasodilation and Mechanism of Action of Nitroglycerin, London, England, June, 1988.
37. Invited speaker, FASEB Summer Research Conference on Endothelium and Cardiovascular Function, Copper Mountain, Colorado, August, 1988.
38. Moderator and Speaker, UCLA CHS School of Medicine Interdepartmental Conference, Pharmacology of Vasodilators, 1989.

39. Invited speaker, Debate: Is EDRF Nitric Oxide?, F.A.S.E.B., New Orleans, April, 1989.
40. Invited speaker, First International Symposium on Endothelium-Derived Vasoactive Factors, Alteration of Endothelium-Dependent Relaxation by Arginine Analogs and Arginine Depletion, Philadelphia, May, 1989.
41. Invited speaker, 3rd Cardiovascular Pharmacotherapy International Symposium on Nitrate Research: Present Status and Future Prospects, Kyoto, Japan, October, 1989.
42. Invited speaker, 3rd Cardiovascular Pharmacotherapy International Symposium on Prostaglandins and the Endothelium in the Cardiovascular System, Kyoto, Japan, October, 1989.
43. Invited Chairman and Moderator, 3rd Cardiovascular Pharmacotherapy International Symposium, Free Communication session on Endothelium-Dependent Vasodilator Responses; and Free Communication session on Nitrates in the Treatment of Angina, Kyoto, Japan, October, 1989.
44. Invited Lecturer, American Society of Clinical Pharmacology and Therapeutics, Heme-Dependent Activation of Guanylate Cyclase by Nitrogen-Containing Free Radicals Derived Endogenously or from Drugs, San Francisco, March, 1990.
45. Invited Lecturer, Symposium on Calcium and Hypertension: Theory and Clinical Applications, Modulation of Endothelium-Dependent Vascular Smooth Muscle Relaxation by Calcium, Magnesium and Cyclic GMP, Phoenix, March, 1990.
46. Invited Lecturer, Symposium on The Coronary Vasculature: Scientific Theories and Therapeutic Considerations, Endothelium-Dependent Vascular Smooth Muscle Relaxation, Monterey, June, 1990.
47. Invited Lecturer and session Chairman, IUPHAR Satellite Symposium on EDRF and EDRF-Related Substances, Endothelium-Dependent Modulation of Cyclic GMP Biosynthesis by L-Arginine and Structural Analogs of L-Arginine, Antwerp, Belgium, June, 1990.
48. Invited Lecturer and session Chairman, 1990 IUPHAR, Heme-Dependent Activation of Cytosolic Guanylate Cyclase by L-Arginine-Derived Nitric Oxide Represents a Novel Transduction Mechanism for Transcellular Signaling, Amsterdam, The Netherlands, July, 1990.
49. Invited Lecturer, 7th International Symposium on Vascular Neuroeffector Mechanisms, Heme-dependent activation of guanylate cyclase by nitric oxide: A novel signal transduction mechanism, Bonn, Germany, July, 1990.
50. Invited Speaker, CIBA-GEIGY Workshop, Nitrate Tolerance: Mechanisms and New Pharmacologic Strategies, The mechanism of action of nitric oxide and organic nitrate esters, Atlantic City, New Jersey, July, 1990.
51. Symposium Speaker and Co-Chairman, Endothelium-Derived Vasoactive Substances in Perinatal Research, Physiological significance of endogenous nitric oxide, NICHD, NIH, September, 1990.
52. Symposium Speaker, 13th Annual UC Riverside-Nichols Institute Symposium on Cellular and Molecular Endocrinology, Nitric oxide and cyclic GMP: A novel signal transduction mechanism for transcellular communication, Riverside, CA, March, 1991.

53. Symposium Speaker, The Biological Role of Nitric Oxide, The physiological role of nitric oxide and cyclic GMP in electrically induced arterial dilation and penile erection, Baltimore, MD, May, 1991.
54. Symposium Speaker, Annual Meeting of the German Physiological Society, Inhibitory nonadrenergic-noncholinergic (NANC) neurotransmission in vascular tissue involves the L-arginine-nitric oxide (NO)-cyclic GMP pathway, Freiburg, Germany, September 8, 1991.
55. Symposium Speaker, Biology of Nitric Oxide, Myocardial reoxygenation injury after ischemia is mediated by the L-arginine-nitric oxide pathway, London, U.K., September 30, 1991.
56. Session Chairman, Biology of Nitric Oxide, Cardiovascular Aspects, London, U.K., September 30, 1991.
57. Invited State-of The-Art Lecture, 64th Scientific Sessions of the American Heart Association, The L-arginine-nitric oxide-cyclic GMP pathway: A potent endogenous mechanism for modulating pulmonary vascular tone, Anaheim, CA, November 11, 1991.
58. Session Chairman, Chemistry of Nitric Oxide and Nitrovasodilators, 64th Scientific Sessions of the American Heart Association, Anaheim, CA, November 11, 1991.
59. Symposium Speaker, International Symposium on Smooth Muscle, Mechanism of action of exogenous and endogenous nitric oxide: heme-dependent activation of guanylate cyclase represents a unifying signal transduction mechanism, Fukuoka, Japan, January, 1992.
60. Invited State-of-The-Art Lecture, 2nd International Symposium on Endothelium-Derived Vasoactive Factors, The L-arginine-nitric oxide-cyclic GMP pathway mediates inhibitory nonadrenergic noncholinergic neurotransmission, Basel, Switzerland, April, 1992.
61. Symposium Speaker, The XIV World Congress of the International Society for Heart Research, Physiological and pathophysiological roles of endothelium-derived nitric oxide in the heart, Kobe, Japan, May, 1992.
62. Symposium Speaker, William Harvey Research Conference on Nitric oxide- the rational basis for nitrate therapy, Cyclic GMP - mechanism of action of nitric oxide and nitrovasodilators, London, U.K., May, 1992.
63. Invited State-of-The-Art Lecture, A Century of Pediatrics in Groningen, Cellular mechanisms of endothelial cell activation and vascular smooth muscle relaxation, Groningen, Holland, May, 1992.
64. Symposium Speaker, IBC International Conference on Nitrate Therapy, Role of the L-arginine-NO-cyclic GMP pathway in NANC neurotransmission, Philadelphia, June, 1992.
65. Invited Speaker, Gordon Research Conference on Vascular Biology, Endothelium-derived NO and the control of vascular tone, New London, N.H., July, 1992.
66. Invited Speaker, Gordon Research Conference on Medicinal Chemistry, Novel physiological and pathophysiological actions of NO, New London, N.H., August, 1992.

67. Invited State-of-the-Art Lecture, American Motility Conference, Biosynthesis, pharmacology, and biological actions of NO, Granlibakken (Lake Tahoe), September, 1992.
68. Symposium Speaker, Nitric Oxide: Brain and Immune Systems, Role of the L-arginine-NO-cyclic GMP pathway in nonadrenergic-noncholinergic transmission and penile erection, Paraelios, Calabria, Italy, September, 1992.
69. Guest Speaker, American College of Rheumatology, Physiology and pathophysiology of nitric oxide, Atlanta, GA, September, 1992.
70. Invited Speaker, Gordon Research Conference on Kinins, Pharmacological advances in nitric oxide research, Ventura, CA, February, 1993.
71. Guest Speaker, 9th Annual ECMO Conference, Cellular mechanisms of vascular endothelial function, Keystone, CO, March, 1993.
72. Symposium Speaker, American Society of Neurochemistry, Role of nitric oxide as a neuronal mediator of penile erection, Richmond, VA, March, 1993.
73. Symposium Chairman and Speaker, Experimental Biology 93, Regulation of Vascular Vasomotor Tone, Physiological significance of NO in the mammal, New Orleans, LA, March, 1993.
74. Symposium Chairman and Speaker, Experimental Biology 93, Role of Nitric Oxide in the Central and Peripheral Nervous Systems, NANC and NO mediated vasodilation in the corpus cavernosum, New Orleans, LA, March, 1993.
75. Invited Speaker, Roussel UCLAF Symposium on Nitric Oxide, Neurotransmitter role of nitric oxide, Paris, France, April, 1993.
76. Invited Speaker, Association of University Anesthesiologists, Physiological and pathophysiological significance of nitric oxide in mammalian cell function, Asheville, NC, May, 1993.
77. Invited Speaker, American Thoracic Society, Modulation of vasomotor control by nitric oxide, San Francisco, CA, May, 1993.
78. Invited Speaker, American Thoracic Society, Nitric oxide: a ubiquitous multifunctional mediator, San Francisco, CA, May, 1993.
79. Keynote Speaker, Canadian Hypertension Society, Physiological significance of nitric oxide in the cardiovascular system, Toronto, Ontario, Canada, May, 1993.
80. Invited Speaker, XII International Congress of Nephrology, Role of nitric oxide in the regulation of vascular function, Jerusalem, Israel, June, 1993.
81. Invited Speaker, XIV International Congress of Thrombosis and Haemostasis, Role of nitric oxide in modulating cardiovascular function, New York, NY, July, 1993.
82. Symposium Chairman and Speaker, American Society for Pharmacology and Experimental Therapeutics, Physiological and pathophysiological significance of nitric oxide, San Francisco, CA, July, 1993.
83. Invited Symposium Speaker, American Society for Pharmacology and Experimental Therapeutics, Pathophysiological actions of nitric oxide in myocardial reoxygenation injury, San Francisco, CA, July, 1993.

84. Invited Symposium Speaker, Bioinorganic Chemistry Conference, Regulation of nitric oxide synthase by nitric oxide, La Jolla, CA, August, 1993.
85. Invited Symposium Chairman and Speaker, Third International Conference on the Biology of Nitric Oxide, Detection of free nitric oxide from L-arginine catalyzed by nitric oxide synthase, Cologne, Germany, October, 1993.
86. Invited Symposium Chairman, Speaker, and Poster Discussant, American heart Association Symposium on Nitric Oxide and Endothelin, Regulatory role of nitric oxide in the cardiovascular system, Boston, MA, October, 1993.
87. Invited Symposium Speaker, Functionality of the Endothelium in Health and Diseased States: A Comprehensive Review, Endothelium-dependent vasorelaxation; biosynthesis and metabolism of endothelium-derived relaxing factor, Veracruz City, Mexico, November, 1993.
88. Invited Symposium Chairman and Speaker, Uehara Memorial Foundation Symposium on Endothelium-Derived Factors and vascular Functions, Regulation of vascular endothelial cell function by nitric oxide: direct inhibition of nitric oxide synthase, Tokyo, Japan, December, 1993.
89. Invited Symposium Speaker, Western Eye Research Conference V, Overview of nitric oxide in the circulation, Lake Arrowhead, CA, January, 1994.
90. Conference Chairman and Speaker, Nitric Oxide - New Therapeutic Strategies for the Treatment of Human Diseases, Cambridge Healthtech Institute, Physiological and pathophysiological significance of nitric oxide, New Orleans, LA, February, 1994.
91. Invited Gordon Research Conference Speaker, Oxygen Radicals in Biology, Nitric oxide as a reactive radical in biological systems, Ventura, CA, February, 1994.
92. Conference Chair and Symposium Speaker - IBC 3rd International Conference on Nitric Oxide - Philadelphia, PA, March, 1994.
93. Invited Symposium Speaker - 1st International Conference on Oxidative Stress and Aging, Regulation of NO synthase activity by oxygen, oxygen-derived radicals, and NO, Kailua-Kona, Hawaii, March, 1994.
94. Invited Symposium Speaker - William Harvey Research Conferences, Endothelial Cells and their Enzymes as Targets for New Drugs, Neuronal regulation of erectile function by nitric oxide, Philadelphia, PA, April, 1994.
95. Invited Symposium Speaker - Experimental Biology 94 - two talks: 1) Regulation of NO synthase activity by NO and tetrahydrobiopterin; 2) Biological roles of nitric oxide in mammalian cells - Anaheim, CA, April, 1994.
96. Invited Symposium Speaker - Midnight Sun School on Vasoactive Control of Perinatal Circulation, Regulation of nitric oxide formation in mammalian cells, Turku, Finland, June, 1994.
97. Invited Symposium Speaker - 14th European Congress of Perinatal Medicine, Regulation of nitric oxide biosynthesis by endogenous substances, Helsinki, Finland, June, 1994.
98. Conference Co-Chair and Speaker - FASEB Summer Conference on Endothelium and Cardiovascular Control - Copper Mountain, CO, June, 1994.

99. Conference Organizer and Chairman - First International Conference on the Biochemistry and Molecular Biology of Nitric Oxide, Sunset Village, Westwood, California, July, 1994.
100. Invited Symposium Speaker - 20th Anniversary Symposium for the Whitaker Cardiovascular Institute, Physiological roles for nitric oxide in mammalian systems, Boston, MA, October, 1994.
101. Invited Symposium Speaker - Aprather Symposium on Endothelial Factors, History and overview of nitric oxide, Wuppertal, Germany, October, 1994.
102. Recipient of the Roussel Uclaf Prize for "Cell Communication and Signaling", Physiological significance of the nitric oxide-cyclic GMP signal transduction pathway, Paris, France, October, 1994.
103. Keynote Speaker - Division of Cardiology Meeting, Physiological and pathophysiological significance of nitric oxide, UCLA School of Medicine, Westwood, California, November, 1994.
104. Conference Co-Chair and Speaker - First Gordon Research Conference on Nitric Oxide in Biochemistry and Biology, Ventura, California, February, 1995.
105. Invited Symposium Speaker - Nitrate Compounds in Cardiovascular Disease: Clinical Significance and Basic Mechanisms of Action and Tolerance Development, Cyclic GMP as a mediator of vascular signaling, Baden-Baden, Germany, March, 1995.
106. Invited Symposium Speaker - First International Seminar on Vascular Biology and Medicine, Biological role of the nitric oxide-cyclic GMP pathway in vascular function, Pamplona, Spain, April, 1995.
107. Invited Symposium Speaker - 1st Orvieto Symposium: New developments in Nitric Oxide Research, Biosynthesis of nitric oxide: regulation by tetrahydrobiopterin, nitric oxide and superoxide dismutase, Orvieto, Italy, April, 1995.
108. Wellcome Visiting Professor - Marshall University School of Medicine, Huntington, West Virginia, May, 1995.
109. Invited Symposium Speaker and Session Chairman - Instituto Juan March: Center for International Meetings on Biology - Workshop on Molecular Biology and Pathophysiology of Nitric Oxide - Transcriptional regulation of inflammatory NO synthase by antioxidants, metal chelators, proteasome inhibitors and NSAIDs, Madrid, Spain, June, 1995.
110. Keynote Speaker - Great Lakes Chapter of ASPET - Physiological and pathophysiological significance of nitric oxide in mammalian cell function, Rush University, Chicago, Illinois, June, 1995.
111. Invited Faculty Congress Lecturer - 13th International Congress of Nephrology - Satellite Symposium on Hypertension: Cause and Consequence of Renal Injury - Physiology and pathophysiology of nitric oxide, Barcelona, Spain, July, 1995.
112. Invited Symposium Speaker - 9th International Conference on Cytochrome P450 - Regulation of NO synthase activity by NO: A negative feedback modulation, Zurich, Switzerland, July, 1995.

113. Invited Symposium Speaker and Session Chairman - Fourth International Meeting Biology of Nitric Oxide - Nonsteroidal antiinflammatory drugs prevent transcriptional expression of the inducible NO synthase gene in macrophages by interfering with NF- κ B activation, Amelia island, Florida, September, 1995.
114. Invited Symposium Speaker and Session Chairman - 8th European Congress of Intensive Care Medicine - Physiology and pathophysiology of nitric oxide, Athens, Greece, October, 1995.
115. Guest Speaker - Medical Scientist Lecture Series for the M.D. - Ph.D. Program at the University of California at Irvine, School of Medicine - Physiology and pathophysiology of nitric oxide in mammalian cell function, Irvine, California, November, 1995.
116. Invited Speaker - Oxygen '95 - Annual conference of The Oxygen Society - Regulation of nitric oxide synthesis and action, Pasadena, California, November, 1995.
117. Invited Symposium Speaker - 211th American Chemical Society National Meeting & Exposition Program - The biology of nitric oxide, New Orleans, Louisiana, March, 1996.
118. Invited Guest Symposium Speaker - Physiological Responses of Nitric Oxide: A Tribute to Robert F. Furchgott - Physiological and pathophysiological roles of nitric oxide, Baltimore, Maryland, May, 1996.
119. Conference Organizer and Chairman - Second International Conference on the Biochemistry and Molecular Biology of Nitric Oxide, Sunset Village, Westwood, California, July, 1996.
120. Invited Symposium Speaker - VIII Biennial Meeting of the International Society for Free Radical Research - Interactions between nitric oxide and oxygen radicals, Barcelona, Spain, October, 1996.
121. Invited Opening Lecture - 4th Annual Meeting of the Japanese Vascular Biology Organization - Physiological and pathophysiological roles of nitric oxide in vascular function, Kobe, Japan, October, 1996.
122. Invited Symposium Speaker - Kobe International Symposium on Nitric Oxide in Cardiovascular Disease - Regulation of expression and catalytic activity of inducible NO synthase, Kobe, Japan, October, 1996.
123. Keynote Lecture - 4th Congreso Argentino de Hipertension Arterial - Physiological and pathophysiological roles of nitric oxide in mammalian cell function, Buenos Aires, Argentina, November, 1996.
124. Honorary Doctorate Degree - Special Lecture - University of Buenos Aires, Faculty of Pharmacy and Biochemistry - Physiology and pathophysiology of nitric oxide, Buenos Aires, Argentina, November, 1996.
125. Conference Organizer and Chairman - Second Gordon Research Conference on Nitric Oxide in Biochemistry and Biology - Ventura, California, February, 1997.
126. Presidential Lecture - 7th International Symposium on Clinical Intensive Care Medicine - Nitric oxide (NO): the story of a gas, Bremen, Germany, February, 1997.
127. Special Lecture - Royal College of Physicians of London - Endothelial Factors for Clinicians: Their Impact on Disease and Possible Future Therapeutic Implications - Nitric Oxide, London, U.K., February, 1997.

128. Invited Symposium Speaker - Oxygen Club of California - Oxidants and Antioxidants in Biology - Oxidative stress and the induction of high-output nitric oxide production, Santa Barbara, California, February, 1997.
129. Invited Symposium Speaker - American Society for Pharmacology and Experimental Therapeutics - Nitric Oxide: New Discoveries and their Clinical Implications - Nitric oxide and gene regulation in chronic inflammatory diseases, San Diego, California, March, 1997.
130. Presidential Lecture - Society for Gynecological Investigation - Physiology and pathophysiology of nitric oxide in mammalian systems, San Diego, San California, March, 1997.
131. American Physiological Society Respiration Dinner Speaker - Nitric Oxide: Past, Present and Future, New Orleans, Louisiana, April, 1997.
132. James O. Davis Graduate Student Lectureship - Physiology and pathophysiology of the arginine-nitric oxide pathway, Columbia, Missouri, April, 1997.
133. Opening Lecture - International Symposium on Nitric Oxide: Basic and Clinical Pharmacology - Nitric oxide: from nitroglycerin to EDRF to ubiquity, Odense, Denmark, June, 1997.
134. Nobel Series Lectures - Nobel Forum - Karolinska Institute - Physiological and pathophysiological roles of nitric oxide in mammalian cells, Stockholm, Sweden, June, 1997.
135. Conference Organizer and Chairman - FASEB Summer Research Conference - Endothelium and Cardiovascular Control - Copper Mountain, Colorado, July, 1997.
136. Invited Speaker - FASEB Summer Research Conference - Endothelium and Cardiovascular Control - Regulation of high output production of nitric oxide - Copper Mountain, Colorado, July, 1997.
137. Symposium Organizer and Chairman - Nitric Oxide and Cardiovascular Function - XIX Annual Meeting International Society for Heart Research, Vancouver, British Columbia, Canada, July, 1997.
138. Invited Speaker - Nitric Oxide and Cardiovascular Function - XIX Annual Meeting International Society for Heart Research, Nitric oxide: a biological mediator, Vancouver, British Columbia, Canada, July, 1997.
139. Invited Speaker and Session Chairman - Brazilian Society of Cardiology - Brazilian Congress of Cardiology - Role of nitric oxide in cardiovascular function, Sao Paulo, Brazil, September, 1997.
140. Scientific Advisory Board: Fifth International Conference on the Biology of Nitric Oxide - Kyoto, Japan, September, 1997.
141. Invited Speaker and Session Chairman - Fifth International Conference on the Biology of Nitric Oxide - Co-regulation of inducible NO synthase and arginase in endothelial and tumor cells, Kyoto, Japan, September, 1997.
142. Invited Speaker - Symposium on Cardiovascular Actions of Nitric Oxide - Factors affecting the high output production of NO, Nagoya, Japan, September, 1997.

143. Invited Speaker - Symposium on Inducible NO Synthase - Role of arginase in controlling arginine availability for iNOS, Tokyo, Japan, September, 1997.
144. Invited Opening Lecturer - International Congress on NITRIC OXIDE in Reproductive and Perinatal Medicine - Genoa, Italy, September, 1997 - Physiological and Pathophysiological Roles of Nitric Oxide.
145. Special Lecture - Society for Neuroscience - Physiology and Pathophysiology of Nitric Oxide. New Orleans, Louisiana, October, 1997.
146. Session Chairman - Oxygen Club of California - 1998 World Congress - Oxidants and Antioxidants in Biology. Santa Barbara, California, February, 1998.
147. Invited Guest Speaker - 14th Annual CMMC Symposium on ECMO & Advanced Therapies for Respiratory Failure. "Pathophysiological Properties of Nitric Oxide". Keystone, Colorado, March, 1998.
148. Juan March Foundation for Investigational Studies - NO: From Discovery to the Clinic - "Novel roles of the arginine-NO pathway in the regulation of cell proliferation". Madrid, Spain, June, 1998.
149. Conference Organizer and Chairman - Third International Conference on the Biochemistry and Molecular Biology of Nitric Oxide. Sunset Village, UCLA, Westwood, California, July, 1998.
150. Plenary Lecturer - XIII International Congress of Pharmacology (IUPHAR)- Novel Physiological Roles for Nitric Oxide. Munich, Germany, July, 1998.
151. Invited Guest Lecturer and Session Chairman- Biological Chemistry and Cellular Targets of Nitric Oxide - Nitric Oxide Cyclic GMP Signal Transduction Mechanisms. Graz, Austria, August, 1998.
152. Organizing Committee, Plenary Lecturer, and Session Chairman - IX Biennial Meeting International Society for Free Radical Research. "The Physiology of Nitric Oxide". San Paulo, Brazil, September, 1998.
153. Invited Lecturer - Vascular Biology Symposium: Endothelium, Nitric Oxide, and Atherosclerosis - 50 Year Anniversary of the NHLBI. "Nitric Oxide and Smooth Muscle Relaxation". Bethesda, Maryland, September, 1998.
154. Invited Lecturer - Symposium on Nitro-Aspirin. "Novel anti-proliferative effects of the arginine-nitric oxide pathway". Nice, France, October, 1998.
155. Invited Lecturer - International Conference on Osteoarthritis. "Physiological significance of nitric oxide". Florence, Italy, October, 1998.
156. Nobel Ceremony and Banquet - Nobel Laureate in Physiology or Medicine - December 1998.
157. Invited Speaker - 3rd Gordon Research Conference on the Chemistry of Nitric Oxide - "Roles of Arginase and NO Synthase in Regulation of Cell Proliferation". Ventura, California, February, 1999.
158. Invited Lecturer - Opening of the Wales Cardiovascular Research Institute - Lecture on "Physiological and Pathophysiological Roles of Nitric Oxide". Cardiff, Wales, U.K., February, 1999.

159. Invited Lecturer - UCLA Vascular Symposium on Nitric Oxide and Cardiovascular Disease - "NO as a Signaling Molecule in Vascular Function". UCLA, March, 1999.
160. Invited Keynote Speaker - NIH NICHD Symposium on Vasoactive Substances and Free Radicals in Perinatal Biology - "Reflections on Nitric Oxide Biology and Medicine". Alexandria, Virginia, May, 1999.
161. Invited Keynote Speaker - International Congress on Thrombosis and Hemostasis - "Nitric oxide as a unique signaling molecule in the cardiovascular system". Lisbon, Portugal, June, 1999.
162. Symposium Plenary Speaker - International Union on Cardiovascular Physiology - "Nitric oxide as a unique signaling molecule in the cardiovascular system". Capri, Italy, June, 1999.
163. Invited Keynote Speaker - Nitric Oxide in Cardiovascular Health and Disease - "Nitric oxide as a unique signaling molecule in the cardiovascular system". Naples, Italy, June, 1999.
164. Honorary Medical Degree from both Schools of Medicine at the University of Naples, Italy, June, 1999.
165. Honorary Citizenship from the city of Torre del Greco in Naples, Italy, June, 1999.
166. Invited After Dinner Speaker at the Gordon Research Conference on Atherosclerosis - "The Road to Stockholm - A Nobel Mission", New Hampshire, June, 1999.
167. Invited Keynote Speaker - Chemical Advances in Drug Discovery - "Nitric oxide as a unique signaling molecule in the cardiovascular system; new insights into drug discovery", Pasadena, California, July, 1999.
168. Invited Keynote Speaker - 120 Years of Nitrate Therapy - "Nitric oxide in health and disease". Berlin, Germany, September, 1999.
169. Invited Keynote Speaker - Pfizer Pharmaceuticals Symposium - "Significance of nitric oxide in vascular biology and medicine", Osaka, Japan, September, 1999.
170. Invited Keynote Speaker - Symposium on Advances in Cardiovascular Therapy - "Nitric oxide in cardiovascular disease". Nagoya, Japan, September, Japan, 1999.
171. Invited Plenary Speaker - Japanese Biochemical Society Annual Meeting - "Nitric oxide as a unique signaling molecule in the cardiovascular system". Yokohama, Japan, October, 1999.
172. Invited Keynote Speaker - Vascular Satellite Symposium of the Japanese Biochemical Society - "Nitric oxide in the regulation of vascular smooth muscle function". Yokohama, Japan, 1999.
173. Invited Keynote Speaker - Kowa Pharmaceuticals Symposium - Novel drugs in cardiovascular disease - "Nitric oxide in the therapy of cardiovascular disease". Tokyo, Japan, 1999.
174. Invited Plenary Speaker - Japanese Heart Failure Society Symposium - "Nitric oxide and cardiovascular disease". Fukuoka, Japan, October, 1999.

175. Invited Plenary Speaker - International Union of Biochemistry and Molecular Biology - "Nitric oxide as a unique signaling molecule in the cardiovascular system". Seoul, Korea, October, 1999.
176. Invited Keynote Speaker - International Symposium on Antioxidants in Health and Disease - "Nitric oxide as a unique signaling molecule in the cardiovascular system". Montevideo, Uruguay, November, 1999.
177. New Century Health Care Promotion Foundation Symposium - "Nitric oxide in health and disease". Taipei, Taiwan, November, 1999.
178. Fernandez Cruz Memorial Lecture - "Nitric oxide as a unique signaling molecule in the cardiovascular system". Madrid, Spain, December, 1999.
179. Invited Keynote Speaker - Concepts and Controversies in Cardiovascular Medicine - "Nitric oxide as a unique signaling molecule in the cardiovascular system". Amsterdam, Netherlands, December, 1999.
180. Invited Keynote Speaker - French Society of Cardiology - "Nitric oxide as a unique signaling molecule in the cardiovascular system". Paris, France, January, 2000.
181. Invited Banquet Plenary Speaker - Gordon Research Conference - Oxygen Radicals in Biology - "Nitric oxide as a unique signaling molecule in the cardiovascular system". Ventura, California, February, 2000.
182. Invited Special Lecture - Club NO - NO 2000 - "Nitric oxide as a unique signaling molecule in the cardiovascular system". Paris, France, March, 2000.
183. Invited Plenary Speaker - Euro-Pediatrics 2000 - "Nitric oxide in Health and Disease". Rome, Italy, March, 2000.
184. Invited Keynote Speaker - Japanese Circulation Society - 64th Annual Scientific Meeting - "Nitric oxide as a unique signaling molecule in the cardiovascular system". Osaka, Japan, April, 2000.
185. Invited Keynote Speaker - Japanese Urology Association - "Role of nitric oxide in erectile function". Sapporo, Japan, April, 2000.
186. Invited Keynote Speaker - European Association of Urology - XVth Congress - "Nitric oxide as a unique signaling molecule in the cardiovascular system". Brussels, Belgium, April, 2000.
187. Invited Keynote Speaker - 16th International Congress on Thrombosis - "Nitric oxide as a unique signaling molecule in the cardiovascular system". Porto, Portugal, May, 2000.
188. Invited Keynote Speaker - Advances in the Treatment of Hypertension - Menarini Conference - "Nitric oxide as a unique signaling molecule in the cardiovascular system". Rome, Italy, May, 2000.
189. Invited Keynote Speaker - Menarini Lectures in Cardiovascular Medicine - "Nitric oxide as a unique signaling molecule in the cardiovascular system". Glasgow, Scotland, May, 2000.
190. Recipient of Honoris Causa in Medicine - Norte University - Asuncion, Paraguay, May, 2000.

191. Invited Keynote Speaker - International Conference on Therapy of Heart Disease - "Nitric oxide as a unique signaling molecule in the cardiovascular system". Bratislava, Slovak Republic, June, 2000.
192. Invited Speaker – Symposium on Chronic Inflammation – sponsored by NicOx, Inc. – "Role of nitric oxide as an anti-inflammatory molecule". Nice, France, July, 2000.
193. Invited Keynote Speaker – Erectile Dysfunction and its Treatment – sponsored by Pfizer, Inc. – "Nitric oxide and cyclic GMP as signaling molecules in erectile function". Chicago, IL, August, 2000.
194. Invited Keynote Speaker – World Congress on Lung Health – sponsored by Aerocrine, Inc. – "Nitric oxide as a unique signaling molecule in cardiovascular and pulmonary function". Florence, Italy, August, 2000.
195. Invited to testify before the House Appropriations Subcommittee on N.I.H. funding. Washington, DC, September, 2000.
196. Invited Keynote Speaker – International Porphyrin Symposium – "Guanylate cyclase and interactions with nitric oxide, porphyrins and metalloporphyrins". Paris, France, September, 2000.
197. Recipient of Honoris Causa in Medicine – Charles University – Prague, Czech Republic, September, 2000.
198. Recipient of Honoris Causa in Medicine – University of Bologna – Bologna, Italy, September, 2000.
199. Invited Keynote Speaker – American Society of Anesthesiology – "Nitric oxide as a unique signaling molecule in the vascular system". San Francisco, CA, October, 2000.
200. Invited Keynote Speaker – Excellence in Science Symposium – sponsored by Johnson & Johnson – "Nitric oxide as a unique signaling molecule in the cardiovascular system". New Brunswick, NJ, October, 2000.
201. Invited Keynote Speaker – Menarini Foundation Symposium on Treatment of Heart Disease – "Nitric oxide and cyclic GMP as modulators of vascular function". Florence, Italy, November, 2000.
202. Invited Guest Speaker – Symposium on erectile dysfunction – sponsored by Pfizer, Inc. – "Nitric oxide as a NANC neurotransmitter; the consequence of deficient neuronal release". Tel Aviv, Israel, November, 2000.
203. Invited Keynote Speaker – Oswaldo Cruz Foundation Symposium on Nitric Oxide and Immune Function – "Nitric oxide as a unique and global signaling molecule in immunophysiology". Rio de Janeiro, Brazil, December, 2000.
204. Invited Speaker – International Symposium on Nitric Oxide and Inflammation – sponsored by NicOx, Inc. – "Antioxidant properties of nitric oxide". London, U.K., January, 2001.
205. Invited Speaker – Prostaglandins and Nitric Oxide in Inflammation – sponsored by NicOx, Inc. – "Anti-inflammatory properties of nitric oxide; is cyclic GMP involved?". Paris, France, January, 2001.

206. Invited Keynote Speaker – The Genome Project and our Society – “What is gene transfer and how can it aid in the treatment of disease”. Florence, Italy, February, 2001.
207. Invited Keynote Speaker – Cardiology Update 2001 – “Nitric oxide as a unique protective molecule against cardiovascular disease”. Davos, Switzerland, February, 2001.
208. Invited After Dinner Speaker – Viagra Marketing Meeting – sponsored by Pfizer, Inc. – “Nitric oxide as a unique signaling molecule in the cardiovascular system”. Cancun, Mexico, March, 2001.
209. Invited Lectureship – The John E. Hoopes Lecture – “Nitric oxide as a unique signaling molecule in Physiology”. Baltimore, MD, April, 2001.
210. Invited Keynote Speaker – Breakthroughs in BioScience at Pacific Union College – “Nitric oxide as a unique signaling molecule in the cardiovascular system”. Napa Valley, CA, April, 2001.
211. Invited Keynote Speaker – Menarini Foundation Symposium on Beta Receptor Blockers – “Nitric oxide releasing beta blockers in the treatment of heart disease”. Florence, Italy, May, 2001.
212. Invited Keynote Speaker – Novel Therapy of Chronic Inflammation – “Nitric oxide in the protection against gastrointestinal inflammation”. Capri, Italy, May, 2001.
213. Recipient of Honoris Causa in Science – Tulane University – New Orleans, LA, May, 2001.
214. Invited Meeting Chairman – Menarini International Satellite Symposium – Endothelial Dysfunction and Hypertension: Nebivolol, an Innovative Therapeutic Approach. Milan, Italy, June, 2001.
215. Invited Lecture Tour in the United Kingdom – Menarini Foundation Symposium Series – Physiological Roles of Nitric Oxide in the Cardiovascular System. Lectures: Kendal, Stratford-Upon-Avon, Queen Elizabeth Hospital in Birmingham, Derbyshire, Cambridge University, Guy’s Hospital in London, Royal Victoria Hospital in Belfast, and the Parliament Buildings in Belfast – June, 2001.
216. Invited Speaker – Rotary Club of Los Angeles – Presentation: The Road To Stockholm – A Nobel Experience, July, 2001.
217. Invited Lecture Tour in the United Kingdom – Menarini Foundation Symposium Series – Physiological Roles of Nitric Oxide in the Cardiovascular System. Lectures: Glasgow Royal Infirmary-Scotland, Glasgow Royal Concert Hall, Royal Victoria Postgraduate Center in Newcastle-Upon-Tyne, Welsh Heart Institute in Cardiff-Wales, Fitzpatrick Castle in Dublin-Ireland, Arundel-West Sussex, University of Clinical Sciences for Research & Education in Liverpool, Royal Marsden in London, Oxford University, and British Natural History Museum. September, 2001.
218. Invited Plenary Speaker – Symposium on Role of NO and other molecules in the cardiovascular system – “Role of NO in the Regulation of Cardiovascular Function”. Leipzig, Germany, September, 2001.
219. Invited Speaker – Menarini Foundation Symposium on Beta Blockers in Heart Failure. “Physiological Roles of Nitric Oxide in Cardiovascular Function”. Buenos Aires and Cordoba, Argentina, September, 2001.

220. 2001 Occidental Petroleum Nobel Laureate Lecturer at the Mayo Clinic – “Nitric Oxide as a unique signaling molecule in the vascular system”. Rochester, Minnesota, October, 2001.
221. Invited Lecturer – Wei Lun Visiting Professorial Lecture. “Nitric oxide in the regulation of vascular function: A historical overview”. Honk Kong, China, November, 2001.
222. Invited Lecturer – A Century of Nobel Achievements – American Heart Association Meeting. “Nitric oxide: A unique signaling molecule”. Anaheim, California, November, 2001.
223. 100-Year Anniversary Celebration of the Nobel Prizes – Invited Speaker for various events in Stockholm. Stockholm, Sweden, December, 2001.
224. Invited Lecturer – Official Opening Lecture - British Heart Foundation Laboratories at University College London. “Nitric Oxide as a unique signaling molecule in the cardiovascular system”. London, England, January, 2002.
225. Invited Speaker – Scientific Advisory Group for NicOx Incorporated. “Role of nitric oxide in the regulation of vascular smooth muscle cell proliferation”. Nice, France, January, 2002.
226. Invited Plenary Speaker – Pacific Coast Surgical Association. “Role of nitric oxide as a signaling molecule”. Las Vegas, Nevada, February, 2002.
227. Invited Lecturer – The James W. Fisher Lecture. Tulane University School of Medicine. “Nitric oxide as a unique signaling molecule in vascular biology”. New Orleans, Louisiana, March, 2002.
228. Invited Speaker – Southern California Rheumatology Society Meeting. “Physiological significance of nitric oxide”. Beverly Hills, California, March, 2002.
229. After Dinner Speaker – Ladies Auxiliary Group of Los Angeles. “The Road to Stockholm: A Nobel Mission”. Brentwood, California, March, 2002.
230. Invited Speaker – Lancôme Paris. Tokyo, Japan, January, 2003.
231. Invited Speaker – Nagoya University. Nagoya, Japan, February, 2003.
232. Invited Speaker – Menarini Foundation Symposium. Istanbul, Turkey, March, 2003.
233. Invited Speaker – Pharmacia Corporation 35th International Symposium on GH and Growth Factors in Endocrinology and Metabolism. “Role of nitric oxide as a signaling molecule in the cardiovascular system”. Prague, Czech Republic, April, 2003.
234. Invited Plenary Speaker – West Virginia University Health Sciences Center research Day. “The Road to Stockholm: A Nobel Mission”. Morgantown, West Virginia, April, 2003.
235. Invited Speaker – University of Calgary Pharmacology and Therapeutics Seminar. “Nitric oxide as a unique signaling molecule in vascular biology”. Alberta, Canada, April, 2003.

236. Invited Speaker – The Hellenic Cardiological Society 18th Annual International Meeting on Clinical Cardiology. “New scientific data related to the therapeutic role of NO”. Athens, Greece, May, 2003.
237. Invited Speaker – The 20th International Kumamoto Medical BioScience Symposium. “Nitric oxide as a unique signaling molecule in vascular biology”. Kumamoto, Japan, May, 2003.
238. Invited Speaker – Science Congress. “Nitric oxide as a unique signaling molecule in vascular biology”. Torino, Italy, June, 2003.
239. Invited Speaker – 55th Congress of the German Urological Association. “Sex and NO”. Hamburg, Germany, September, 2003.
240. Invited Lecturer – The Earl W. Sutherland Lecture. Vanderbilt University Department of Molecular Physiology & Biophysics. “Nitric oxide as a unique signaling molecule in vascular biology”. Nashville, Tennessee, October, 2003.
241. Invited Speaker – GEMI Fund Grant Award Ceremony. “Nitric oxide in biology”. Boston, Massachusetts, October, 2003.
242. Invited Lecturer – XX Congress of the Italian Society of Andrology. “NO as a mediator of erectile function”. Capri, Italy, October, 2003.
243. Invited Speaker – 1st Congress of NO. Bonn, Germany, November, 2003.
244. Invited Speaker – Lancôme Paris – Paris, France, January, 2004.
255. Invited Nobel Lecturer - A. Menarini Portugal - NO Endothelial Dysfunction on Hypertension. Lisbon, Portugal, February, 2004.
256. Invited Speaker – Berlin-Chemie. “From basic science to therapeutic concept – my long way to the Nobel Prize”. Hannover, Germany, March, 2004.
257. Invited Speaker – A. Menarini International – 2nd International Meeting on Nitric Oxide. Two lectures: “NO as a signaling molecule” and “The Road to Stockholm: A Nobel Mission”. Istanbul, Turkey, May, 2004.
258. Invited Speaker – Berlin-Chemie – Vascular NO: From Bench to Bedside. “From basic science to therapeutic concept – my long way to the Nobel Prize”. Berlin, Germany, May, 2004.
259. Invited Keynote Speaker – 15th Annual Scientific Sessions of the Society for Vascular Medicine and Biology. “Nitric oxide and protection against cardiovascular disease”. Anaheim, California, June, 2004.
260. Invited Nobel Lecturer – Nitric Oxide, Cytokines, and Inflammation: An International Symposium. “Nitric oxide and nitric oxide-releasing drugs as inhibitors of cell proliferation”. Rio de Janeiro, Brazil, June, 2004.
261. Invited Keynote Speaker – Update on Cardiovascular Diseases: The Latest News for the Clinician. “Role of nitric oxide as a signaling molecule in the cardiovascular system”. Naples, Italy, June, 2004.
262. Invited Speaker – Nestle Research Center. “Nitric oxide: a unique signaling molecule that can improve health and fitness”. Lausanne, Switzerland, September, 2004.

263. Invited Speaker – University of California, San Diego Department of Pharmacology Seminar Series. “Nitric oxide as a widespread signaling molecule in biology”. San Diego, California, September, 2004.
264. Invited Speaker – Metabolic Engineering Conference. Lake Tahoe, Nevada, September, 2004.
265. Invited Speaker – Nobel Spotlight – Tulane University Health Sciences Center 170th Anniversary. “The Road to Stockholm: A Nobel Mission”. New Orleans, Louisiana, October, 2004.
266. Invited Speaker – The Nagai Foundation. “Nitric oxide as a unique signaling molecule in the cardiovascular system”. Kumamoto, Japan, October, 2004.
267. Invited Plenary Speaker – American Society of Anesthesiologists. “Nitric oxide as a unique signaling molecule in biology”. Las Vegas, Nevada, October, 2004.
268. Invited Speaker – State University of New York at Stony Brook School of Medicine Grand Rounds. “The Road to Stockholm: A Nobel Mission”. Stony Brook, New York, November, 2004.
269. Invited Speaker – Korean Society of Food Science & Nutrition. “Nitric oxide history: past, present & future”. Jeju Island, Korea, November, 2004.
270. Invited Lecturer – A. Menarini International – A New Class Therapeutic. Two lectures: “Biologic effects of NO” and “My road to the Nobel Prize”. Caracas, Venezuela, December, 2004.
271. Invited Speaker – 3rd International Congress on Immunosuppression. “Nitric oxide history: past, present & future”. San Diego, California, December, 2004.
272. Invited Speaker – California Club Distinguished Speaker Series. “The Road to Stockholm: A Nobel Mission”. Los Angeles, California, April, 2005.
273. Invited Speaker – Menarini International 3rd International Meeting on Nitric Oxide. “The Road to Stockholm: A Nobel Mission”. Berlin, Germany, April, 2005.
274. Invited Lecturer – The Fred W. Schueler Lecture. “Nitric oxide as a unique signaling molecule”. New Orleans, Louisiana, May, 2005.
275. Invited Lecturer – The Gerald D. Aurbach Memorial Lecture. “The Road to Stockholm: A Nobel Mission”. Nashville, Tennessee, September, 2005.
276. Invited Keynote Speaker – 3rd Annual Antiangiogenesis Symposium. “The multifaceted role of nitric oxide in endothelial function in health and disease”. Boston, Massachusetts, October, 2005.
277. Invited Speaker – University of California, Los Angeles Department of Pediatrics Grand Rounds. “Nitric oxide as a unique signaling molecule in the cardiovascular system”. Los Angeles, California, November, 2005.
278. Invited Speaker – University of California, Los Angeles Department of Medicine Grand

Rounds. "Nitric oxide as a unique signaling molecule in the cardiovascular system". Los Angeles, California, February, 2006.

279. Invited Lecturer – Founders Lecture for the Association for Academic Surgery. "Unique role of nitric oxide in cardiovascular function". San Diego, California, February, 2006.
280. Recipient of Honoris Causa in Medicine – Medical University of Warsaw – Warsaw, Poland, May, 2006.

COMMITTEES (Tulane):

1. Medical School Curriculum Committee (1973 - 1974)
2. Pharmacology Medical Course Committee (1974 - 1985)
3. Clinical Correlations to Basic Medical Sciences (1973 - 1974)
4. First Faculty Advisor to the Tulane Medical School Basic Science Club (1975 - 1977)
5. Tulane Medical School Admissions Committee (1978 - 1981)

COMMITTEES (Outside Tulane):

1. Pharmacology Study Section, N.I.H. (1981-1985)
2. John Jacob Abel Award Committee (1984-1985)

TEACHING RESPONSIBILITIES (Tulane):

1. Medical Pharmacology (medical course with laboratory)
2. Principles of Pharmacology (graduate course)
3. Clinical Toxicology (medical/graduate course)
4. Clinical Pharmacology (medical course)
5. Cell Biology (medical course)
6. Cellular Pharmacology (graduate course)
7. Advanced Research Techniques (interdepartmental graduate course)

ADMINISTRATIVE/ORGANIZATIONAL RESPONSIBILITIES (Tulane):

1. Advanced Research Techniques (interdepartmental graduate course)
2. Co-organizer of Principles of Pharmacology (graduate course)
3. Co-organizer of 1978 ASPET Meeting in New Orleans
4. Pharmacology Seminar Chairman (1973 - 1980)

ADMINISTRATIVE/ORGANIZATIONAL RESPONSIBILITIES AND COMMITTEES (UCLA):

1. Education Policy Curriculum Committee (1986 - present)
2. Medical Pharmacology Course Coordinator (1986 - present)
3. Olympic Analytical Laboratory (1986 - present)
4. Graduate Training Committee (1986 - present)
5. Department of Surgery Chairperson Search Committee (1986 - 1987)
6. Medical School Interactive Teaching Committee (1987 - present)
7. Faculty Executive Committee (1987 - 1990)
8. Medical School Education Task Force (1987 - present)
9. Selection of Annual UCLA School of Medicine Lecturer (Chairman, 1988 - present)
10. Laubisch Cardiovascular Fund Committee (1987 - present)
11. Chair, Ad Hoc Promotion Committees - departmental and university (1987 - present)
12. Faculty Marshal, Class of 1987, UCLA School of Medicine (1987)
13. Strategic Planning Action Committee (1988 - present)
14. Hippocratic Oath Ceremony Committee (1988 - present)
15. Acting Chairman, Department of Pharmacology (1989 - 1990)
16. Vice Chairman, Faculty Executive Committee, UCLA School of Medicine (1989 - 1992)
17. Member of the UCLA Medical Education, Research & Instructional Center (MERIC) (1989 - present); including subcommittees on Advisory Committee, Faculty Education, and Neuroscience Curriculum Working Group
18. Chair, Neurosciences Curriculum Committee (1989 - present)
19. Member, Minority Graduate Student Recruiting Committee (1989 - present)
20. Member, Physiology Search Committee for recruiting new faculty (1989 - 1990)
21. Member, LCME Subcommittee on Faculty (1989 - 1991)
22. Member, Legislative Assembly, UCLA School of Medicine (1988 - 1991)
23. SPAC Subcommittee on Graduate Student Education (1989 - present)

24. Member, Faculty Council (1989 - present)
25. Member, Medical Student Conduct Committee (1990 - present)
26. Member, Educational Board, UCLA Medicine Magazine (1990 - present)
27. Assistant Dean for Student Research (1990 - 1996)
28. Member, Alpha Omega Alpha (AOA) Research Award Committee (1990 - present)

TEACHING RESPONSIBILITIES:

1. Medical Pharmacology 201: Coordinator and 30 lectures
2. Cellular and Molecular Pharmacology
3. Methods in Pharmacology
4. Medical Physiology 201
5. Basic Neurology 203
6. Pharmacology Journal Club: Chair

UCLA TEACHING AWARDS:

1. UCLA School of Medicine - Outstanding Teacher Award (1986)
2. 1987 AMSA **Golden Apple Award**
3. 1988 AMSA **Golden Apple Award**
4. 1989 AMSA **Golden Apple Award**
5. 1990 AMSA **Golden Apple Award**
6. 1991 AMSA **Golden Apple Award**
7. 1992 Outstanding Professor Award for Teaching
8. 1993 AMSA **Golden Apple Award**
9. 1993 UCLA School of Medicine **Award for Excellence in Education**
10. 1994 AMSA **Golden Apple Award**
11. 1995 AMSA **Golden Apple Award**
12. 1996 AMSA **Golden Apple Award**
13. 1998 AMSA **Golden Apple Award**
14. 1999 AMSA **Golden Apple Award**

OUTSIDE FUNCTIONS:

1. Member, American Heart Association, Los Angeles Affiliate (1987 - present)
2. Judge, 1989 American Heart Association's Young Investigators Forum (1989)
3. Member, **Otto Kraye Award** Selection Committee (1991)

GRADUATE STUDENTS (at UCLA):

Michele E. Gold (1986 - 1990)
 Andrew A. Lettes (Thesis committee; Pharmacology; 1985 - 1988)
 Hal Fong Yee, Jr. (Thesis committee; MSTP Program - Physiology; 1985 - 1990)
 Peggy A. Bush (1989 - 1992)
 Jeanette Griscavage (1990 - 1995)
 Nita J. Patel (Thesis committee; Pharmacology; 1986 - 1990)
 Gordon Cohen, M.D. (1991 - 1996)
 Kuang-Yuh Chyu (Thesis committee; Physiology; 1988 - 1992)
 Karen H. Gyls, (Thesis committee; Pharmacology; 1987 - 1992)
 Anjay Rastogi, M.D. (1995 - 2000)
 Aaron Jacobs (1996 - 2002)
 Deborah Lin (1997 - 1999) (M.S. degree)
 Philip Michael Bauer (1997 - 2001)

POSTDOCTORAL FELLOWS:

Toshio Hayashi, Ph.D. (1991 – 1993)
 Hong Sheng, Ph.D. (1992 - 1994)
 Adrian Hobbs, Ph.D. (1992 - 1996)
 Waldemar Radziszewski, M.D., Ph.D. (1993 - 1995)
 Rajan Singh, Ph.D. (1996 - 1998)
 Hermes Garban, M.D., Ph.D. (2000 -)
 Daigo Sumi, Ph.D. (2001 -)
 Linda Connelly, Ph.D. (2001 -)
 Nobutake Sadamasa, M.D. (2005 -)
 Fumio Ohta, Ph.D. (2006 -)

PHYSICIAN FELLOWS:

Ronald W. Day, M.D. (1989 - 1991)
 William Aronson, M.D. (1989 - 1991)
 Wyman Lai, M.D. (1990 - 1992)
 Kenneth Leong (1995 - 1998)

VISITING SCIENTISTS:

Toshio Hayashi, M.D., Ph.D. (1991 - 1993)

SPECIAL AWARDS:

To my Physician Fellow - William Aronson, M.D. - First Place in the Wesson Resident Essay Competition of the American Urological Association - March, 1991 - Essay entitled “The Chemical mediator of Human Penile Erection is Nitric Oxide”.

To my Surgery Resident Graduate Student - Gordon Cohen, M.D. - Recipient of the 1991 American College of Surgeons Scholarship for Advanced Study - July 1991.

INVITED SEMINARS (only 1982 - present):

University of Tennessee (Pharmacology) - Regulation of Cyclic GMP Metabolism and Cellular Function, 1982.

University of Missouri-Columbia (Pharmacology) - Role of Cyclic GMP in Vasodilatation and Platelet Aggregation, 1982.

University of Mississippi-Jackson (Pharmacology) - Regulation of Cyclic GMP Formation and Effects on Vascular Smooth Muscle, 1982.

University of Texas-Houston (Pharmacy/Pharmacology) - Role of Cyclic Nucleotides in Modulating Vascular Reactivity, 1983.

Tulane University (Pharmacology) - Mechanism of Action of Nitrogen Oxide-Containing Vasodilators, 1983.

F.D.A. (Washington, D.C.) - Regulation of Cyclic GMP Formation and Its Relationship to Vasodilatation, 1983.

Louisiana State University (Biochemistry) - Purification and Properties of Soluble Guanylate Cyclase, 1983.

University of California-Los Angeles (Pharmacology) - Regulation of Guanylate Cyclase by Porphyrins and Metalloporphyrins, 1983.

Tulane University (Biochemistry) - Mechanisms of Guanylate Cyclase Activation by NO, Phenylhydrazine and Arachidonic Acid, 1983.

Tulane University (Physiology) - Mechanisms of Vasodilatation by Nitrogen Oxides, Acetylcholine and Arachidonic Acid, 1983.

University of California-Los Angeles (Pharmacology) - Mechanisms of Action of Endothelium-Dependent and Independent Vasodilators, 1984.

Tulane University (Physiology) - Endothelium-Dependent Vascular Smooth Muscle Relaxation, 1985.

University of South Alabama (Pharmacology) - Regulation of Soluble Guanylate Cyclase by Porphyrins and Metalloporphyrins, 1985.

UCLA (Chemistry/Pharmacology) - Regulation of Guanylate Cyclase by Porphyrins and Metalloporphyrins, 1986.

University of California-Irvine - Similarities Between Endothelium-Dependent and Endothelium-Independent Relaxation of Vascular Smooth Muscle, 1987.

UCLA (Pathology) - Role of Endothelium in Regulation of Vascular Smooth Muscle Tone, 1987.

Loma Linda University (Physiology) - Regulatory Role of Cyclic GMP in Mediating Endothelium-Dependent and Independent Vasodilation, 1987.

UCLA (Pharmacology) - The Pharmacology and Physiology of Endothelium-Derived Relaxing Factor (EDRF), February, 1988.

Emory University School of Medicine (Pharmacology) - Identification and Characterization of Endothelium-Derived Relaxing Factor, March, 1988.

New York Medical College (Physiology) - Identification and Characterization of EDRF from Artery and Vein as Nitric Oxide, April, 1988.

Cornell Medical College (Pharmacology) - Identification and Properties of Endothelium-Derived Relaxing Factor, April, 1988.

University of London, Hammersmith Medical School (Cardiology) - Pharmacology and Physiology of Endothelium-Derived Relaxing Factor, July, 1988.

Wellcome Research Laboratories, Beckenham, Kent (invited by Salvador Moncada) - Characterization and Pharmacology of Endothelium-Derived Nitric Oxide, July, 1988.

University of Graz, School of Medicine, Austria (Pharmacology and Toxicology) - Identification and Properties of Endothelium-Derived Relaxing Factor, July, 1988.

University of California, San Francisco (Pharmaceutical Chemistry) - Endothelium-Derived Nitric Oxide and its Relationship to Pharmacologic Actions of Nitroglycerin, January, 1989.

University of Texas Medical School, Houston (Pharmacology) - Pharmacology of Endothelium-Derived Nitric Oxide, February, 1989.

Joint Baylor University-University of Texas School of Medicine, Houston (Grand Rounds) - Pharmacology and Clinical Significance of Endothelium-Derived Relaxing Factor, February, 1989.

Ohio State University, School of Pharmacy, Columbus (Pharmacology) - Endothelium-Derived Relaxing Factor: Pharmacological and Chemical Properties, October, 1989.

Sepulveda - Veterans Administration Medical Center (Grand Rounds) - Pharmacology and Clinical Significance of Endothelium-Derived Relaxing Factor, September, 1989.

UCLA (Physiology) - The Biosynthesis, Metabolism, and Actions of Endothelium-Derived Nitric Oxide, April, 1990.

Specialty Laboratories, Inc., Santa Monica - Molecular Mechanisms of Vasodilation, May, 1990.

Michigan State University, School of Medicine (Pharmacology & Physiology) - Biosynthesis, Metabolism, and Actions of Endogenous Nitric Oxide, October, 1990.

UCLA (Pharmacology) - From Nitric Oxide and Cyclic GMP to the Control of Vascular and Platelet Function, November, 1990.

Loma Linda University (Biochemistry) - Bioregulation of Cellular Function by Modulation of the L-Arginine to Nitric Oxide Pathway and Cyclic GMP, November, 1990.

Parke-Davis Company (Pharmacology/Physiology)- The Biology Significance of Nitric Oxide, August, 1991.

Italfarmaco, Ltd. (Cardiovascular Research)- The Physiological and Pathophysiological Roles of Endogenous Nitric Oxide, August, 1991.

Amgen - Role of the L-arginine-nitric oxide pathway in mammalian physiology, February, 1992.

University of Minnesota, School of Medicine (Pharmacology)- Physiological and pathophysiological roles of nitric oxide in mammalian cells, February, 1992.

Veterans Administration Medical Center, Minneapolis, MN (Nephrology)- Physiological and pathophysiological roles of nitric oxide in mammalian cells, February, 1992.

Harvard Medical School (Cardiology)- Physiological and pathophysiological roles of endothelium-derived nitric oxide, March, 1992.

ICI Americas Pharmaceutical Group- Physiological and pathophysiological roles of nitric oxide in mammalian cells, Wilmington, Delaware, July, 1992.

UCLA - Combined Endocrine Conference - Role of nitric oxide in erectile function and dysfunction, October, 1992.

University of Kansas Medical Center (Pharmacology, Toxicology and Therapeutics) - Physiological and pathophysiological roles of nitric oxide in mammalian cell function, December, 1992.

UCLA - Jerry Lewis Center Seminar Series - Physiological and pathophysiological actions of nitric oxide, February, 1993.

UCLA - Pharmacology - The physiological basis of the L-arginine-nitric oxide-cyclic GMP pathway in mammalian cells, February, 1993.

UCLA - Interdepartmental Conferences - Moderator and Speaker - Role of nitric oxide in mediating penile erection, February, 1993.

Duke University School of Medicine - Pharmacology - Cell Biology - Marine Biology - Physiological and pathophysiological significance of nitric oxide, May, 1993.

Columbia University Physicians & Surgeons - Anesthesiology - Role of nitric oxide in physiology and pathophysiology, June, 1993.

Columbia University Physicians & Surgeons - Pharmacology - Biosynthesis and actions of nitric oxide in the cardiovascular system, June, 1993.

Ciba-Geigy Corporation - Regulation of NO synthase activity in mammalian cells, January, 1994.

University of Pittsburgh, School of Medicine - Surgery - Regulation of NO synthase activity by NO, heme iron, and redox agents, May, 1994.

Medical College of Wisconsin, School of Medicine - Physiology - Physiological and pathophysiological roles of nitric oxide in mammalian cell function, May, 1995.

Berlex Biosciences - Vascular Division - Biosynthesis of nitric oxide: Regulation of NO synthase transcription, catalysis and L-arginine availability, May, 1995.

Harbor-UCLA Medical Center - Surgery - Nitric oxide - practical implications and future potentials, September, 1995.

University of California, Irvine - Medical Scientist Program - Significance of nitric oxide in physiology and medicine, November, 1995.

Louisiana State University, School of Medicine - Physiology - Physiological and pathophysiological roles of nitric oxide in mammalian cells, March, 1996.

University of Maryland and University of Maryland Biotechnology Institute - School of Pharmacy - Physiological significance of nitric oxide in mammals, May, 1996.

Nycomed Corporation - Oslo, Norway - two talks: (1) Role of nitric oxide in cardiovascular function, and (2) Mechanism of action of nitrovasodilators - November, 1996.

Duke University School of Medicine - two talks (Medicine and Cardiology): (1) Physiology and pathophysiology of nitric oxide in mammalian cell function, and (2) Cardiovascular significance of nitric oxide - February, 1997.

University of Missouri School of Medicine - Physiology - Roles of nitric oxide in mammalian cell physiology - April, 1997.

Lilly Pharmaceuticals - Research Center - Physiology and pathophysiology of nitric oxide in mammalian systems, Indianapolis, Indiana, May, 1997.

Cedars-Sinai Medical Center - Nephrology and Endocrinology - Nitric oxide: endothelium-derived autocrine/paracrine modulator of vascular function, Los Angeles, California, May, 1997.

Karolinska Institute - Huddinge Hospital - Cardiovascular significance of nitric oxide, Stockholm, Sweden, June, 1997.

UCLA - Joint Seminars in Neuroscience - "The Biological Significance of Nitric Oxide". Los Angeles, California, February, 1998.

Johns Hopkins University School of Medicine - Department of Anesthesiology - Grand Rounds - Physiological and Pathophysiological Roles of Nitric Oxide in Mammalian Cell Function - April, 1998.

University of Naples - School of Medicine and School of Pharmacy - Physiological and pathophysiological roles of nitric oxide in mammalian cell function. October, 1998.

Beverly Hills - California - Public Lecture on "What the Nobel Prize Means to Medicine in the Next Millennium". Los Angeles, California, January, 1999

UCLA Board of Visitors Meeting - "The Importance of Private Giving in Biomedical Research". Los Angeles, California, February, 1999.

UCLA Access Graduate Student Program - Special Lecture - "Physiology and Pathophysiology of Nitric Oxide in Mammalian Cell Function". Los Angeles, California, March, 1999.

UCLA School of Dentistry - Seminar - "Nitric Oxide as a Signaling Molecule in Cardiovascular Function". Los Angeles, California, March, 1999.

UCLA Fundraising Luncheon - Talk on "Highlights of the Nobel Experience". Los Angeles, California, March, 1999.

Astra Pharmaceuticals - Gothenburg - "The Importance of Nitric Oxide and Cyclic GMP as Signaling Molecules in Biology". Gothenburg, Sweden, March, 1999.

Yale University School of Medicine - Department of Pharmacology - "Nitric Oxide as a Signaling Molecule in Health and Disease". New Haven, Connecticut, April, 1999.

University of Texas Health Sciences Center - Breckenridge Lecturer - Scientific Talk on "Role of Nitric Oxide as a Signaling Molecule in Biology". Public Talk on "The Importance of Nitric Oxide to Health and Disease in the Next Millennium". San Antonio, Texas, April, 1999.

Special Menarini Lecturer for the Country of Italy - "Physiological Roles of Nitric Oxide Systems in Cardiovascular Biology and Medicine". Rome, Italy, April 28, 1999.

Louisiana State University - Department of Physiology - Wellcome Lecturer - “Nitric Oxide as a Signaling Molecule in Vascular Biology”. New Orleans, Louisiana, May, 1999.

Cedars-Sinai Hospital Board of Governors Meeting - “The Importance of Private Giving in Biomedical Research”. Los Angeles, California, May, 1999.

UCLA Chancellor’s Lecture - “The Road to Stockholm; a Nobel Mission”. Los Angeles, California, May, 1999.

Cedars-Sinai Hospital - The Goldberg Lecture - “Nitric Oxide in Health and Disease”. Los Angeles, California, May, 1999.

University of Minnesota School of Medicine - Department of Pharmacology - A Tribute to Frederick E. Shideman - “Nitric Oxide as a Signaling Molecule in the Cardiovascular System”. Minneapolis, Minnesota, May, 1999.

Pfizer - Departments of Pharmacology and Drug Development - “Role of Nitric Oxide in Erectile Function”. Sandwich, U.K., August, 1999.

Encino-Tarzana Regional Medical Center - “Nitric Oxide in Health and Disease”. Tarzana, California, September, 1999.

Nagoya University School of Medicine - Dept. Geriatrics - “Recent progress in nitric oxide research”. Nagoya, Japan, September, 1999.

Kumamoto University - Dept. Microbiology and Molecular Biology - “Why is nitric oxide important in mammalian physiology?”. Kumamoto, Japan, October, 1999.

Wonkwang University School of Medicine - Dept. Microbiology & Immunology - “Nitric oxide in physiology and pathophysiology”. Seoul, Korea, October, 1999.

University of the Republic School of Medicine - Dept. Biochemistry - “Nitric oxide and the NO synthase pathway inhibit the growth of vascular smooth muscle cells and tumor cells”. Montevideo, Uruguay, November, 1999.

University of Buenos Aires School of Medicine - Department of Biochemistry - “Nitric oxide as a unique signaling molecule in the cardiovascular system”. Buenos Aires, Argentina, November, 1999.

Biomedical Research Institute, Academia Sinica - “Nitric oxide as a unique signaling molecule in the cardiovascular system”. Taipei, Taiwan, November, 1999.

National Cheng Kung University Medical College - “Nitric oxide as a unique signaling molecule in the cardiovascular system”. Tainan, Taiwan, November, 1999.

Groningen Hospital - Special Lecture - “Nitric oxide in health and disease”. Groningen, Netherlands, December, 1999.

Utrecht National Hospital - Special Lecture - “Nitric oxide in health and disease”. Utrecht, Netherlands, December, 1999.

Eindhoven Medical Center - Special Lecture - “Nitric oxide in health and disease”. Eindhoven, Netherlands, December, 1999.

NicOx, Inc. - Special Lecture - “Role of the nitric oxide pathway in the regulation of cell proliferation”. Nice, France, February, 2000.

Hokkaido University School of Medicine - Dept. of Cardiovascular Medicine - “Nitric oxide as a unique signaling molecule in the cardiovascular system”. Sapporo, Japan, April, 2000.

Columbia University College of Physicians & Surgeons - College Lecture - “Nitric oxide as a unique signaling molecule in the cardiovascular system”. New York, New York, April, 2000.

University of Mississippi School of Medicine - Dept. of Physiology and Biophysics - “Nitric oxide as a unique signaling molecule in the cardiovascular system”. Jackson, Mississippi, April, 2000.

University of Alabama at Birmingham - School of Medicine - Dept. of Anesthesiology - “Nitric oxide as a unique signaling molecule in the cardiovascular system”. Birmingham, Alabama, April, 2000.

University of Pamplona Medical Center - Dept. of Medicine - “Nitric oxide as a unique signaling molecule in the cardiovascular system”. Pamplona, Spain, May, 2000.

Norte University School of Medicine - Dept. of Medicine - “Nitric oxide as a unique signaling molecule in the cardiovascular system”. Asuncion, Paraguay, May, 2000.

Cleveland Clinic – Department of Immunology – “Nitric oxide as a unique signaling molecule in physiology and pathobiology”. Cleveland, OH, October, 2000.

University of Louisville – Division of Cardiology – “Nitric oxide and cyclic GMP as modulators of cardiovascular function”. Louisville, KY, October, 2000.

UCLA School of Medicine – Cardiothoracic Surgery Grand Rounds – “Nitric oxide as a unique signaling molecule in the cardiovascular system”. December, 2000.

USC Health Sciences Campus – Keck School of Medicine – Opening Lecture of seminar series – “Nitric oxide as a unique signaling molecule”. January, 2001.

University of Naples School of Medicine – Department of Experimental Pharmacology – “Nitric oxide in physiology and pathobiology”. Naples, Italy, May, 2001.

UCLA School of Medicine – BioBasics Lecture. “One Nobel Prize, Eleven Golden Apple Awards, and the Possibility of Extended Life for Thousands”. February, 2002.

NOTE: from here on please refer, instead, to the section on Special Events continuing with Number 227.